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ABSTRACT 
Lynch syndrome (LS) is the most prevalent cause of hereditary colorectal 
cancer (CRC) and confers high risks for several other types of cancer. Universal 
tumor screening (UTS) of all newly diagnosed patients with CRC can improve LS 
identification and decrease associated morbidity and mortality among patients 
and family members. However, for UTS to be effective, patients who screen 
positive must pursue genetic counseling and confirmatory germline testing (i.e., 
high patient reach). The purposes of this study were to characterize UTS 
programs, identify barriers and facilitators to implementation, document whether 
there have been negative outcomes, and determine institutional and 
implementation conditions that are associated with high and low patient reach. 
Using two conceptual frameworks, RE-AIM and Consolidated Framework for 
Implementation Research, a baseline survey was conducted of 25 
representatives from different institutions performing UTS. Descriptive statistics 
were used to illustrate similarities and differences among programs. A multiple-
case study was then conducted by extracting data from surveys and interviews of 
representatives from 15 different institutions where UTS programs had been 
operational for over 6 months and where aggregated patient outcome data were 
available. Qualitative comparative analysis was performed to make systematic 
cross-case comparisons and identify conditions uniquely associated with high or 
low patient reach. Data were triangulated to create models explaining how UTS 
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implementation and system-level factors influence patient reach. 
Few patient concerns or negative outcomes were reported. UTS procedures 
and patient reach were highly variable. All 5 high-reach (H-R) centers have 
genetics professionals disclose positive screening results and either do not 
require a referral from another health care provider or have streamlined the 
referral process. Although 2 of the 5 mid-reach (M-R) centers also share these 
conditions, they have a less automated follow-up procedure and report difficulty 
contacting patients as a barrier. Both of the academic institutions with low patient 
reach (L-R) did not receive patient information that would allow them to follow-up 
on positive screening results. The three non-academic L-R institutions reported a 
high proportion of challenges to facilitators during implementation and did not 
have genetic professionals disclose positive screening results to patients. 
Implementing a combination of procedures to streamline UTS protocols and 
procedures, eliminate barriers to patient follow-through after a positive tumor 
screen, and incorporate a high level of involvement of genetic professionals in 
contacting patients and disclosing screening results are expected to lead to 
improvement in patient reach.
 1 
 
 
 
 
 
SECTION I: INTRODUCTION 
Background and Significance 
 Colorectal cancer (CRC) is the third most common type of cancer and 
third leading cause of cancer-related death in the United States (U.S.) 
("Colorectal Cancer Facts & Figures 2011-2013,"). Lynch syndrome (LS) is the 
most prevalent cause of hereditary CRC, occurring in 1 out of every 35 CRC 
patients (Hampel et al., 2008). Several retrospective studies have found that LS 
confers a 50-70% lifetime risk of CRC (Barrow et al., 2008; Hampel et al., 2005; 
Stoffel et al., 2009), a 40-60% chance of endometrial cancer in females (Barrow 
et al., 2009; Hampel et al., 2005; Stoffel et al., 2009), and increased risks for 
several other malignancies including cancers of the ovary, stomach, small 
intestine, hepatobiliary tract, urinary tract, brain, and skin (Barrow et al., 2009; 
Watson et al., 2008). The first prospective study confirmed prior retrospective 
study findings and also found pancreatic cancer and female breast cancer risks 
are increased among LS carriers (Win et al., 2012). 
Diagnosing LS alters cancer surveillance recommendations for patients 
with CRC (due to high risks for secondary cancers) and provides the opportunity 
to prevent cancer among patients' at-risk relatives through increased cancer 
screening and/or surgical prevention options (Järvinen et al., 2009; Schmeler et 
al., 2006; Stupart, Goldberg, Algar, & Ramesar, 2009; Vasen et al., 2010). The 
public health significance of diagnosing LS is acknowledged in the following 
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provisional Healthy People (HP) 2020 Genomics Objective: “Increase the 
proportion of persons with newly diagnosed colorectal cancer [CRC] who receive 
genetic testing to identify Lynch syndrome (or familial CRC syndromes)” 
("Genomics - Healthy People,"). 
 Despite the public health significance of diagnosing LS, 28% to 70% of 
CRC patients who have LS remain unidentified when screening is limited to 
tumors from patients who meet certain age or family history criteria (Hampel et 
al., 2008; Morrison et al., 2011; Tranø, Sjursen, Wasmuth, Hofsli, & Vatten, 2010; 
van Lier et al., 2011). Universal screening of tumors from all newly diagnosed 
patients with CRC has the potential to improve the identification of LS. Several 
studies have demonstrated the feasibility, efficacy, and theoretical cost-
effectiveness of universal tumor screening (UTS) for LS (Gudgeon et al., 2011; 
Hampel et al., 2008; Ladabaum et al., 2011; Morrison et al., 2011; Mvundura, 
Grosse, Hampel, & Palomaki, 2010; Tranø et al., 2010). Nevertheless, the impact 
that universal genetic screening policies will have on institutions or individuals is 
largely uncertain as UTS for LS is the first universal screening to be implemented 
for the purpose of detecting hereditary disease in adults.  
 Currently, in the United States, at least 35 cancer centers or hospitals are 
performing UTS for LS, with wide institutional variability in terms of the following: 
a) tumor screening methodology (i.e., IHC, MSI, with or without automatic reflex 
testing via hypermethylation or BRAF); b) whether explicit informed consent is 
obtained or an option to “opt out” is presented; c) what types of information are 
provided to the patients; d) who is responsible for follow-up with positive 
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(abnormal) screens; and e) how patients are given results (Beamer et al., 2012; 
Cohen, 2013). In addition, the percentage of patients with a positive screen who 
follow-through with genetic counseling and testing (i.e., patient reach) is highly 
variable, differing by more than 50% across cancer centers for which data has 
been published (Heald et al., 2013; Lynch, 2011; South et al., 2009).  
 Potential risks of UTS for LS are believed to be minimal (Hampel, 2010). 
However, in several studies that occurred prior to UTS implementation, patients 
with CRC expressed concern that genetic testing for hereditary CRC may lead to 
adverse psychological outcomes for themselves or their family members (Kinney 
et al., 2000; Kinney, DeVellis, Skrzynia, & Millikan, 2001; Lerman, Marshall, 
Audrain, & Gomez-Caminero, 1996; Ramsey, Wilson, Spencer, Geidzinska, & 
Newcomb, 2003). Patients with CRC have also expressed concerns about costs 
associated with genetic testing (Cragun, Malo, Pal, Shibata, & Vadaparampil, 
2012; Kinney et al., 2001; Ramsey et al., 2003).  
 Recognizing the need to pool Lynch syndrome tumor screening resources 
and to track outcomes, several institutions came together in September of 2011 
to form the Lynch Syndrome Screening Network (LSSN). Since the initial 
meeting, the LSSN has grown to include approximately 91 institutions across the 
United States; however, as of June 2012, only 35 of these institutional members 
were known to be performing routine screening for LS on tumors from all newly 
diagnosed CRC patients. To meet the needs of the many centers that are still 
trying to implement UTS, the LSSN has already created a website that houses 
tumor screening resources (www.lynchscreening.net). However, information 
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about keys to successful implementation, “best practices”, and ways to overcome 
barriers is lacking from the website.   
Three centers have previously reported aggregated patient data showing the 
percentage of patients who follow through with genetic counseling and germline 
genetic testing after a positive screen (i.e., patient reach) varies by over 50% 
(Lynch, 2011; South et al., 2009; Heald et. al, 2013). Two of these centers have 
also published or presented prospective data suggesting that changes in their 
protocol and follow-up procedures have improved patient reach (Hampel et. al, 
2012; Heald et. al, 2013). However, further research into 'real-world' 
implementation is needed to assess cost effectiveness as well as unanticipated 
consequences or negative patient outcomes. Furthermore, determining how 
implementation and system-level factors influence patient reach can help identify 
'best practices' that can be used to maximize the effectiveness of UTS programs 
in order to justify the development of infrastructure and cost required for UTS 
implementation on a national level.  
 This research is significant to public health because programs that 
automatically screen tumors from all newly diagnosed CRC patients have the 
potential to identify the 28% to 70% of CRC patients with LS who are missed 
using common practices of limiting screening to those who fulfill certain age (<50 
years) or medical/family history criteria (Hampel et al., 2008; Morrison et al., 
2011; Tranø et al., 2010; van Lier et al., 2011). This allows for the prevention or 
early detection of secondary cancers among patients and provides an 
opportunity to diagnose family members who have LS in order to prevent 
 5 
 
associated morbidity and mortality. UTS also has the potential to improve the 
identification of LS among ethnic minorities who are currently less likely to be 
identified and/or referred for genetic counseling and testing for hereditary cancer 
(Hall & Olopade, 2006; Kupfer, McCaffrey, & Kim, 2006; Shields, Burke, & Levy, 
2008).  
Study Purpose and Objectives 
 The long-term goal of this ongoing line of research is to improve the ability 
of universal tumor screening programs (UTS) programs to achieve the Healthy 
People 2020 provisional objective: “Increase the proportion of persons with newly 
diagnosed CRC who receive genetic testing to identify Lynch syndrome” 
(“Genomics - Healthy People”.) and thereby reduce the morbidity and mortality 
associated with hereditary cancer. The objectives of the current study were: 1) to 
compare current UTS screening programs at U.S. institutions (i.e., hospitals and 
cancer centers); 2) compile a list of “lessons learned” during implementation; 3) 
document any negative outcomes; and 4) determine “best UTS practices”. 
Theoretical Frameworks, Research Questions, and Hypothesis 
The RE-AIM evaluation framework ("DCCPS: Cancer Control Research: 
Implementation Science: RE-AIM," ; Glasgow, Klesges, Dzewaltowski, 
Estabrooks, & Vogt, 2006; Glasgow, Nelson, Strycker, & King, 2006; Glasgow, 
Vogt, & Boles, 1999) and constructs from the Consolidated Framework for 
Implementation Research (CFIR) (Damschroder et al., 2009; Damschroder & 
Hagedorn, 2011) were used to meet the aforementioned objectives and answer 
research questions listed in Table I-1. The goal of RE-AIM is to enhance the 
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quality, speed, and impact of efforts to translate research into practice in a 
manner that considers both internal and external validity (“DCCPS: Cancer 
Control Research: Implementation Science: RE-AIM,” n.d.; Glasgow et al., 1999). 
RE-AIM aids in evaluating programs by assessing the following dimensions that 
may impact generalizability of findings: Reach, Effectiveness, Adoption, 
Implementation, and Maintenance (see Table I-1 for dimension descriptions). In 
the current study, RE-AIM was used to identify patient Reach (i.e., the proportion 
of patients with an abnormal screen who follow-through with genetic counseling 
and germline testing), real-world Effectiveness (i.e., unanticipated consequences 
/ negative outcomes of UTS), reasons for UTS program Adoption, differences in 
program Implementation, and the extent to which programs have changed (i.e., 
Maintenance).  
 The Consolidated Framework for Implementation Research (CFIR) aided 
in identifying key system-level and implementation factors related to UTS. The 
CFIR was developed in 2009 to open the black box of the Implementation 
dimension in RE-AIM and aids in research planning by consolidating constructs 
from various implementation theories and an established evidence base 
spanning multiple scientific disciplines (Damschroder et al., 2009). These 
constructs are organized into five domains described in Table I-2. Various 
constructs were selected for inclusion in the CFIR based on their perceived 
relevance in a variety of health care contexts and research demonstrating that 
they are related to the adoption, implementation, and/or effectiveness of 
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evidence-based recommendations (Damschroder et al., 2009). Table I-2 lists 
constructs from the CFIR and provides a brief description of each.  
 A number of CFIR constructs come from Diffusion of Innovations, which is 
a theoretical framework explaining how and why new ideas, practices, or 
technologies (i.e., innovations) are communicated through channels over time 
(Rogers, 2003). Diffusion of Innovations is primarily used to explain factors 
associated with decisions to adopt, implement, maintain, and sustain innovations 
(Glanz, 2008; Rogers, 2003). Research guided by Diffusion of Innovations has 
provided a number of valuable insights, including a recognition regarding “...the 
importance of achieving a good fit between the attributes of an innovation, the 
adopting individual or organization, and the environment or context where the 
process takes place” (Glanz et al., 2008; p. 330). 
 Ironically, this insight also highlights some acknowledged criticisms of 
diffusion research, including a “tendency to hold individuals responsible for their 
problems, rather than the system of which the individual is a part” (Glanz et al., 
2008; p.329) and limitations in the ability of Diffusion of Innovations to contribute 
to an understanding of the complex organizations where innovation adoption 
decisions often take place (Glanz et al., 2008). The CFIR addresses these 
concerns through its focus on institutions as important units of analysis and its 
inclusion of a number of constructs specific to organizations. These additional 
constructs can be used to explore how organizational characteristics or system-
level factors may influence adoption, implementation processes, and 
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effectiveness of innovations. Additionally, the CFIR includes constructs specific to 
the implementation process itself, and thereby allows exploration into how 
aspects of this process may increase or reduce the chance for successful 
outcomes that result from innovation implementation. CFIR developers never 
intended for all constructs to be utilized in any single study (Damschroder et al., 
2009; Damschroder & Hagedorn, 2011). As such, a subset of constructs (i.e., 
contextual factors) from the CFIR that were hypothesized to play a role in 
implementation and effectiveness of LS UTS programs were used to develop 
questions for the surveys and interview guides. Table I-3 lists outcomes used to 
define successful UTS programs as well as conditions that might influence these 
outcomes. 
 Subsequently, the central hypothesis for the current study was that high 
patient Reach and few unanticipated or negative outcomes occur among UTS 
programs that possess one or more combinations of the following contextual 
factors: 1) streamlined UTS procedures (i.e., fewer steps need to be taken by 
patients in order to follow-up with genetic counseling and germline testing or 
patients can have genetic counseling at the same time or in the same location as 
other follow-up appointments); 2) direct involvement of genetic professionals in 
patient follow-up; 3) high quality communication among specialists (based on 
self-reported ratings by the primary contact and others involved with UTS at each 
institution); 4) consideration of patient needs and resources; 5) positive 
implementation climate (i.e., ratings of the extent to which UTS is rewarded, 
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supported, and expected within the institution) (Klein & Sorra, 1996); 6) high level 
of implementation readiness (based on ratings of how open the institution is to 
new initiatives and how much planning was done prior to implementation); and 7) 
positive attitudes toward LS UTS among key personnel who serve in 
administrative positions or are directly involved with UTS. The central study 
hypothesis was tested by employing a multiple-case study and qualitative 
comparative analysis (QCA) of data from several UTS programs. 
Dissertation Organization 
This dissertation includes two manuscripts that will eventually be 
submitted to peer-reviewed journals. The first manuscript presents the main 
findings of the current study within the RE-AIM framework (Section II). The 
purpose of the second manuscript (Section III) is to disseminate information on 
the utility of Qualitative Comparative Analysis in mixed methods research. To this 
end, the second manuscript includes: 1) findings from systematic reviews in Pub 
Med and the Journal of Mixed Methods Research illustrating the slow rate of 
diffusion of Qualitative Comparative Analysis (QCA) into health research and 
limited adoption among mixed-methods researchers; 2) a practical illustration of 
how to apply this hybrid technique using data from the multiple-case study; and 
3) advantages and limitations to QCA. Section IV of this dissertation concludes 
with an overall summary, study implications, future directions, and a description 
of additional manuscripts that are planned after the submission of this 
dissertation.
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Table I-1. Applying the RE-AIM Framework and Consolidated Framework for Implementation 
Research (CFIR) to Evaluate Lynch Syndrome Universal Tumor Screening (LS UTS) Programs 
RE-AIM Dimension Research Questions Relevant CFIR 
Domains (see 
Table I-2) 
Reach  
Absolute number, proportion, 
and representativeness of 
individuals who participate. 
• What proportion of patients who screen 
positive follow-through with genetic 
counseling and germline testing at 
each respective institution? 
• NA 
Efficacy / effectiveness 
The impact of an intervention 
on outcomes (including 
potential negative effects). 
• Have there been any unexpected 
outcomes or negative effects 
associated with UTS implementation?  
 
• NA 
 
 
Adoption 
Absolute number, proportion, 
and representativeness of 
settings and staff who 
currently offer a program. 
Characteristics of the 
intervention may increase the 
likelihood of adoption. 
• What led to the adoption of UTS? 
• Who was involved in making the 
decision to adopt UTS? 
• What characteristics of the 
centers/institutions may increase the 
likelihood of adopting UTS?  
• What characteristics of UTS (e.g., 
compatibility, complexity) relate to the 
decision to adopt it? 
• Individuals 
involved 
• Inner setting, 
Outer setting 
• Intervention 
characteristics   
Implementation 
Consistency of delivery, time 
and cost of the program, and 
what adaptations to the 
program are made in various 
settings. 
• Describe those involved in 
implementation. Were they the same 
as those who decided to adopt UTS? 
• What impact did key individuals have 
on implementation? 
• How was screening implemented (what 
was involved in planning & initiation)? 
• What challenges had to be overcome 
when implementing screening? 
• What is the institution's screening 
protocol? 
• Does implementation vary based on 
characteristics of the protocol chosen, 
institution, or individuals? 
• Individuals 
involved 
• Implementation 
Process 
• Intervention 
(protocol) 
characteristics, 
Inner setting, 
Outer setting, 
Individuals 
involved 
Maintenance 
How the intervention and its 
effects change over time. 
What changes have been made to UTS 
programs over time? 
• Individuals  
• Inner & Outer 
setting 
• Intervention 
characteristics   
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Table I-2. Domains and Constructs of the Consolidated Framework for Implementation Research 
(CFIR) 
CFIR 
Domains and 
Constructs  
Description 
Intervention -- Characteristics of the intervention such as complexity, cost, and relative 
advantage that influence adoption, implementation, etc. 
Intervention 
source 
Perception of key stakeholders about whether the intervention is externally or 
internally developed to solve a local problem and the legitimacy of the source 
(Greenhalgh, Robert, Macfarlane, Bate, & Kyriakidou, 2004). Externally 
developed interventions and lack of user input can lead to ineffective 
implementation (Helfrich, Weiner, McKinney, & Minasian, 2007; Kitson et al., 
2008; Klein, Conn, & Sorra, 2001). 
Evidence 
strength and 
quality 
Stakeholder's perceptions of the quality and validity of evidence that the 
intervention will have desired outcomes (Fitzgerald, Ferlie, & Hawkins, 2003). 
Although evidence to support the intervention is important and can increase the 
likelihood that it will be adopted (Kitson et al., 2008), evidence is typically not 
sufficient to ensure adoption, nor is it always a primary consideration when 
deciding whether to adopt an innovation (Denis, Hébert, Langley, Lozeau, & 
Trottier, 2002; Fitzgerald et al., 2003). 
Relative 
advantage 
Stakeholder beliefs about the benefits of UTS compared with the status quo or an 
alternative (Rogers, 2003). Relative advantage and observability are constructs 
from Diffusion of Innovations (Rogers, 2003). They are combined because 
benefits, if visible to the stakeholders, aid adoption and implementation (Denis et 
al., 2002; Feldstein & Glasgow, 2008; Greenhalgh et al., 2004; Grol & Grimshaw, 
2003; Grol, Bosch, Hulscher, Eccles, & Wensing, 2007).  
Adaptability Perceptions about whether and how an intervention can be tailored to meet 
specific needs or characteristics of an institution (Rogers, 2003). There are 
generally 'core components' that are necessary elements of the intervention and 
an 'adaptable periphery' (Greenhalgh et al., 2004). According to Diffusion of 
Innovations, programs that can easily be modified to are more likely to be 
adopted (Rogers, 2003).  
Trialability  Ability to test an intervention on a small scale and reverse implementation if 
warranted (Rogers, 2003). According to Diffusion of Innovations, trialability has a 
strong positive association with adoption (Greenhalgh et al., 2004; Rogers, 
2003). It also increases the likelihood of effective implementation because 
piloting provides experience that can be used to improve full scale 
implementation (Kitson et al., 2008)  
Complexity Perceived difficulty of implementation (duration, scope, radicalness, 
disruptiveness, centrality and number of steps required) (Rogers, 2003). 
According to Diffusion of Innovations complexity plays a critical role in the 
decision to adopt an innovation. In addition, simple interventions are more likely 
to be effective (Greenhalgh et al., 2004). Assessing complexity can also help in 
understanding and avoiding unintended consequences (Kochevar & Yano, 2006).  
Design quality 
and 
packaging 
Perceived excellence in how the intervention is presented/assembled (Grol et al., 
2007). When the quality of the intervention is perceived to be poor, it can evoke 
negative attitudes among users and decrease intervention use and effectiveness 
(Grol et al., 2007; Helfrich et al., 2007; K J Klein, Conn, & Sorra, 2001). 
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Table I-2 (continued). 
Costs Costs of the intervention as well as implementation costs (Rogers, 2003). Cost is 
a characteristic from Diffusion of Innovations and is negatively associated with 
adoption (Rogers, 2003; Teplensky, Pauly, Kimberly, Hillman, & Schwartz, 1995). 
Cost is also likely to influence how the intervention is implemented and its overall 
effectiveness. 
Outer setting - Economic, political, and social context in which an organization resides.  
Patient needs 
and resources 
The extent to which patient needs, barriers, and facilitators are accurately 
known and prioritized. (Feldstein & Glasgow, 2008; Graham & Logan, 2004). A 
number of implementation theories postulate that taking these issues into 
account will increase the chance that the intervention will be effective (Ferlie & 
Shortell, 2001; Kitson et al., 2008). Quality improvement initiatives have proven 
more successful if there has been a strong focus on the patients' needs (Ferlie 
& Shortell, 2001). 
Cosmo-
politanism 
Degree to which the organization is networked with other external institutions 
(i.e., social capital of the organization) (Greenhalgh et al., 2004). The degree of 
external networking increases the likelihood of implementing new practices 
quickly once advantages become apparent (Greenhalgh et al., 2004). 
Peer pressure Competitive pressure to implement an intervention (to either obtain a 
competitive edge or because other organizations already have implemented it) 
(Greenhalgh et al., 2004). There is strong evidence that peer pressure 
influences organizational adoption or programs / interventions / technologies 
(Greenhalgh et al., 2004). 
External 
policies and 
incentives 
External strategies to spread interventions (e.g., mandates, pay-for-
performance, political directives, recommendations, collaboratives) (Greenhalgh 
et al., 2004; Mendel, Meredith, Schoenbaum, Sherbourne, & Wells, 2008). 
Many times these strategies lead to adoption and increase effective 
implementation, but there are some exceptions (Greenhalgh et al., 2004; Grol et 
al., 2007; Klein & Sorra, 1996). 
Inner setting - Structural, political, and cultural contexts through which implementation 
proceeds. 
Structural 
characteristics 
Social architecture (i.e., how people are clustered into smaller groups and how 
actions are coordinated), age, maturity, and size of an organization 
(Damanpour, 1991; Greenhalgh et al., 2004). Several structural characteristics 
have been found to be significantly associated with implementation 
effectiveness, often with mixed results (Frambach & Schillewaert, 2002). A 
greater number of departments involved in decision making may slow down the 
process, but generally increases successful implementation (Damanpour, 1991; 
Greenhalgh et al., 2004).  
Networks and 
communication 
 
Nature, quality, and extent of social networks (social capital). Formal and 
informal communications within an organization (Greenhalgh et al., 2004; 
Helfrich et al., 2007). Coordination and teamwork across departments and 
specialties is typically important for effective implementation of programs or 
initiatives (Feldstein & Glasgow, 2008; Ferlie & Shortell, 2001). Clear role 
definitions and high quality communication increase the likelihood of success 
(Simpson & Dansereau, 2007).  
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Table I-2 (continued). 
Organizational 
Culture 
 
Norms, values and basic assumptions of a given organization (these are 
relatively stable, socially constructed, subconscious) (Gershon, Stone, Bakken, 
& Larson, 2004; Scott, Mannion, Davies, & Marshall, 2003). The ways in which 
culture is defined vary, but it has been shown to influence implementation 
effectiveness in complex ways (Helfrich et al., 2007; Scott et al., 2003). 
Organizations that emphasize or value flexibility over centralized control and 
those that value human relations and a supportive climate are expected to be 
more successful with implementation.  
Implementation 
climate 
 
Absorptive capacity for change, shared receptivity of those involved, extent to 
which involvement with the intervention is rewarded, supported, or expected 
within the organization. (Gershon et al., 2004; Greenhalgh et al., 2004; Klein & 
Sorra, 1996). Climate includes the following 6 sub-constructs: 
Tension for change – degree to which stakeholders perceive current situation as 
needing change.  
 
Compatibility – degree of fit between the meaning and values of the intervention 
and individual's and institution's values as well as fit with work flow and 
systems. Greater perceived fit = greater likelihood of adoption according to 
Diffusion of Innovations and empirical research (Greenhalgh et al., 2004; Klein 
& Sorra, 1996; Rogers, 2003).   
 
Relative priority – shared perception of how important implementation is. The 
higher the priority the more likely  it is to be successful (Helfrich et al., 2007). 
 
Organizational incentives/rewards – include but are not limited to goal-sharing 
awards, performance reviews, raises in salary, increased stature or respect. 
Strong incentives increase the likelihood of implementation success (Helfrich et 
al., 2007; Klein et al., 2001). The number of different types of incentives has 
been positively related to use of best practices by healthcare organizations 
(Shortell et al., 2001).  
 
Goals and feedback – Goals that are specific, incremental, and attainable 
increase effective implementation. Feedback has been shown to have small to 
moderate effects (Jamtvedt, Young, Kristoffersen, O'Brien, & Oxman, 2006). 
 
Learning climate – climate where leaders recognize they are fallible and need 
input, and team members feel their input is valued. This is hypothesized to 
influence the ability of an organization to fully assimilate an intervention 
(Greenhalgh et al., 2004). 
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Table I-2 (continued). 
Readiness for 
implementation 
Tangible and immediate indicators of organizational commitment to its decision 
(Greenhalgh et al., 2004; Kitson et al., 2008). This includes 3 sub-constructs. 
 
Leadership engagement – commitment, involvement, and accountability of 
managers. This is critical to successful implementation (Meyer & Goes, 1988). It 
leads to a stronger implementation climate (Helfrich et al., 2007; Klein, et al., 
2001). 
 
Available resources – level of resources implemented (i.e., money, time, space). 
The level of resources is positively associated with implementation, but does 
not guarantee success (Klein et al., 2001).  
 
Access to information and knowledge – Access to easy to use information about 
UTS and how to incorporate it is essential for successful implementation 
(Greenhalgh et al., 2004; Helfrich et al., 2007; K J Klein et al., 2001). Timely, on 
the job training (particularly if provided at a team level) contributes to success 
(Greenhalgh et al., 2004). This is also critical to get key stakeholders engaged 
(Grol et al., 2007). 
Individuals - Individuals in the inner or outer setting can promote or hinder the 
implementation process and alter program effectiveness. 
Knowledge 
and beliefs 
about the 
intervention 
Familiarity with principles related to the intervention and how-to knowledge as 
well as positive and negative attitudes about the intervention and value placed on 
the intervention (Klein & Sorra, 1996; Rogers, 2003). Principles and how-to 
knowledge are constructs from Diffusion of Innovations (Rogers, 2003).  Attitudes 
are key constructs in some theories that explain individual behavior change. 
Self-efficacy Individual belief in capability to execute behavior needed to achieve 
implementation goals. Perceived ability to perform a specific action within a 
specific context (Bandura, 1997). This construct is included in multiple theories of 
behavior change (Glanz, Rimer, & Viswanath, 2008) However, self-efficacy is 
originally attributed to Bandura.  
Individual 
stage of 
change 
Progression toward use of the intervention. Stage depends on the specific model 
used (i.e., Prochaska's Transtheoretical model, Roger's Diffusion of Innovations, 
etc) (Levesque, Cummins, Prochaska, & Prochaska, 2006; Prochaska & 
DiClemente, 1983; Rogers, 2003). 
Individual 
identification 
with the 
organization  
How individuals perceive the organization and their relationship and commitment 
to the organization ("AHRQ Innovations Exchange | Will It Work Here? A 
Decisionmaker's Guide to Adopting Innovations," ; Cropanzano, Rupp, & Byrne, 
2003). This can affect the willingness of individuals to fully engage in 
implementation efforts, but this construct has not been widely studied in health 
care settings. 
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Table I-2 (continued). 
Process - Include actions that lead to implementation, protocol and procedures, and 
ongoing reflection. 
Planning Degree to which the methods and tasks for implementation and evaluation are 
developed (Damanpour, 1991; Greenhalgh et al., 2004; Rogers, 2003). Although 
planning is generally necessary for implementing institutional programs 
(Greenhalgh et al., 2004), additional research is needed into how planning 
influences implementation effectiveness. 
Engaging Attracting and involving appropriate people in implementation using social 
marketing, education, role modeling, training, and other activities (“AHRQ 
Innovations Exchange | Will It Work Here? A Decisionmaker’s Guide to Adopting 
Innovations,” n.d.; Greenhalgh et al., 2004; Kitson et al., 2008). If implementation 
leaders are similar to intended users they are more likely to adopt the 
intervention (Greenhalgh et al., 2004). Chances of success are greater if all 
stakeholders are engaged early on in the process (Greenhalgh et al., 2004).  
Executing Carrying out the implementation according to plan (Carroll et al., 2007; 
Damanpour, 1991; Edmondson, Bohmer, & Pisano, 2001; Helfrich et al., 2007). 
In cases where there is not a plan, assessing execution is difficult. Execution 
quality may be related to the following: level of fidelity to the plan, intensity of 
implementation, timeliness of task completion, and degree of engagement of key 
stakeholders (Carroll et al., 2007; Edmondson et al., 2001). 
Reflecting 
and 
evaluating 
Quantitative and qualitative feedback about the progress and quality of 
implementation. Team debriefing and reflection ("AHRQ Innovations Exchange | 
Will It Work Here? A Decisionmaker's Guide to Adopting Innovations,").  
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Table I-3. Study Outcomes and Contextual Factors for Qualitative Comparative Analysis 
(QCA) 
Outcomes of Lynch Syndrome Universal Tumor Screening (LS UTS) 
1. The proportion of patients who screen positive and follow-through with genetic 
counseling and germline testing 
 
2. Unexpected problems, patient concerns, negative outcomes 
 
3. Problems with reimbursement for tumor screening 
 
Conditionsa that May Influence LS UTS Outcomes 
• Intervention Characteristics 
o Complexity 
o Costs 
• Outer Setting 
o Knowledge of patient needs and resources 
o Extent to which patient needs are considered 
• Inner Setting 
o Quality of communication within the organization, coordination across 
departments, and clearly defined roles 
o Degree to which implementation was supported 
• Process 
o Ability to attract and motivate the appropriate people necessary for 
implementation 
o How UTS was implemented (procedures/protocol) including: 
• screening method (IHC, MSI, both) 
• when and how positive results are given to patients 
• how results are tracked 
• whether a referral is necessary for patient to receive genetic 
counseling 
• Individuals involved 
o Attitudes, knowledge, and experiences regarding UTS 
o Who discloses positive tumor screening results and follows-up with patients 
o Who tracks results 
o Who discusses germline testing 
 
Note: aConditions are derived from the 5 domains of the Consolidated Framework for 
Implementation Research 
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SECTION II: IMPLEMENTATION EFFECTIVENESS OF UNIVERSAL TUMOR 
SCREENING FOR LYNCH SYNDROME 
Abstract 
Background: Universal tumor screening (UTS) of all newly diagnosed 
colorectal cancer (CRC) patients improves the identification of Lynch syndrome, 
the most common cause of hereditary CRC, and provides an opportunity for 
prevention and early detection of cancers. However, for UTS to be effective, a 
high proportion of patients who screen positive must pursue genetic counseling 
and germline testing (i.e., high patient reach).  
Objective: This study uses the RE-AIM framework to characterize UTS 
programs, identify barriers and facilitators to UTS implementation, document any 
negative outcomes, and identify implementation factors associated with different 
levels of patient reach. 
Methods: A web-based survey was conducted of 25 key contacts from 
institutions in the U.S. that were actively implementing UTS. Frequencies were 
used to identify similarities and differences among programs. Qualitative 
comparative analysis (QCA) of all 15 institutions where patient outcome data 
were available was performed to identify conditions uniquely associated with 
levels of patient reach. 
Results: All 5 high-reach (H-R) centers have genetics professionals 
disclose positive screening results and either do not require a referral from 
another health care provider or have streamlined the referral process. Although 2 
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of the 5 mid-reach (M-R) centers also share these conditions, they have a less 
automated UTS protocol and report difficulty contacting patients as a barrier. The 
3 remaining M-R centers and all 5 low-reach centers lacked all of the key 
conditions associated with H-R centers. 
Conclusions: Streamlining UTS procedures, eliminating key barriers, and 
incorporating a high level of involvement of genetics professionals is expected to 
improve patient reach. 
Introduction 
Colorectal cancer (CRC) is the third most common type of cancer and third 
leading cause of cancer-related death in the United States ("Colorectal Cancer 
Facts & Figures 2011-2013,"). Occurring in approximately 1 out of every 35 
patients with CRC, Lynch syndrome is the most common cause of hereditary 
CRC (Hampel et al., 2008). Lynch syndrome confers a 50-70% lifetime risk of 
CRC (Barrow et al., 2008; Hampel et al., 2005; Stoffel et al., 2009) , a 40-60% 
chance of endometrial cancer (Barrow et al., 2009; Hampel et al., 2005; Stoffel et 
al., 2009), and increased risks for several other malignancies (Barrow et al., 
2009; Watson et al., 2008).  
The significance of diagnosing Lynch syndrome for preventing cancers 
and improving health outcomes has been acknowledged in the following 
provisional Healthy People (HP) 2020 Genomics Objective: “Increase the 
proportion of persons with newly diagnosed colorectal cancer [CRC] who receive 
genetic testing to identify Lynch syndrome (or familial CRC syndromes)” 
(“Genomics - Healthy People”). Screening tumors from all newly diagnosed 
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patients with CRC has the potential to substantially improve the identification of 
Lynch syndrome; and reduce cancer incidence among at-risk family members 
("Recommendations from the EGAPP Working Group," 2009). Furthermore, 
several studies have demonstrated universal tumor screening (UTS) feasibility, 
efficacy, and theoretical cost-effectiveness (Gudgeon et al., 2011; Hampel et al., 
2008; Ladabaum et al., 2011; Morrison et al., 2011; Mvundura et al., 2010; Tranø 
et al., 2010).  
At least 35 institutions (i.e., cancer centers, hospitals) in the U.S. perform 
UTS, but screening methods vary across institutions (Beamer et al., 2012; 
Cohen, 2013). For example, microsatellite instability (MSI) testing and/or 
immunohistochemical (IHC) testing can be used as the initial screening method. 
Secondary screening tests using BRAF or hypermethylation can be performed on 
a sub-set of screen-positive tumors in order to reduce the need to follow-up with 
a proportion of screen-positive patients who do not likely have Lynch syndrome 
(Bellcross et al., 2012; Palomaki, McClain, Melillo, Hampel, & Thibodeau, 2009; 
"Recommendations from the EGAPP Working Group," 2009).  
Regardless of the screening protocol, UTS will only be successful if 
patients who screen positive subsequently undergo genetic counseling and 
germline testing. Genetic counseling is critical to help the patient understand the 
following: 1) Lynch syndrome substantially increases lifetime risks for several 
types of cancer; 2) family members could also have Lynch syndrome; and 3) 
successful prevention or early detection of cancers among patients with Lynch 
syndrome is possible through increased surveillance and surgical options. 
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Germline testing to identify the underlying gene mutation in a family allows other 
unaffected relatives to be tested for Lynch syndrome. The percentage of patients 
with a positive screen who follow-through with genetic counseling and germline 
testing (i.e., patient reach) is highly variable, differing by more than 50% across 
the few cancer centers for which data has been published (Heald et al., 2013; 
Lynch, 2011; South et al., 2009).  
Recognizing the need for additional research into the public health impact 
of UTS and desire to enhance the effectiveness of these efforts, the RE-AIM 
evaluation framework (Glasgow et al., 1999) was employed to conduct a 
multiple-case study of UTS programs. The RE-AIM framework aids in multi-level, 
comprehensive program evaluation through the identification of factors within five 
dimensions defined in the current study as follows:  
1) Reach - percentage of patients at an institution with a positive tumor 
screen who follow-through with genetic counseling and germline testing 
2) Efficacy - potential negative effects and unanticipated outcomes 
3) Adoption - reasons for performing UTS and characteristics of 
participating institutions that have adopted UTS 
4) Implementation - consistency of UTS delivery as well as adaptations 
made in various settings 
5) Maintenance - changes in the intervention and its effects over time.  
Subsequently, the objectives of this study were to: 1) quantify patient 
Reach at multiple different institutions that have implemented UTS; 2) identify 
negative or unanticipated outcomes of UTS (i.e., Effectiveness); 3) determine 
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reasons for UTS Adoption; 4) characterize similarities and differences in 
Implementation across institutions; 5) identify barriers and facilitators to 
Implementation; and 6) determine what conditions are associated with high and 
low patient Reach in order to characterize “best UTS practices. 
With regard to the sixth objective, the researchers hypothesized that high 
patient Reach would occur among programs that possess one or more 
combinations of the following conditions: 1) streamlined UTS procedures (i.e., 
implementation of automatic reflex testing, fewer steps need to be taken by 
patients in order to follow-up with genetic counseling and germline testing, and/or 
referrals from other health care providers are not a barrier); 2) direct involvement 
of genetic professionals in results disclosure and patient follow-up; and 3) 
support for implementation (i.e., facilitators outweigh barriers or challenges that 
were faced during implementation). Conversely, low patient reach was 
hypothesized to occur when one or more of these factors were not present.   
Methods 
Study Design 
After obtaining approval from the University's Institutional Review Board a 
multiple-case study was initiated in the fall of 2012. Data for the multiple-case 
study were obtained primarily from initial surveys of primary institutional 
representatives. In addition, data from follow-up surveys and interviews 
performed approximately six-months after the initial surveys were used to 
illustrate the RE-AIM dimension Maintenance and inform the interpretation of the 
findings. 
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Participant Recruitment and Procedures 
 Initial surveys of primary institutional representatives. Using the 
LSSN listserv, an e-mail invitation containing information about the study was 
directed to all primary representatives of the 35 institutional members of the 
Lynch Syndrome Screening Network (LSSN) that were performing universal 
tumor screening (UTS), and to approximately 27 institutional representatives that 
were in the process of actively planning or implementing UTS. Institutions that 
limit screening based on age or other criteria were not included in the study. 
Interested representatives who contacted the principal investigator (PI) and 
qualified for the study were asked to review the consent form, complete an online 
survey, and indicate whether they would be willing to be contacted in the future.   
Follow-up survey and interview with institutional representatives. 
Nearly six months after the baseline survey, all 15 participants from institutions 
that had been screening for more than six-months at the time of the initial survey 
and had access to patient reach data were sent a personal e-mail invitation and 
link to complete a follow-up survey designed to obtain patient reach updates, 
UTS protocol/procedural details or changes, and interest in participating in a 
follow-up interview.  
Interviews lasting an average of 50 minutes were conducted by the PI 
with10 of the 15 institutional representatives. Interview data was used to fill in 
missing details and to clarify discrepant information from the two surveys. During 
the interviews notes were taken by the PI and interviews were audio recorded in 
order for the PI to verify details as needed. At the end of the interviews 
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participants were asked to forward an invitation to participate in a brief interview 
or survey to other individuals at their institution who had been involved with UTS.   
Interviews with additional key personnel. Eight primary representatives 
agreed to forward an e-mail invitation to one or two individuals at their center. 
Brief 15-30 minute interviews were completed with three pathologists and one 
program director from four institutions and 45-60 minute interviews were 
completed with two individuals who could fill in missing details about 
implementation at a fifth institution.  
Measures 
Initial survey. The baseline survey was developed to collect information 
regarding: a) institutional characteristics; b) factors influencing UTS adoption; c) 
UTS protocol (including follow-up procedures); d) barriers and facilitators to UTS 
implementation; e) percentage of patients who follow-through with genetic 
counseling and germline testing after a positive screen; and f) barriers or 
facilitators to patient follow-through. The survey was reviewed for face and 
content validity by a medical geneticist, two genetic counselors, an 
epidemiologist, and a behavioral cancer scientist, all of whom were familiar with 
Lynch syndrome tumor screening. The revised survey included five open-ended 
questions and approximately 20 multi-part, closed-ended questions that also 
allowed participants to write in additional responses or details. The online survey 
was piloted by two genetic counselors and a nurse practitioner, all of whom were 
involved in setting up a UTS program for Lynch syndrome at their respective 
institutions.   
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Patient reach was operationalized using two survey questions that assessed 
the percentage of screen positive patients under the current institutional 
screening protocol who 1) pursue germline genetic testing and 2) receive genetic 
counseling. Response options were the same for both questions: 1 = <10%; 2 = 
11-25%; 3 = 26-40%; 4 = 41-55%; 5 = 56-70%; 6 = 71-85%; and  7 =>85%. 
Ordinal response categories for the two questions were averaged to create 
patient reach scores with a possible range from 1-7. After arranging cases in 
descending order by patient reach, the researchers identified two natural breaks 
and used these to categorize cases into the following three groups; “high-reach” 
(H-R); “mid-reach” (M-R); and “low-reach” (L-R).  
Follow-up survey. The follow-up survey was developed by the PI to help 
clarify responses from the initial survey, obtain additional details, and identify 
changes that may have occurred in patient reach and UTS protocol or 
procedures. The follow-up survey was reviewed for face and content validity by a 
medical geneticist, three genetic counselors, and a behavioral cancer scientist, 
all of whom were familiar with Lynch syndrome tumor screening.   
Interview guides. Semi-structured interview guides used for follow-up 
interviews included several open-ended questions about UTS implementation 
and experiences as well as several institution-specific questions designed to 
clarify and expand upon information collected from the surveys. The guides were 
tailored for each participating institution by the PI with input from a medical 
geneticist and experts in behavioral health research. A subset of relevant 
questions was selected by the PI for inclusion in interviews of other key 
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personnel based on their expertise and role in UTS implementation. 
Data Analysis 
Frequencies and percentages for responses to closed-ended survey 
questions were generated using an Excel spreadsheet. After grouping together 
eight centers where patient reach data were not available and stratifying the 
other fifteen centers according to patient reach, frequencies of responses to 
closed-ended questions were generated for each of the four groups. Open-ended 
survey and interview responses were categorized according to patient reach and 
then reviewed by the PI to identify commonalities and diversity in themes across 
centers for each of the RE-AIM dimensions.  
Qualitative comparative analysis (QCA) was used to test the study 
hypothesis and determine which combinations of factors were uniquely 
associated with high and low patient reach among the 15 centers where patient 
reach data were available. QCA is an analytic technique for performing cross-
case comparative analyses in order to systematically identify and simplify key 
factors (i.e., conditions) that are “sufficient” for an outcome of interest to occur 
(Ragin, 1989; Rihoux & Ragin, 2009). Although QCA is different from inferential 
statistics, conditions are analogous to independent variables that are 
hypothesized to influence the outcome of interest (i.e., patient reach).  
Conditions were coded for use in QCA as follows: 1=condition present; 
and 0=condition absent. Patient reach was coded into two variables as follows: 1) 
H-R=1 for all institutions with a patient reach score of 5 or above and H-R=0 for 
all other institutions; 2) L-R=1 for all institutions with a patient reach score of 2 or 
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below and L-R=0 for all other institutions.  Specialized software (fsQCA 2.0) was 
used to perform a sufficiency analysis using the truth table approach ("Citing 
fs/QCA 2.0,") in order to determine whether one or more combination of 
conditions are unique to centers that reported high patient reach (H-R). A 
separate sufficiency analysis was performed to determine combinations of 
conditions that are unique to centers reporting low patient reach (L-R). Steps 
used to perform QCA are included in Table II.1. 
Results 
Institutions and Participants 
Of the 35 health care providers who were serving as institutional 
representatives for the Lynch Syndrome Screening Network (LSSN) and worked 
at institutions that had implemented UTS, 20 (57%) responded to an e-mail 
invitation and provided baseline data via the online survey. An additional 3 
representatives from centers that were in the process of implementing UTS also 
completed relevant portions of the survey. Based on survey responses, 15 
institutions met the following a priori inclusion criteria for use in hypothesis 
testing: 1) UTS had been fully implemented for 6 months or longer at the time of 
the initial survey; and 2) data needed to determine patient reach were provided.  
All primary contact persons were genetic counselors, except for one 
physician who responded from an institution that was still in the process of 
implementing UTS. Table II-2 provides demographic characteristics of all 
participating institutions and lists these same characteristics after stratifying 
centers into four groups according to the availability of patient reach data. Four of 
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the five H-R institutions were academic/research centers that were designated by 
the National Cancer Institute (NCI) as either a comprehensive cancer center 
(CCC) or cancer center (CC). In contrast, three of the five M-R and three of the 
five L-R institutions were classified as non-academic institutions with only one 
classified as a NCI-CCC. Most institutions had been performing UTS for over one 
year as of October 2012. The total number of colorectal cancer patients screened 
and number of positive screens over a six month time period were highly variable 
across institutions (Table II-2). 
Patient Reach 
 Frequencies showing the percentages of patients who followed through 
with genetic counseling and with germline testing after a positive tumor screen 
are reported in Table II-3. There is wide variability on these two measures across 
centers, with no overlap between H-R and L-R institutions. 
Effectiveness  
 Patient concerns, unanticipated outcomes, or problems with 
reimbursement related to UTS rarely or sometimes occurred (Table II-3).  
Institutional representatives provided descriptions of these events in open-ended 
responses or follow-up interviews. For instance, one representative described 
how a couple of patients expressed surprise because they were unaware that 
tumor screening was part of the surgical informed consent they signed; and two 
representatives indicated that a few patients expressed concerns about their 
inability to pay for genetic counseling and/or germline testing. One representative 
also indicated that one patient did not really want the results but felt obliged to 
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follow-up on them and undergo germline testing. Unanticipated outcomes that 
were described included the need to plan for how to handle results from prison 
inmates or from patients who are deceased. Other challenges included how to 
follow-up when results are equivocal (i.e., partial loss of protein expression on 
IHC) or when results are atypical (i.e., absence of MLH1 and MSH6).   
A fair number of institutional representatives were uncertain whether 
reimbursement for tumor screening was an issue. However, in follow-up 
interviews, individuals at four centers where screening is performed on tumor 
resections indicated that there is usually no additional fee recovered for tumor 
screening because it is included as part of the overall costs that insurers 
reimburse as part of the inpatient surgery. At another institution where the 
protocol was changed so that tumor biopsies rather than tumor resections are 
screened, the pathologist indicated that because biopsies are performed as 
outpatient procedures, fees could be recovered.  
Reasons for UTS Adoption  
The most commonly identified reason for adopting UTS was to “improve 
the identification of individuals with Lynch syndrome”, followed by “to benefit 
relatives of patients with Lynch syndrome”. Several other reasons were also 
selected and are listed in Table II-4. None of the centers checked “to increase 
revenue” as a reason for adoption. The number of reasons checked by 
representatives varied, but there did not appear to be any consistent patterns or 
associations between reasons for adoption and patient reach. 
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Barriers and Facilitators to Implementation 
 Only three institutional representatives checked “no real barriers or 
challenges” when asked about barriers to implementing UTS at their institution 
(Table II-5). Interestingly, all three representatives reporting no barriers 
represented academic institutions, including two H-R centers and 1 L-R center. 
Concerns about informed consent and about screening costs or reimbursement 
were the most commonly cited barriers or challenges to implementation. Difficulty 
convincing key stakeholders why UTS is important, general lack of knowledge by 
key stakeholders, and communication barriers between stakeholders were 
reported by institutional representatives from several M-R and L-R centers as 
well as centers where outcomes data were not reported; in contrast, these were 
selected as barriers to implementation at the non-academic H-R center, but none 
of the other H-R centers. 
The most commonly cited facilitators to implementation were collaborative 
relationships that existed across departments, obtaining useful information from 
other centers that had implemented UTS, and having an institutional champion 
who worked hard to implement UTS (Table II-5). None of the institutional 
representatives reported having protected time for planning UTS. There were no 
apparent trends between implementation facilitators and patient reach.  However, 
all institutions except three L-R centers and the 1 non-academic H-R center 
reported a greater number of implementation facilitators than barriers/challenges. 
Heterogeneity in Implementation 
UTS protocols were found to be heterogeneous among the different 
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institutions (Table II-6). In reviewing the type of screening performed by each 
institution (IHC versus MSI), who orders the screening, where the screening is 
performed, or whether patients are consented or receive information prior to 
screening, no clear patterns seemed to distinguish centers with high or low 
patient reach. Most centers use immunohistochemical (IHC) testing in 
conjunction with automatic reflex testing (i.e. BRAF or hypermethylation) to help 
rule out Lynch syndrome in patients who screen positive on IHC (due to absence 
of the MLH1 protein), but do not need to follow-up with genetic counseling or 
germline testing unless their personal or family history would indicate otherwise.  
In contrast to screening protocols, follow-up procedures when patients 
have a positive tumor screen appeared to systematically differ by patient reach 
(Table II-7). With the exception of two L-R centers, a Master’s trained genetic 
counselor routinely receives information on patients who screen positive. In 
addition, all H-R centers routinely have genetic counselors disclose positive 
screening results to patients; two of the five M-R centers also have genetic 
counselors routinely disclose positive screening results to patients. In contrast, all 
L-R centers have various and even multiple types of non-genetics professionals 
disclose screening results. Additionally, all L-R centers and three M-R centers 
indicated that the primary mechanism by which germline testing is ordered 
required that the patient’s physician refer the patient for genetic counseling.  
Although none of the H-R centers indicated that referral was the primary 
mechanism by which germline testing is ordered, two H-R centers do have 
genetic counselors obtain referrals or enter referrals into the system on behalf of 
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the physicians.  
Differences in procedures for handling negative tumor screening results 
were also identified (Table II-8). Most centers include negative results as an 
addendum in the pathology report, but do not report these results to patients. 
Two centers send letters with results of negative screening to the patients. In 
their letters they include a list of clinical characteristics that may indicate a 
hereditary predisposition to cancer and recommend that patients see a genetic 
counselor if any of these pertain to the patient or their family. A few primary 
contact persons indicated that they will review negative screening results and 
contact physicians if patients are young (i.e., under age 40 or 50) or if medical 
records document any personal or family history features that might indicate a 
hereditary predisposition. 
System-level and Implementation Influences on Patient Reach  
Potential barriers to high patient reach. Barriers to patient follow-
through with genetic counseling or germline testing on closed-ended survey 
items are summarized in Table II-9. Lack of insurance or financial means to pay 
for genetic counseling or germline testing and patients are dealing with too many 
concerns at the time of diagnosis were the most commonly checked barriers by 
the institutional representatives. Only one H-R institution cited lack of referral as 
a barrier; and at this center other health professionals occasionally disclose 
positive screening results. Lack of patient referral was reported as a problem for 
all M-R and L-R centers except the 2 M-R centers where genetic counselors 
routinely disclose positive screening results. All L-R centers and over half of the 
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M-R centers reported lack of understanding about the importance of germline 
testing among health care providers as a barrier, but this was not cited as a 
barrier by any of the H-R centers. Difficulty contacting patients was cited as a 
barrier at three M-R centers including the two where a genetic counselor usually 
discloses positive screening results and a third where the genetic counselor 
contacts physicians to solicit referrals before following up with patients to arrange 
genetic counseling and germline testing. 
Potential facilitators for high patient reach. Due to the researchers’ 
uncertainty about potential facilitators to genetic counseling and germline testing, 
facilitators were assessed using two open-ended questions asking participants 
what they have found to help or what they think might help to increase patient 
follow-through with genetic counseling and germline testing. The majority of 
participants completed these open-ended questions; and their answers primarily 
consisted of ways to reduce key barriers. 
Two of the four H-R centers whose representative completed the question 
about genetic counseling facilitators identified that meeting the patients at 
another follow-up appointment (i.e. post-operative visit) was helpful; and the 
other two indicated that having the genetic counselor contact patients facilitates 
genetic counseling follow-through. The other H-R representative did not provide 
a comment. Two representatives from M-R centers commented that increasing 
the likelihood that physicians make referrals or that continuing education of 
physicians regarding the importance of genetic counseling and germline testing 
for patients with a positive screen would facilitate higher rates of patient follow-
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through with genetic counseling. All but one L-R center representative provided a 
comment; and their responses all indicated that genetic counselors need to 
contact patients directly and/or that physicians need more education on the 
importance of genetic counseling and germline testing.  
The only two H-R centers that commented on how to facilitate germline 
testing indicated that improved insurance would facilitate testing. One of the M-R 
centers again commented that physicians need more education. Another M-R 
center suggested that physicians need to stress to the patient why it is important 
that the patient follow-through when they make a referral. This respondent also 
mentioned the need for better insurance coverage to facilitate testing. All four L-R 
centers that responded to this question reiterated the need to get patients in for 
genetic counseling or have the genetic counselor contact patients directly.  
Implementation factors associated with high and low patient reach. 
The presence and absence of conditions hypothesized to be associated with high 
and/or low patient reach based on data from the initial survey are shown in Table 
II-10. Although patterns of configurations are discernible based on this table, 
QCA was used to systematically formulate concise solutions that show which 
conditions are uniquely and consistently associated with high patient reach as 
well as those associated with low patient reach. QCA solutions are listed as part 
of a results summary table (Table II-11).  
Maintenance at Six-month Follow-up 
Although results from the initial and follow-up surveys were largely 
consistent, several centers reported changes in patient reach at the six-month 
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follow-up. By far the most striking case was one L-R institution where Reach 
changed from 1.5 on the initial survey to 5 at six-month follow-up. This change in 
patient reach coincided with the initiation of automatic reflex testing to rule out 
some patients who did not need to be referred for genetic counseling because 
they were unlikely to have Lynch syndrome. Another explanation postulated by 
the primary representative for the increase in patient Reach included additional 
physician education that occurred over time and a subsequent increase in 
referrals. Although genetic counselors at this institution do not disclose screen-
positive results to patients, a genetic counselor routinely attends a bi-weekly 
case conference where each of the patients is discussed. At that time the 
counselor reminds physicians of the need for and importance of referral for 
patients with a positive tumor screen. Additionally, after the case conference, the 
genetic counselor mails and faxes letters to one or more of the patients’ treating 
physicians in order to reiterate what was discussed during the case conference 
and provide directions on how to complete the patient referral. Once a referral is 
received, the genetic counselor contacts the patients. Thus the genetic counselor 
is highly involved in follow-up with the physicians and patients, despite not 
disclosing positive screening results. 
No other institutions reported changes in their protocols since the initial 
survey. However three other institutions moved into or out of the M-R set due to 
relatively small changes in patient reach. The institution with the second highest 
patient reach score of the five original M-R centers shifted into the bottom of the 
H-R set at six-month follow-up. Interviews with the primary contact and two other 
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individuals involved with UTS at this institution suggested that their success may 
be due to the extensive efforts of the genetic counselor who requests referrals 
from one or more of the treating physicians for each patient with a positive 
screen. Although she does not disclose screening results directly to patients she 
reports typically being successful at obtaining a referral; she then calls the patient 
to arrange follow-up and explain the importance of counseling and germline 
testing. Additionally, it was clear from interviews that the genetic counselor, a key 
administrator, the pathologist, and many (if not most) physicians at this institution 
are supportive of UTS and have received a substantial amount of education 
about hereditary colorectal cancer from various sources including the genetic 
counselor, presentations at a regularly held multidisciplinary tumor board, and 
two representatives from a laboratory that offers germline testing for Lynch 
syndrome.  
This institution, along with the aforementioned L-R institution where patient 
reach improved after ensuring that BRAF reflex testing is automatic, both 
demonstrate that if the environment is supportive, physicians are well educated, 
and the genetic counselor takes on an extensive role to follow-up on all positive 
tumor screening results, then patient reach can be relatively high even when 
various different referring physicians disclose results of tumor screening to 
patients. Nevertheless, despite improvements, patient reach scores at these two 
centers remained lower than the six-month follow-up scores at the four academic 
H-R centers where genetic counselors routinely disclose positive results. 
The only H-R institution that is not an academic center reported a small 
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decrease in patient reach, changing from 5 to 4.5 at six-month follow-up. Upon 
interviewing the counselor at this institution, she indicated that her initial report of 
the percentage of patients with a positive screen who had genetic counseling 
was more reflective of the proportion of patients she talks to and offers genetic 
counseling, but some patients who are concerned about costs of genetic 
counseling, who have Medicaid (which does not cover the cost of genetic 
counseling in that state), or who lack insurance do not actually come in for 
genetic counseling even though she talks with them by phone. Furthermore, she 
reported that a couple of physicians do not always let her disclose positive tumor 
screening results to their patients. 
The last institution to be reclassified was originally at the very bottom of 
the M-R set in terms of patient reach. At six-month follow-up this institution would 
have been reclassified into the L-R group due to a small decrease in patient 
reach from 2.5 to 2. Notably, this institution did not share any of the 
characteristics associated with H-R centers. 
Results Summary and Proposed Model of High and Low Patient Reach 
Table II-11 provides a summary of study results within the RE-AIM 
framework. Consistent with the methodology employed in the multiple-case study 
(Ragin, 1989), QCA solutions in conjunction with substantive knowledge obtained 
at six-month follow-up were used to formulate a causal model to explain high and 
low patient reach. 
High patient reach. Institutions with high patient reach (H-R) have 
instituted a combination of procedures to streamline UTS protocols and 
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procedures, eliminate barriers to patient follow-through after a positive tumor 
screen, and incorporate a high level of involvement of genetic professionals in 
contacting physicians and/or patients. More specifically, H-R centers either do not 
require patients who have a positive screen to be referred by another health care 
provider for genetic counseling and germline testing or obtaining a referral is not 
reported as a barrier because genetic counselors contact physicians to request 
referrals as part of a standardized process that is agreed upon and/or supported 
by the physicians. The need for referrals presumably adds complexity to the 
procedures and causes patient reach to be highly contingent upon multiple 
different health care providers' knowledge about the importance of genetic 
counseling and germline testing as well as health care providers' actions to both 
convey this importance to the patient and to make a referral. 
In the current study, elimination of the need for referral altogether only 
occurred at centers where genetic professionals receive and disclose positive 
screening results to patients. This latter condition could be contributing to higher 
patient follow-through because direct patient contact allows the genetics 
professional to build rapport with the patients early on in the process and to 
convey to patients the importance of genetic counseling and germline testing. At 
four of the original H-R centers, disclosure of positive screening results was 
almost always performed by a master’s trained genetic counselor. However, at 
one H-R center, it has become increasingly common for patients to receive 
positive results disclosure by a nurse who is knowledgeable about Lynch 
syndrome, had years of experience working with and observing cancer genetic 
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counseling sessions, and was considered highly qualified by the genetic 
counselor.  
Even if a genetic counselor or someone knowledgeable and well-trained in 
cancer genetic counseling discloses positive screening results, patient reach is 
logically contingent upon successfully contacting the patients. In the current 
study, difficulties contacting patients were reported as a barrier to patient reach 
by the two M-R centers where genetic counselors usually disclosed positive 
tumor screening results to patients, but not at any H-R centers. Nevertheless, at 
six-month follow-up, representatives from H-R centers admitted that patient 
contact was occasionally a barrier or that patient contact used to pose a barrier; 
however, three of these centers helped to overcome this barrier by having a 
genetic counselor or nurse meet the patient at a follow-up appointment (i.e., 
surgical post-op appointment). Unfortunately this approach is not always feasible 
due to limited genetics personnel or at centers where follow-up appointments 
occur at several different locations that are not in close proximity to the 
counselors (i.e., private practices). Interestingly, physical distance between the 
locations of genetic counselors and post-op appointments was the impetus for 
having a nurse, rather than master’s trained genetic counselor, disclose positive 
screening results during post-op appointments at one of the original H-R centers.  
Additional reasons why certain institutions may experience difficulty with 
patient follow-through were elucidated during a follow-up interview with a genetic 
counselor who personally discloses positive screening results to patients by 
phone at one of the M-R institutions. Her institution is located in a 
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socioeconomically disadvantaged city where several patients do not even attend 
their post-operative appointments. Therefore, even if genetic counselors were 
available to meet patients at the post-op appointments, patient reach may 
continue to be problematic.   
Finally, automatic reflex testing streamlines the tumor screening process 
by eliminating the need to follow-up with a proportion of patients who do not likely 
have Lynch syndrome and by eliminating additional steps required to order reflex 
testing. The absence of automatic reflex testing may also partially explain why 
the two M-R centers where genetic counselors disclose results reported lower 
patient reach than H-R centers. 
Low patient reach. Conditions associated with low patient reach (L-R) 
provide additional insights into the potential relationships between 
implementation and patient reach. One of the two conditional configurations 
unique to L-R centers included the absence of having a genetics professional 
disclose the results of positive tumor screening to patients in combination with 
the presence of a higher ratio of implementation challenges compared to 
implementation facilitators. The latter condition may be indicative of several 
different types of organizational challenges or communication barriers that could 
inhibit high patient reach.  
Nevertheless, challenges during implementation are insufficient to prevent 
relatively high patient reach from eventually being achieved. Evidence for this 
comes from two participating institutions. The first is the non-academic center 
that was originally classified in the H-R set, but dropped into the M-R set at six-
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month follow-up. Despite facing a number of implementation challenges, UTS 
planning occurred during a period of over two years, several people worked very 
hard to implement UTS, and patient reach was relatively low when first 
implemented. Notably, two individuals from this institution commented that it 
takes time for physicians to really see the benefits of UTS and/or to agree to 
have the counselor disclose screening results to patients. Indeed a key 
difference between this center and the L-R centers is that the genetic counselor 
usually discloses screening results to patients. The other center that proves a 
high ratio of implementation challenges to facilitators does not prevent 
improvement in patient reach is the L-R center that was able to achieve relatively 
high patient reach at six-month follow-up after streamlining their protocol. 
As for the two academic L-R centers, neither of the representatives at 
these institutions reported experiencing more challenges than facilitators during 
the implementation process. However, these centers presumably have low 
patient reach because the genetic counselors do not routinely receive a list of 
patients who screen positive and they are subsequently unable to follow-up with 
physicians or patients. Interestingly, the representative at one of these two 
centers indicated in open-ended responses that patient follow-through was 
higher under her old protocol when she used to receive a list of patients who 
screened positive and could contact physicians to help ensure patients were 
referred. Unfortunately the protocol was changed due to concerns that were 
raised about patient privacy under the Health Insurance Portability and 
Accountability Act (i.e., HIPAA).   
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With the exception of these two L-R centers, all other institutional 
representatives reported receiving key information on patients who had a positive 
screen. A few of the representatives volunteered that they were given access to 
this information by making the argument that genetics was part of the healthcare 
team and/or that having one person review all results is critical for quality 
assurance or to reduce legal liability for the institution. Recognizing the legal 
liability issue, the L-R academic center that never provided patient results to the 
genetics program began doing so just prior to the six-month follow-up. At that 
time, the institutional representative confirmed that a number of patients had not 
been referred. Furthermore, in at least one case, the screening result had not 
been followed up on appropriately because BRAF testing had not been 
completed. Subsequently automatic BRAF testing was initiated along with 
changes that would allow the genetic counselor to disclose positive screening 
results and directly follow-up with patients. 
Discussion 
To our knowledge this is the first study to quantify and compare outcomes 
at multiple institutions that have implemented universal tumor screening (UTS) 
programs, whereby tumors from all newly diagnosed patients with colorectal 
cancer (CRC) are screened for Lynch syndrome. Two prior national surveys 
revealed heterogeneity in the implementation of Lynch syndrome tumor 
screening protocols across the U.S. and documented that a high proportion of 
centers reported problems with patients not following through with genetic 
counseling and germline testing after a positive screen (Beamer et al., 2012; 
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Cohen, 2013). Additionally, two centers have now independently reported data on 
their institutional experiences with UTS which revealed how patient reach 
increased following changes to their institutional follow-up procedures so that 
genetic counselors receive and disclose positive screening results to patients 
and take an active role to initiate genetic counseling and germline testing (Heald 
et al., 2013; Hampel, 2012).   
Despite the longitudinal experiences at these two institutions, whether or 
not genetic counselors received and disclosed the results of screen positive 
tumors was not correlated with whether or not problems with patient follow-
through were reported according to results from a recently published national 
survey of cancer genetic counselors (Cohen, 2013). Importantly, differences in 
patient follow-through were not quantified as part of that national survey and the 
bivariate statistical approach did not allow for the possibility that having genetic 
counselors disclose positive screening results was alone insufficient to prevent 
difficulties with patient follow-through.  
The current study expands upon these earlier studies and contributes 
uniquely to the literature by documenting wide institutional variation in patient 
reach and providing additional evidence for several key leverage points that are 
likely to improve patient reach. The current study also provides potential insights 
as to why a finding from the national survey by Cohen (2013) initially seemed 
contradictory to the longitudinal experiences that have been reported. More 
specifically, in the current study, genetic counselor disclosure of screen-positive 
results was indeed insufficient to ensure high patient reach. However, this did not 
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mean that the involvement of genetic counselors was unimportant. On the 
contrary, results from the current study suggest that the involvement of genetic 
counselors is part of a more complex recipe for achieving high patient reach; a 
recipe in which difficulties with patient contact and other barriers such as the 
need for a physician referral must be overcome.  
 There are several strengths to the current multiple-case study that support 
data credibility, reliability and validity (Baxter & Jack, 2008; Yin, 2008) Baxter. 
First, information gathered six months after the initial survey from institutional 
representatives at 13 of the 15 institutions enabled confirmation of initial survey 
results. In addition, member checks were initiated in which summaries of the 
institutional data were shared with institutional representatives and reviewed for 
accuracy during an interview or e-mail correspondence with 11 of the15 
institutional representatives. Almost all institutional representatives reported 
having good tracking systems in place and they were quite confident in the 
accuracy of the patient reach numbers they reported. However, there were a 
couple of centers where the representatives were not as confident in their 
numbers because they admitted that germline testing could be performed by a 
surgeon or oncologist without their knowledge. However, these representatives 
did not believe this was occurring regularly. 
One limitation of the study was the inability to verify or collect patient reach 
data in a systematic fashion and necessitated the reliance on numbers reported 
by each institutional representative. Other study limitations stemmed from an 
imperfect system of categorizing institutions into three patient reach groups as 
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well as fluctuations in patient reach that occurred over time. Nevertheless, with 
the exception of the center where the protocol changed, institutions remained in 
their classification group or there was limited movement of institutions into or out 
of the M-R group. Furthermore, evidence for the proposed model is supported by 
findings that M-R institutions with the highest patient reach shared more key 
characteristics of H-R centers, whereas M-R centers with the lowest patient 
reach tended to share features of L-R institutions.   
Additional limitations related to the measures used in the current study 
include the use of: data collected from a single individual at all but five of the 
institutions; conditions that were measured as either absent or present; and 
measures that failed to capture a number of nuances that distinguish between 
institutions. Additional data from open-ended survey responses and at six-month 
follow-up helped to elucidate some of these nuances. Thus, despite 
measurement limitations, general patterns of conditions associated with high and 
low patient reach among these cases remained evident in support of the 
proposed models. 
Although models generated from multiple case studies can serve as a 
“vehicle for generalizing results” (Yin, 2008; p. 40), the ability to generalize 
findings from this study may also be limited because the primary institutional 
representatives were all genetic counselors and a fair number of centers that 
participated in the current study are believed to be innovators and early adopters 
(Rogers, 2004). Thus, the conditions identified as being important for high patient 
reach in this study may not be feasible at all institutions and additional paths to 
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success may need to be identified or forged. Therefore other institutions that 
have achieved high patient reach should continue to be identified in order to 
confirm, revise, or add to the institution-level mechanisms identified to be 
associated with high patient reach in the current model.  
Although the study design limits the ability to assert causality, the “causal” 
model is strengthened given that two institutions have meticulously documented 
improvements in patient reach after implementing some of the same follow-up 
procedures identified to be important in the current study (Hampel, 2012, Leach 
et al, 2013). Furthermore, one representative from a L-R institution in the current 
study reported that patient follow-through was higher under her institution’s 
former protocol where she received results of positive screens and could follow-
up with physicians to help ensure a referral was made. Lastly, the L-R institution 
that improved patient reach substantially at six-month follow-up streamlined their 
procedures by instituting automatic reflex testing, thereby providing additional 
support for this component of the complex causal model associated with high 
patient reach. Together these experiences increase confidence that if institutions 
model their UTS program after the H-R institutions in this study they have greater 
odds of experiencing higher patient reach.  However, simply modeling UTS 
procedures after H-R institutions would not necessarily guarantee high patient 
reach, especially if the patient population is difficult to contact or has a high rate 
of uninsured or underinsured patients.  
Finally, data available for the current study did not allow us to account for 
the influence that differences in patient populations may have on patient reach. 
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Nevertheless, patient-level factors were identified in the current study as barriers 
to patient follow-through by institutional representatives, particularly those at 
centers with streamlined procedures, a high level of involvement in follow-up by 
genetic counselors, and removal of other system-level barriers. In order to 
determine the relative influence of patient-level versus system-level effects on 
patient outcomes, a large, multi-site effectiveness study that employs multilevel 
modeling should be undertaken. 
Utilization of the RE-AIM framework in planning, evaluating, and 
presenting findings from future studies are needed to provide a more complete 
assessment of the public health impact of UTS programs. Although RE-AIM 
aided in planning and summarizing results, the current study was not designed to 
fully characterize each RE-AIM dimension. For instance, practical considerations 
necessitated limiting the definition of patient reach even though the true public 
health impact of UTS lies in its ability to have broader reach through the 
identification of family members with Lynch syndrome. Additionally, the current 
study was not designed to assess the overall proportion or representativeness of 
all U.S. institutions that have adopted UTS. Subsequently, data on adoption 
using more representative sampling techniques is needed to determine the 
overall public health impact of UTS, confirm that a disproportionately high 
number of academic/ research institutions across the U.S. have adopted UTS as 
suggested by findings from two national surveys (Beamer, et al 2012; Cohen, 
2013), and determine whether those institutions that employ a master’s trained 
genetic counselor are also more likely to adopt UTS compared to other 
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institutions. This additional information on adoption would be useful because 
adoption patterns have the potential to increase disparities in the identification of 
hereditary cancer among certain geographic regions or minority populations.  
Conclusion 
 Universal screening of tumors from all newly diagnosed patients with 
colorectal cancer is a promising method to achieve the Healthy People 2020 
provisional objective: “Increase the proportion of persons with newly diagnosed 
colorectal cancer [CRC] who receive genetic testing to identify Lynch syndrome”. 
Current results provide evidence that universal tumor screening programs can be 
successful. In addition, the study provides a model based on empirical data from 
15 institutions that helps to further explain how implementation and system-level 
factors can influence patient reach. This information could be used to inform 
decision-making by stakeholders and potentially improve patient reach so that 
the long-term goal of reducing high levels of morbidity and mortality associated 
with hereditary cancer can be achieved.  
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Table II-1. Summary of Steps Used to Perform Crisp-set QCA 
csQCA steps Application of QCA steps in the current study 
Step 1: 
(a) Determine, define, 
and operationalize the 
outcome of interest  
 
(b) Assign 
dichotomous set 
membership scores for 
the outcome  
(a) Outcome =patient reach 
Defined as the percentage of patients who follow-through with genetic 
counseling and germline testing following an abnormal tumor screen at 
each institution. Operationalized based on two survey questions as 
described in the manuscript.  
(b) Cases naturally fell into three groups or sets: high-reach (H-R); mid-
reach (M-R); and low-reach (L-R). Cases with a patient reach score >5 
were included in the H-R set (coded as H-R=1).  All other cases were 
coded H-R=0 and are referred to with a tilde to indicate they are not in 
the high-reach set (i.e., ~H-R). For the second analysis, cases with a 
patient reach score <2 were coded as L-R=1 and all others as L-R=0. 
Step 2: Select Cases Several high-reach and several low-reach institutions were needed. 
However, to maximize both sample size and diversity in contextual 
variables, all available cases that met the minimum a priori inclusion 
criteria were used in the analysis.  
Step 3:  
(a) Identify key 
conditions  
 
(b) Assign 
dichotomous set 
membership scores for 
each condition 
 
(c) Create a data 
matrix of scores for 
conditions 
 
(a) Based on theory and knowledge of the cases, the following 
conditions were hypothesized to be associated with H-R when either 
present (+) or absent (-): 1) reflex testing on a subset of tumors is 
performed automatically to rule out patients with an initial positive 
screen who do not need genetic counseling and germline testing (+); 2) 
genetics professional discloses positive screening results to patients 
(+); 3) difficulty contacting patients was reported as a barrier (-); 4) 
referral from another health care provider was reported as the primary 
mechanism by which germline testing is conducted (-). Similarly, the 
following conditions hypothesized to be associated with  L-R when 
either present (+) or absent (-) were selected based on theory and 
knowledge of the cases: 1) number of barriers to implementation were 
> to number of facilitators (+); 2) genetics receives a copy of all positive 
screens (-); 3) genetics professional discloses positive screening 
results to patients (-); 4) referral is needed as a primary mechanism by 
which germline testing is ordered (+) 
(b) All of the conditions were already dichotomized as either present=1 
or absent=0 based on how they were asked as part of the survey. 
(c) A data matrix was created by listing membership scores for the 
outcome and key conditions for each case. 
Step 4: Determine 
whether conditions are 
necessary for the 
outcome 
None of the conditions were originally hypothesized to be necessary for 
either high patient reach or low patient reach. Thus, a necessary 
analysis was not conducted. 
Step 5: Determine 
whether certain 
conditions are sufficient 
for the outcome using 
the “truth table” 
approach  
Although not necessary for the presence of high or low patient reach, 
conditions may still be sufficient for the respective outcome either when 
occurring alone or in combination with other conditions. Using fsQCA 
2.0, two truth tables were created showing all possible configurations of 
conditions for each of the two selected outcomes (i.e., H-R and L-R). 
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Table II-1 (continued). 
Step 6: Examine the 
truth table and resolve 
contradictions 
No contradictions were identified. 
 
Step 7: Use computer 
software to generate 
solutions through 
multiple comparisons 
of case configurations 
in the truth table 
Using fsQCA 2.0 software, a “Standard Analysis” was performed to 
identify conditions associated with H-R and a second analysis was 
performed to identify conditions associated with L-R. This software 
uses the Quine-McCluskey algorithm (which is based on Boolean 
simplification) to make multiple comparisons of case configurations 
represented in the truth table and logically simplify the data. The idea 
behind this minimization procedure is that if two configurations differ in 
only one condition, yet produce the same outcome, then the condition 
that distinguishes the two configurations can be considered irrelevant 
to the outcome and removed to create a simpler expression.  
During this process, input from the researchers was required to select 
prime implicants and determine which simplifying assumptions were 
tenable. The software then used this information to generate three 
solutions (complex, parsimonious, and intermediate) with H-R as the 
outcome; and in a separate analysis three solutions were generated 
with L-R as the outcome. Only the intermediate or parsimonious 
solutions are shown in Table II-11. The other solutions are available 
from the primary author. 
Step 8: Determine if 
the influence of 
conditions is 
symmetrical 
To determine if conditions associated with H-R are the same as those 
associated with the absence of the outcome (~H-R), steps 4-6 were 
repeated using ~H-R as the outcome. Similarly, these steps were 
repeated using ~L-R as the outcome. 
Step 9: Evaluate the 
consistency and 
coverage of the 
solutions 
For each of the analyses for the four outcomes (H-R, L-R, ~H-R, and 
~L-R) the overall solution consistencies were 1; indicating that the 
respective combination of conditions were consistently associated with 
the respective outcome. For each analysis the overall coverage was 1; 
indicating that all of the cases with the presence of the outcome fit the 
solution. 
Step 10: Interpret the 
resulting solutions and 
create causal models 
Even when conditions are uniquely and consistently associated with an 
outcome, it does not necessarily mean they cause the outcome. 
However, these solutions in conjunction with theories, frameworks, and 
details about the cases can be used to develop a causal theoretical 
model that describes how the conditions might lead to the outcome. 
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Table II-2.  Demographic Characteristics of Institutions and their Respective Universal Tumor Screening 
(UTS) Programs 
Characteristics 
All   
institutions 
(N=23) 
H-R 
(n=5) 
M-R 
(n=5) 
L-R 
(n=5) 
Outcome 
not 
reported 
(n=8) 
n (%) n (%) n (%) n (%) n (%) 
Institution type       
 Academic / research institution 10 (44) 4 (80) 2 (40) 2 (40) 2 (25) 
 Non-academic  institution 13 (56) 1 (20) 3 (60) 3 (60) 6 (75) 
Designationsa       
 National Comprehensive 
Cancer Network Member 
4 (17) 2 (40) 1 (20) 1 (20) 0 (0) 
 NCI designated comprehensive 
cancer center 
6 (26) 3 (60) 2 (40) 1 (20) 0 (0) 
 NCI designated cancer center 2 (9) 1 (20) 0 (0) 0 (0) 1 (12.5) 
How long ago screening was 
initiated  
 
    
 Currently in the process  3 (13) 0 (0) 0 (0) 0 (0) 3 (37.5) 
 <3 months 1 (4) 0 (0) 0 (0) 0 (0) 1 (12.5) 
 3-5 months 1 (4) 0 (0) 0 (0) 0 (0) 1 (12.5) 
 6-12 months 5 (22) 0 (0) 2 (40) 2 (40) 1 (12.5) 
 >1 year 13 (54) 5 (100) 3 (60) 3 (60) 2 (25) 
# patients that have been screened 
in last 6 months or less if recently 
implemented UTS   
 
    
 <10 1 (4) 0 (0) 0 (0) 0 (0) 1 (12.5) 
 10-29 3 (13) 1 (20) 0 (0) 0 (0) 2 (25) 
 30-49 5 (22) 0 (0) 3 (60) 1 (20) 1 (12.5) 
 50-69 2 (9) 1 (20) 0 (0) 1 (20) 0 (0) 
 70-89 3 (13) 0 (0) 1 (20) 2 (40) 0 (0) 
 90-109 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 >110  5 (22) 3 (60) 0 (0) 1 (20) 1 (12.5) 
 Uncertain/ not applicable 
 
4 (17) 0 (0) 1 (20) 0 (0) 3 (37.5) 
# patients with a positive screen in 
last 6 months or less if recently 
implemented UTS   
 
    
 0 2 (9) 0 (0) 0 (0) 0 (0) 2 (25) 
 1-2 1 (4) 0 (0) 1 (20) 0 (0) 0 (0) 
 3-5 5 (22) 1 (20) 1 (20) 2 (40) 1 (12.5) 
 6-10 6 (26) 1 (20) 2 (40) 2 (40) 1 (12.5) 
 11-15 3 (13) 2 (40) 0 (0) 1 (20) 0 (0) 
 16-20 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 over 20  2 (9) 1 (20) 1 (20) 0 (0) 0 (0) 
 Uncertain / not applicable 
 
4 (17) 0 (0) 0 (0) 0 (0) 4 (50) 
 Notes: aNCCN and NCI designations are independent, but there is overlap and thus column 
percentages  
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Table II-3.  Patient Reacha and Effectiveness b  
Questions and response options 
All   
institutions 
(N=23) 
H-R 
(n=5) 
M-R 
(n=5) 
L-R 
(n=5) 
Outcome 
not 
reported* 
(n=8) 
% patients with positive screen 
that receive genetic counseling   
 
    
 <10%  5 (22) 0 (0) 1 (20) 4 (80) 0 (0) 
 11-25% 2 (9) 0 (0) 0 (0) 1 (20) 1 (12.5) 
 26-40% 1 (4) 0 (0) 1 (20) 0 (0) 0 (0) 
 41-55% 3 (13) 1 (20) 2 (40) 0 (0) 0 (0) 
 56-70% 2 (9) 1 (20) 1 (20) 0 (0) 0 (0) 
 71-85% 3 (13) 2 (40) 0 (0) 0 (0) 1 (12.5) 
 >85% 1 (4) 1 (20) 0 (0) 0 (0) 0 (0) 
 Uncertain / not applicable 
 
6 (26) 0 (0) 0 (0) 0 (0) 6 (75) 
% patients with a positive screen 
that pursue germline testing  
 
    
 <10% 5 (22) 0 (0) 0 (0) 5 (100) 0 (0) 
 11-25% 1 (4) 0 (0) 1 (20) 0 (0) 0 (0) 
 26-40% 4 (17) 0 (0) 3 (60) 0 (0) 1 (12.5) 
 41-55% 3 (13) 2 (20) 1 (20) 0 (0) 0 (0) 
 56-70% 1 (4) 1 (20) 0 (0) 0 (0) 0 (0) 
 71-85% 1 (4) 1 (20) 0 (0) 0 (0) 0 (0) 
 >85% 1 (4) 1 (20) 0 (0) 0 (0) 0 (0) 
 Uncertain / not applicable 
 
7 (30) 0 (0) 0 (0) 0 (0) 7 (87.5) 
Patients express concerns about 
UTS  
 
    
 Never 9 (39) 2 (40) 5 (100) 1 (20) 1 (12.5) 
 Rarely 3 (13) 3 (60) 0 (0) 0 (0) 0 (0) 
 Sometimes 1 (4) 0 (0) 0 (0) 0 (0) 1 (12.5) 
 Uncertain / not applicable 10 (43) 0 (0) 0 (0) 4 (60) 6 (75) 
Problems or unanticipated 
outcomes  
 
    
 Never 9 (39) 2 (40) 3 (60) 2 (40) 2 (25) 
 Rarely 6 (26) 2 (40) 1 (20) 2 (40) 1 (12.5) 
 Uncertain / not applicable 8 (35) 1 (20) 1 (20) 1 (20) 5 (62.5) 
Problems with reimbursement  for tumor 
screening  
    
 Never 5 (22) 1 (20) 2 (40) 0 (0) 2 (25) 
 Rarely 2 (9) 1 (20) 0 (0) 1 (20) 0 (0) 
 Uncertain / not applicable 16 (70) 3 (60) 3 (60) 4 (80) 6 (75) 
Notes: aPercentage of patients receiving genetic counseling and germline testing after a positive tumor 
screen. 
bNegative or unanticipated outcomes or problems related to universal tumor screening ( UTS). 
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Table II-4.  Reasons for Universal Tumor Screening (UTS) Adoption  
Survey question 
n (%)a 
All 
Institutions 
(N=22)b 
H-R 
(n=5) 
M-R 
(n=4) 
L-R 
(n=5) 
Outome not 
reported 
(n=8) 
 Recommended by EGAPP  15 (68) 3 (60) 4 (100) 3 (60) 5 (62.5) 
 Improve identification of patients with LS 21 (91) 5 (100) 4 (100) 5 (100) 7 (87.5) 
 Reduce cancer mortality 12 (55) 4 (80) 1 (25) 2 (40) 5 (62.5) 
 “Keep up” with other institutions 10 (45) 1 (25) 3 (75) 2 (40) 4 (50) 
 Generate increased revenue 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 Benefit relatives of patients with LS 17 (77) 5 (100) 3 (75) 4 (80) 5 (62.5) 
 Otherc  2 (9)  1 (25)  1 (12.5) 
Notes: aColumn percentages do not add to 100 because multiple options could be chosen. 
bOne primary contact person representing a M-R institution did not answer these questions because 
she was not involved in the program when UTS was first implemented. 
c
 Other included: “We felt it was becoming standard of care”; “Our umbrella organization recommended” 
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Table II-5.  Implementation Barriers and Facilitators 
Survey question 
n (%)a 
All 
Instituti
ons 
(N=22)
H-R 
(n=5) 
M-R 
(n=4) 
L-R 
(n=5) 
Outcome 
not 
reported 
(n=8) 
Implementation Barriers       
 No real barriers or challenges 3 (14) 2 (40) 0 (0) 1 (20) 0 (0) 
 Lack of stakeholder knowledge about LS 6 (27) 0 (0) 2 (50) 2 (40) 2 (25) 
 Concerns about reimbursement / costs 14 (64) 2 (40) 2 (50) 3 (60) 7 (87.5) 
 Difficulty deciding on screening method 4 (18) 0 (0) 0 (0) 2 (40) 2 (25) 
 Disagreement on how to handle results 3 (14) 0 (0) 1 (25) 2 (40) 0 (0) 
 Difficulty convincing key stakeholders why UTS 
is important 
9 (41) 0 (0) 1 (25) 1 (20) 7 (87.5) 
 Challenge to arrange time for stakeholders to 
meet 
12 (55) 2 (40) 2 (50) 2 (40) 6 (75) 
 Concerns about need for informed consent  16 (73) 3 (60) 2 (50) 4 (80) 7 (87.5) 
 One or more individuals tried to prevent UTS 1 (4.5) 1 (1) 0 (0) 0 (0) 0 (0) 
 Communication barriers existed between 
stakeholders 
7 (32) 0 (0) 1 (25) 2 (40) 4 (50) 
 Whether to include option to 'opt out' was 
debated 
6 (27) 1 (20) 1 (25) 2 (40) 2 (25) 
 Lack of laboratory expertise/resources 2 (9) 0 (0) 0 (0) 0 (0) 2 (25) 
 Perception that other screening method was 
better or more cost effective  
1 (4.5) 1 (20) 0 (0) 0 (0) 0 (0) 
 Otherc     1 (12.5) 
Implementation Facilitators       
 High risk multidisciplinary colorectal cancer clinicclnic 
 
5 (23) 2 (40) 0 (0) 1 (20) 2 (25) 
 Prior to UTS, already routinely screening a 
subset of tumors 
9 (41) 2 (40) 2 (50) 3 (60) 2 (25) 
 “Institutional champion” worked to implement 13 (59) 4 (80) 4 (100) 3 (60) 2 (25) 
 Collaborative relationships across departments 16 (73) 5 (100) 4 (100) 3 (60) 4 (50) 
 Support from high-level administrator or 
supervisor 
12 (55) 
 
2 (40) 3 (75) 3 (60) 4 (50) 
 Protected time provided for planning 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 Useful information obtained from other institution 14 (64) 3 (60) 3 (75) 4 (80) 4 (50) 
 Multiple planning meetings helped facilitate  10 (45) 2 (40) 2 (50) 3 (60) 3 (37.5) 
 Institution willing to try something new to 
improve patient care 
9 (41) 3 (60) 1 (25) 3 (60) 2 (25) 
Total # Barriers > Total # Facilitators  12 (55) 1 (20) 0 (0) 3 (60) 8 (100) 
Notes: aColumn percentages do not add to 100 because multiple options could be chosen. 
bOne primary contact person representing a M-R institution did not answer these questions because she 
was not involved in the program when UTS was first implemented. 
c
“Physicians did not realize that this had become a national and community care standard; our 
pathologists were under a spending freeze and not allowed to bring on new tests; concern about 
Medicare fraud and reimbursement in general; misunderstanding the cost of testing (physicians thought it 
was much higher than it is)” 
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Table II-6.  Variability in Tumor Screening Protocols 
 
All   
institutions 
(aN=22) 
H-R 
(n=5) 
M-R 
(n=5) 
L-R 
(n=5) 
Outcomes 
not 
reported 
(n=7) 
Type of tumors screened       
 Colorectal tumor biopsies 3 (14) 0 (0) 2 (40) 1 (20) 0 (0) 
 Colorectal tumor resections 12 (55) 5 2 (40) 2 (40) 3 (43) 
 Colorectal tumor biopsies and resections 7 (32) 0 (0) 1 (20) 2 (40) 4 (57) 
 Endometrial tumors 14 (64) 5 2 (40) 3 (60) 4 (57) 
Method of screening colorectal tumors      
 Immunohistochemical (IHC) testing  4 (18) 0 (0) 2 (40) 2 (40) 1 (14) 
 IHC with automatic reflex testing 14 (64) 4(80) 3 (60) 1 (20) 5 (71) 
 Microsatellite Instability (MSI) testing 1 (4.5) 0 (0) 0 (0) 0 (0) 1 (14) 
 MSI with automatic reflex testing 2 (9) 0 (0) 0 (0) 2 (40) 0 (0) 
 MSI then IHC with automatic reflex testing 1 (4.5) 1 (20) 0 (0) 0 (0) 0 (0) 
Who orders screening      
 Nobody, automatic 8 (36) 1 (20) 5 (100) 0 (0) 2 (29) 
 Pathologist 6 (27) 2 (40) 0 (0) 4 (80) 0 (0) 
 Surgeon 2 (9) 0 (0) 0 (0) 0 (0) 2 (29) 
 Genetic professional 1 (4.5) 1 (20) 0 (0) 0 (0) 0 (0) 
 Other / unknown 5 (23) 1 (20) 0 (0) 1 (20) 3 (43) 
Where screening is performed      
 Internal lab 15 (68) 3 (60) 4 (80) 4 (80) 4 (57) 
 External lab (send out) 6 (27) 2 (40) 1 (20) 0 (0) 3 (43) 
 Part internal and part external 1 (4.5) 0 (0) 0 (0) 1 (20) 0 (0) 
Prescreening information, consent, “opt out”      
 Information on screening provided to patient 
before results given (usually or always) 
6 (27) 2 (40) 2 (40) 0 (0) 2 (29) 
 Patient informed consent obtained before 
screening (verbal or written) 
5 (23) 1 (20) 1 (20) 0 (0) 3 (43) 
 Option to “opt out” provided 1 (4.5) 0 (0) 1 (20) 0 (0) 0 (0) 
 
Notes: aOne institution with no outcomes reported was still in the process of implementing UTS and 
had not determined their protocol or procedures. 
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Table II-7.  Variability in Follow-up Procedures when Patients Screen Positive for Lynch Syndrome 
 
All   
institutions 
(aN=22) 
H-R 
(n=5) 
M-R 
(n=5) 
L-R 
(n=5) 
Outcome
not 
reported 
(n=7) 
Who discloses positive screen       
     Genetics professional only 9 (41) 4 (80) 1 (20) 0 (0) 4 (57) 
     Both genetics and non-genetics  
     Professionals 
3 (14) 1 (20) 1 (20) 0 (0) 1 (14) 
     Non-genetics professional(s) only 10 (45) 0 (0) 3 (60) 5 (100) 2 (29) 
How positive results are usually disclosed      
     Telephone call 8 (36) 3 (60) 1 (20) 0 (0) 4 (57) 
     At patient visit 6 (28) 2 (40) 2 (40) 1 (20) 1 (14) 
     Unknown / up to non-genetics  
     Professional 
8 (36) 0 (0) 2 (40) 4 (80) 2 (29) 
Primary mechanism germline testing is 
ordered 
 
    
     Patient contacted directly by GC  8 (36) 3 (60) 1 (20) 0 (0) 4 (57) 
     Physician refers patient  10 (45) 0 (0) 3 (60) 5 (100) 2 (29) 
     Genetic counselor calls physician to  
     get referral or permission and then  
     contacts patient directly  
3 (14) 2 (40) 1 (20) 0 (0) 0 (0) 
     Unknown 1 (4.5) 0 (0) 0 (0) 0 (0) 1 (14) 
Who provides pretest discussion of 
germline testing 
 
    
     Genetics professional 18 (82) 5 (100) 4 (80) 5 (100) 5 (71) 
     Both genetics and non-genetics  
     Professionals 
3 (14) 0 (0) 1 (20) 0 (0) 2 (29) 
     Uncertain / not reported 1 (4.5) 0 (0) 0 (0) 0 (0) 0 (0) 
Notes: aOne institution with no outcomes reported was still in the process of implementing UTS and 
had not determined their protocol or procedures. 
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Table II-8. Variability in Follow-up Procedures when Patients Screen Negative 
 
All   
institutions 
(aN=22) 
H-R 
(n=5) 
M-R 
(n=5) 
L-R 
(n=5) 
Outcome 
not 
reported 
(n=7) 
How negative screening results are handled      
 Patients informed in a letter or follow-up 
visit 
3 (14) 1 (20) 1 (20) 0 (0) 1 (14) 
 Non-genetics professional informs patient 1 (4.5) 0 (0) 1 (20) 0 (0) 0 (0) 
 Up to ordering physician 1 (4.5) 0 (0) 0 (0) 1 (20) 0 (0) 
 Results included in pathology report or 
chart but patient is not informed 
15 (68) 4 (80) 3 (60) 4 (80) 4 (50) 
 Uncertain 2 (9) 0 (0) 0 (0) 0 (0) 2 (25) 
Protocol for high risk patients with negative 
screenb 
 
    
 Uncertain 3 (14) 0 (0) 1 (20) 0 (0) 2 (25) 
 Some patients are NOT identified as high 
risk 
6 (27) 1 (20) 2 (40) 3 (60) 0 (0) 
 No formal protocol exists 5 (23) 0 (0) 1 (20) 1 (20) 3 (43) 
 Protocol varies      
 
     According to physician 7 (32) 1 (20) 2 (40) 2 (40) 2 (25) 
 
     Depending on patient scenario 4 (18) 2 (40) 2 (40 0 (0) 0 (0) 
 Referred  to genetics      
 
     Usually 6 (27) 1 (20) 1 (20) 0 (0) 4 (57) 
 
     Sometimes  11 (50) 4 (80) 3 (60) 3 (60) 1 (12.5) 
 
     Rarely 1 (4.5) 0 (0) 0 (0) 0 (0) 1 (12.5) 
 Additional genetic screening or testing is 
considered 
     
 
     Often 4 (18) 1 (20) 1 (20) 0 (0) 2 (29) 
 
     Sometimes 9 (41) 4 (80) 2 (40) 3 (60) 0 (0) 
 
     Rarely 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 Otherc 3 (14) 0 (0) 2 (40) 0 (0) 1 (12.5) 
 
 
Notes: aOne institution with no outcomes reported was still in the process of implementing UTS and 
had not determined their protocol or procedures. 
bHigh risk patients typically have one or more of the following characteristics: cancer under age 40, 
multiple colon polyps, previous history of colorectal cancer or other cancers, multiple family members 
with colorectal or other cancers. 
cOther included the following: GC reviews pathology reports looking for other risk factors; The patient 
is encouraged to contact genetics if they have other red flags that are listed in the patient letter that is 
generated; addendum on path report re: IHC states to still refer pt to genetics if they are high risk. 
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Table II-9. Barriers to Genetic Counseling or Germline Testing Following a Positive Screen for Lynch 
Syndrome 
 
All   
institutions 
(aN=19)  
H-R 
(n=5) 
M-R 
(n=5) 
L-R 
(n=5) 
Outcome 
not 
reported  
(n=4) 
Patient lacks insurance / financial 
difficultiesb 
15 (79) 5 (100) 3 (60) 4 (80) 2 (50) 
Patient never referredb 12 (63) 1 (20) 3 (60) 5 (100) 3 (75) 
Healthcare provider fails to see 
importance of counseling/testingb 11 (58) 0 (0) 3 (60) 5 (100) 3 (75) 
Patients fail to see importance of 
counseling/testingb 13 (68) 4 (80) 3 (60) 2 (40) 4 (100) 
Inconvenient for patients to arrange a 
separate counseling appointment 6 (32) 2 (40) 3 (60) 1 (20) 0 (0) 
Inconvenient for patients to provide 
blood or saliva sample for testing 
 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Difficulty contacting patientsb 4 (21) 0 (0) 3 (60) 0 (0) 1 (25) 
Patients dealing with too many issues at 
initial diagnosisb 
 
15 (79) 4 (80) 4 (80) 3 (60) 4 (100) 
Patients don't want to face possibility of 
risks to familyb 8 (42) 0 (0) 3 (60) 3 (60) 2 (50) 
Patients are concerned about genetic 
discriminationb 
2 (10.5) 1 (20) 0 (0) 0 (0) 1 (25) 
Notes: aThree institutions have not started screening and one institution has had no positive screens. 
bTwo questions were combined so that centers are counted as yes if the representative indicated that the 
item was a barrier to germline testing OR was a barrier to genetic counseling. 
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Table II-10.  Data Matrix Depicting Patient Reach Scores and Conditions 
Institution 
Patient 
reach 
scorea 
# of 
barriers > # 
of 
facilitatorsb 
Automatic 
reflex 
testingb 
Genetics 
usually 
receives 
copy of all 
positive 
screening 
resultsb 
Genetics 
professional 
usually 
discloses 
positive 
screen 
resultb 
Difficulty 
contacting 
patients to 
arrange GC 
or germline 
testingb 
Physician 
refers 
patient for 
germline 
testingb  
High 
reach 
centers 
(H-R) 
 
  
 
   
 H1 6  X X X   
 H2 5.5 
 
X X X 
  
 H3 5 
 
X X X 
  
 H4 5 
 
X X X 
  
 H5 5 X X X X 
  
Mid reach 
centers 
(M-R) 
 
      
 M1 4 
  
X X X 
 
 M2 3.5 
 
X X 
 
X X 
 M3 3 
  
X X X 
 
 M4 3 
 
X X 
  
X 
 M5 2.5 
 
X X 
  
X 
Low reach 
centers 
(L-R) 
 
      
 L1 1.5 X 
 
X 
  
X 
 L2  1 
 
X 
   
X 
 L3  1 
     
X 
 L4 1 X 
 
X 
  
X 
 L5 1 X X X 
  
X 
Notes: aPatient reach was calculated by averaging the ordinal response options from two 
questions estimating the percentage of patients who follow-through with genetic counseling and 
percentage who follow-though with germline testing after a positive screen. 
bThe presence of each condition is indicated with a “X”.  
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Table II-11. Overall Findings from Applying the RE-AIM Framework 
RE-AIM 
Dimension 
Description 
General Findings  Findings specific to High-
Reach (H-R) 
Institutions 
Findings specific to Low-
Reach (L-R) 
Institutions 
Reach  
Percentage of 
screen positive 
patients  who 
follow-through 
with germline 
testing and 
genetic 
counseling 
• Patient Reach was highly 
variable across centers 
(ranging from <10% to 
>85%) 
• High and Low Patient 
Reach were consistently 
associated with specific 
combinations of 
conditions related to 
Implementation 
• Patient reach  
(>56-70%) 
• H-R centers have all of 
the following unique 
conditions based on 
results from QCA: 
 
1) Automatic reflex testing 
is performed on subset 
of screen positive  
tumors  
2)  genetic counselor (GC) 
discloses positive 
results  
3) contacting patients is 
NOT a major barrier 
4) obtaining a referral from 
physician is NOT a 
barrier 
• Patient reach  
(< 25%) 
• L-R centers have either of 
the following unique 
conditions based on QCA 
results: 
 
GC does NOT disclose 
results AND implementation 
barriers > facilitators 
 
OR 
 
GC does NOT receive 
screening results 
Effectiveness 
The impact of an 
intervention on 
outcomes 
(including 
potential 
negative effects) 
• Institutional 
representatives report 
patients rarely or never 
have expressed concerns 
related to UTS 
•  Challenges have been 
encountered at both H-R 
and L-R institutions 
• Only two centers reported 
rarely experiencing 
difficulties with 
reimbursement for tumor 
screening; others did not 
know or reported no 
reimbursement issues 
• H-R centers adapted to 
compensate when faced 
with challenges  
• Early on or prior to UTS, 
two H-R centers 
recognized that 
pathologists were doing 
screening on subset of 
patients, but physicians 
were neither reporting out 
the result to patients nor 
referring patients for 
genetic counseling 
 
• L-R centers reported 
difficulties with patient 
reach, and many reported 
challenges to making 
changes 
•  
Potential negative 
outcomes included: 
• Concern that failure to 
disclose results, refer to 
genetic counseling, or 
order germline testing is a 
liability for institutions 
and/or physicians  
• Concerns raised by one 
L-R center that reflex 
tests are interpreted 
incorrectly or not seen on 
pathology addendum 
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Table II-11 (continued). 
Adoption 
The absolute 
number, 
proportion, and 
representativene
ss of institutions 
and staff who 
currently offer a 
program 
 
Characteristics 
of intervention 
may increase the 
likelihood of 
adoption 
• Academic centers have 
previously been found to 
be more likely to adopt 
UTS (Beamer et al., 2012) 
• At most centers genetic 
counselors were the 
source of the idea for 
UTS, but multiple 
stakeholders were often 
involved in making the 
decision to adopt UTS. 
 
 
• Common reason for UTS 
adoption are to improve 
identification of Lynch 
syndrome patients and 
benefit family members 
• Cost was a key 
characteristic in the 
decision to adopt UTS 
• All but one of the five H-R 
institutions are academic 
/research institutions 
 
 
 
• Two of the five L-R 
centers are academic 
institutions 
 
Implementation 
Consistency of 
delivery, time 
and cost of the 
program, and 
what adaptations 
to the program 
are made in 
various settings. 
• Successful 
implementation required 
buy in from others 
besides genetic 
counselors.  
• Substantial heterogeneity 
in UTS implementation 
exists across institutions 
• Several of the differences 
are NOT consistently 
associated with patient 
reach including method of 
screening IHC versus 
MSI, and whether results 
are disclosed by phone or 
in person. 
• Common barriers and 
facilitators to 
implementation were 
identified (Table II-5) 
 
Several adaptations have 
been made to streamline the 
process and overcome 
barriers: 
• Automate reflex testing to 
reduce the number of 
patients needing 
counseling and germline 
testing 
• GCs disclose results 
• Eliminate the need for a 
referral from another 
health care provider 
entirely 
• Lack of referral overcome 
at a couple of H-R centers 
by GC actively contacting 
physicians to obtain 
permission to contact 
patient directly and log in 
the referral if needed 
• At least 3 H-R centers 
found that meeting the 
patient at a follow-up 
appointment was 
successful because it 
removes additional 
barriers. 
• The number of 
implementation barriers 
was greater than or equal 
to the number of 
facilitators for three of the 
L-R centers 
•  L-R center 
representatives want the 
ability to contact patients 
directly, but physicians are 
resistant. 
• L-R centers where GC 
actively solicits a referral 
from physicians are reliant 
on physician believing 
and expressing the 
importance of genetic 
counseling and germline 
testing to the patient. 
• Not logistically feasible for 
GCs to meet patients at 
follow-up appointments at 
some institutions. 
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Table II-11 (continued). 
Maintenance 
How the 
intervention and 
its effects 
changed over 
time. 
• Some centers have 
modified their protocol 
over time such as making 
BRAF or 
hypermethylation testing 
automatic in a subset of 
tumors.   
• Centers have also 
changed their follow-up 
procedures over time. 
 
• At least 3 H-R centers 
report having changed 
their procedures over time 
to streamline the process 
and increase involvement 
of GCs, which resulted in 
higher patient reach 
• Several L-R centers have 
run into barriers in trying 
to change their protocols 
or procedures 
• At least one L-R center 
has since changed their 
procedures as a result of 
the current study 
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SECTION III: QUALITATIVE COMPARATIVE ANALYSIS (QCA): A HYBRID 
METHOD FOR IDENTIFYING KEYS TO SUCCESSFUL PROGRAM 
IMPLEMENTATION 
Abstract 
Qualitative comparative analysis (QCA) is a hybrid analytic technique that 
combines elements of quantitative and qualitative research. Despite several 
relative advantages of QCA, this article illustrates that it has not been widely 
adopted by mixed methods researchers and has been slow to diffuse through 
health research channels. Applying the Diffusion of Innovations Theory, potential 
reasons for limited diffusion and adoption of QCA are explored. Finally, to reduce 
perceived complexity of QCA, data obtained as part of a multiple-case study is 
used to demonstrate how to perform QCA and illustrate several associated 
limitations and benefits. 
Introduction 
Use of what is still sometimes dichotomized into qualitative and 
quantitative research methods in complimentary or comparative ways has 
become widely accepted in several social science disciplines (Bazeley, 2009). In 
contrast, analytic techniques that fuse or blend qualitative and quantitative 
methods are not routinely utilized (Ragin, 1999). Qualitative comparative analysis 
(QCA) is a method developed by Charles Ragin over 25 years ago (Ragin, 1989) 
to bridge the qualitative and quantitative research gap. Although rooted within a 
qualitative research paradigm (Ragin, 1989), QCA takes a practical approach to 
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understanding complex, real-world situations and therefore may more accurately 
fall within what Morgan (2007) promotes as a pragmatic paradigm. QCA is a 
hybrid technique that cannot easily be dichotomized as either “qualitative” or 
“quantitative”, yet many criticisms that researchers have leveled at QCA originate 
from what researchers have referred to as the “paradigm wars” (Morgan, 
2007).Other criticisms are based on the perceived complexity or lack of relative 
advantage of QCA over other methods (Hawley, 2007).  
Despite criticisms QCA is extremely versatile. For example, researchers 
have used QCA to analyze both unstructured data (e.g., interview transcripts) 
and structured data (e.g., responses to closed-ended survey questions) (Kahwati 
et al., 2011; Shanahan, Vaisey, Erickson, & Smolen, 2008; Weiner, Jacobs, 
Minasian, & Good, 2012). In addition, QCA can be used to analyze small, 
medium, and large sample sizes. Furthermore, QCA has been used in 
conjunction with various types of research designs.  
Although QCA has many applications, it was initially developed for case 
study research in order to derive solutions that contain a list of one or more 
factors that when present or absent are uniquely associated with the presence or 
absence of an outcome. Other methods of performing multiple cross-case 
comparisons exist, but as the number of cases increases, systematic 
comparisons across multiple cases may not be logistically feasible without using 
QCA software. Additionally, journals that publish primarily “quantitative” research 
may look more favorably on QCA due to its mathematical approach and ability to 
quantitatively assess the overall merit of the solutions. 
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QCA may also be particularly useful in theory development and model 
building by determining which combinations of conditions are likely to be 
'necessary' and/or 'sufficient' for a particular outcome of interest to occur. For 
example, knowledge about a positive health behavior may be necessary, but it is 
rarely sufficient to ensure that individuals will perform the health behavior.  
According to the Health Belief Model (Janz & Becker, 1984), individuals often 
require a combination of the following factors in order to perform a positive health 
behavior: 1) knowledge about the behavior; 2) high level of perceived threat to 
their health if they fail to perform the behavior; 3) high-level of perceived benefits 
to performing the behavior; and 4) low-level of perceived barriers to performing 
the behavior. The ability to identify this type of “causal complexity” is one reason 
why QCA can be useful when generating or testing theoretical models (Ragin, 
1989).   
Structural equation modeling (SEM) is a more commonly used analytic 
technique that also allows researchers to incorporate multiple variables and test 
theoretical models. Although Hawley (2007) has argued that SEM would be 
easier to use than QCA, SEM requires large samples and the results are 
interpreted in a reductionist manner by considering the influence that one 
variable has on the outcome while holding all other variables in the model 
constant. Furthermore, unlike QCA, SEM and other inferential statistical analyses 
typically fail to consider the possibility of equifinality, whereby different 
combinations of factors can lead to the same outcome (Ragin, 1989; Rihoux & 
Ragin, 2009). For example, the combination of knowledge about how to perform 
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a behavior and a high level of perceived benefits may be sufficient to elicit a 
positive health behavior among a subset of women who do not face a particular 
barrier; however, additional or different factors may be needed to elicit the 
behavior among other individuals. If a key factor is relevant to the outcome for 
only a subset of individuals, the correlation between the factor and outcome is 
weakened, potentially causing what may be a key factor to be deemed 
insignificant if inferential statistics are used. Additionally, inferential statistics 
assume that the influence of variables is symmetrical even though factors that 
lead to the consistent performance of a health behavior may be different from 
factors that cause poor adherence to the behavior.   
Despite several relative advantages to QCA it remains unclear why this 
hybrid analytic technique has not diffused more widely across academic 
disciplines. In addition, the extent to which QCA has been adopted among 
various populations is not well documented. Thus, the first objective of this article 
is to describe QCA’s lack of both widespread diffusion through health research 
channels and adoption among mixed methods researchers. To achieve this 
objective, results are presented from a literature search of articles indexed by 
PubMed and articles published in the Journal of Mixed Methods Research. The 
second objective is to discuss several potential reasons for the slow diffusion and 
adoption rates of QCA. Subsequently, to promote the broader goal of active QCA 
dissemination, the final objective is to increase knowledge of QCA. To achieve 
the final objective we demonstrate how to perform QCA and illustrate several 
limitations and benefits of QCA using data obtained as part of a multiple-case 
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study. 
Diffusion and Adoption of QCA 
The index term “qualitative comparative analysis” was used for online 
searches of articles indexed by both PubMed and the Journal of Mixed Methods 
Research (JMMR). The abstracts of all articles that were retrieved after typing in 
the search term were reviewed. Several of the complete articles identified in 
PubMed and all of the articles identified in JMMR were reviewed. Articles were 
initially counted if the authors employed QCA in an original research study or 
illustrated the use of QCA using hypothetical data. However, to be more inclusive 
the literature search was extended to include any articles where the author(s) 
described or mentioned QCA.  
Only 25 articles meeting the original criteria had been indexed by PubMed 
as of March 2013. Of these, all but one reported data from an original study. After 
extending the criteria, an additional PubMed article was included. This article 
described QCA and other methods of synthesizing qualitative and quantitative 
evidence. No articles published in the Journal of Mixed Methods Research 
(JMMR) met the initial search criteria, but 7 met the expanded criteria. The single 
article in JMMR to focus solely on QCA was a book review by Hawley (2007). An 
additional six articles mentioned QCA during discussions on various topics 
including: integration in mixed methods research (Bazeley, 2009; Bazeley & 
Kemp, 2012); mixed research synthesis (Sandelowski, Voils, Leeman, & 
Crandell, 2012); triangulation strategies in Comparative Public Policy Research 
(Wolf, 2010); qualitative data analysis tools (Onwuegbuzie, Bustamante, & 
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Nelson, 2010); or data analysis as a process of interpretation (Van Ness, Fried, & 
Gill, 2011).  
Although limited in scope, this literature search substantiates the assertion 
that QCA has been slow to diffuse into health research. The findings also suggest 
that the rate at which QCA is being used in health research may be increasing 
over time. Support for this latter assertion comes from the finding that half of the 
QCA articles identified in PubMed were published between the years 2010 
through 2012; and nine of these articles were published after 2011.  
Diffusion of Innovations Theory (Rogers, 2003) provides several possible 
explanations for these findings. First, an innovation takes time to diffuse within 
and across social groups and the rate of diffusion is dependent on 
communication channels. QCA was developed in the late 1980's by Charles 
Ragin, a Sociologist who studies politics (Ragin, 1989). QCA therefore had to 
spread across members of those disciplines through a limited number of 
communication channels into other disciplines. Second, QCA is viewed by some 
researchers as being incompatible with the methodological paradigm to which 
they may still subscribe (Barbour, 1998). “Qualitative” researchers might view 
QCA as incompatible because it is based on Boolean algebra and a computer 
program is typically used to aid the researcher in identifying solutions which are 
then evaluated using quantitative measures of solution consistency and 
coverage. Whereas “quantitative” researchers may view QCA  as incompatible 
because it entails an iterative process of evaluating data, typically from a non-
random sample, and requires researchers to use their substantive knowledge of 
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the cases to make several 'subjective or interpretive' decisions at multiple points 
during the analysis (Rihoux & Ragin, 2009). Third, knowledge about how QCA 
works may be limited as there appear to be a relatively small number of 
researchers who have been trained to conduct QCA. Fourth, performing QCA 
was complex until computer software became widely available and automated 
much of the process. Nevertheless, Hawley (2007) has pointed out that the 
unique terminology used in QCA also makes learning this technique inherently 
difficult. Furthermore, additional complexities have arisen as researchers have 
developed several different types of QCA or other related configurational 
comparative techniques since QCA was first introduced (Rihoux & Ragin, 2009).   
Given that mixed methods researchers generally take a pragmatic approach 
that transcends the positivist/constructivist or quantitative/qualitative “paradigm 
wars” (Morgan, 2007), findings which suggested that few mixed methods 
researchers have adopted QCA were somewhat surprising. Hawley’s (2007) 
description of QCA in the book review published in JMMR suggests that high 
perceived complexity and lack of relative advantage over other techniques may 
explain the slow diffusion and low adoption rates. Therefore, to reduce 
complexity, the following section provides a stepwise account of how QCA was 
instrumental as an initial step in a multiple-case study designed to evaluate the 
implementation processes and effectiveness of universal tumor screening 
programs at several hospitals and cancer centers.  
Background on Universal Tumor Screening (UTS) for Lynch syndrome 
Occurring in approximately 1 out of every 35 patients with colorectal cancer 
 69 
 
(Hampel et. al., 2008), Lynch syndrome is the most common cause of hereditary 
colorectal cancer (CRC). The identification of Lynch syndrome among CRC 
patients and subsequently their family members is critical as Lynch syndrome 
confers a 50-70% lifetime risk of colorectal cancer (CRC) (Barrow et al., 2008; 
Hampel, Stephens, et al., 2005; E. Stoffel et al., 2009) as well as increased risks 
for secondary cancers and several other types of malignancies (Barrow et al., 
2009; Hampel, Stephens, et al., 2005; Stoffel et al., 2009; Watson et al., 2008).  
Universal tumor screening (UTS) is the process whereby tumors from all 
newly diagnosed CRC patients are screened to identify those patients who may 
have Lynch syndrome. Details about UTS have been described elsewhere 
(Bellcross et al., 2011). Over 35 cancer centers and hospitals across the U.S 
have implemented UTS, but substantial variability in protocols and procedures 
exist across institutions (Beamer et al., 2012; Cohen, 2013). Outcomes also vary 
across institutions as noted by large differences in patient reach, which is defined 
here as the percentage of patients with a positive screen who follow-through with 
genetic counseling and germline testing (Beamer et al., 2012; Lynch, 2011; South 
et al., 2009). In view of the fact that patient reach is critical to the successful 
identification of family members with Lynch syndrome and the prevention or early 
detection of cancers, a multiple-case study was initiated to identify institution-
level factors that might contribute to the wide variability in patient reach.  
Methods 
Study Design 
  A multiple-case study was initiated during the fall of 2012. The rationale 
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for employing  a multiple-case study design was based on the following (adapted 
from Yin, 2008): (a) the key objective was to provide a detailed understanding of 
a complex phenomenon (i.e. UTS program implementation and patient reach) for 
which there is limited data; (b) the purpose was to answer how and why 
questions; (c) the behavior of those involved could not be manipulated; and, (d) it 
was hypothesized that contextual conditions would be relevant to variations in 
patient outcome .  
Conceptual Framework 
The conceptual framework for the multiple-case study was based on the 
RE-AIM evaluation framework and the Consolidated Framework for 
Implementation Research (CFIR) (Damschroder et al., 2009; Glasgow et al., 
1999). The RE-AIM evaluation framework is comprised of five evaluation 
dimensions (Reach, Effectiveness, Adoption, Implementation, and Maintenance) 
that assist with identifying factors for multi-level comprehensive evaluations 
(Glasgow, Klesges, et al., 2006). In the current study the RE-AIM evaluation 
dimensions were defined as follows: 
• Reach: the percentage of patients with a positive tumor screen who follow-
through with genetic counseling and germline genetic testing. 
• Effectiveness: the impact of UTS on outcomes (including potential negative 
effects). 
• Adoption: the absolute number, proportion, and representativeness of 
institutions and staff who implement UTS. 
 71 
 
• Implementation: the consistency of delivery, time and cost of the UTS 
program and what adaptations are made in various settings 
• Maintenance: the effects of UTS over time with regard to both the institution 
and patients.  
RE-AIM was selected based on the expectation that it would increase the 
quality, speed, and impact of stakeholder efforts to more effectively translate 
universal tumor screening for Lynch syndrome into practice. The CFIR provided a 
framework for exploring factors within the Implementation dimension of RE-AIM 
in order to gain a detailed understanding of UTS implementation and identify 
factors that might influence patient reach. Table III-1 lists the five CFIR 
dimensions and several constructs within each (Damschroder et al., 2009). 
Study Participants  
Fifteen representatives for the Lynch Syndrome Screening Network 
(LSSN) who worked at institutions that perform UTS were recruited through the 
LSSN listserv. These participants completed an initial survey and met the 
minimum a priori inclusion criteria as follows: 1) institutions must have been 
performing Lynch syndrome screening on tumors from all newly diagnosed 
colorectal cancer (CRC) patients for at least six months; and 2) institutional data 
on patient follow-through with genetic counseling and genetic testing was shared 
by the institutional representative.  
Measures 
The initial online survey was developed using the RE-AIM and CFIR 
frameworks as well as the researchers’ knowledge of institutional variations in 
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UTS protocols. Information collected included: a) length of time UTS had been 
performed at the institution; b) details on the implementation process, protocol, 
and procedures (e.g., facilitators and barriers to implementation; method of 
screening; who receives and/or discloses positive screening results; who 
discusses germline testing with the patient; and when, where and how screening 
results are disclosed and germline testing is discussed); c) percentage of patients 
who undergo genetic counseling and percentage who undergo germline testing 
that were used to calculate the outcome (i.e., patient reach); and, d) additional 
factors within CFIR domains that may have helped facilitate or impede 
implementation or patient reach. 
Crisp-Set Qualitative Comparative Analysis (csQCA)  
  In the current study QCA was used to identify facilitators, barriers or other 
institution-level conditions that were unique to centers with high patient reach and 
those that were unique to centers that did not report high patient reach. Crisp-set 
QCA (csQCA) was chosen for two main reasons: 1) the conditions assessed as 
part of the survey were dichotomous; and 2) csQCA is simpler to perform and 
interpret than other QCA methods. Steps used to perform csQCA are 
summarized in Table III-2. These steps are somewhat fluid because QCA is an 
iterative process that allows for modifications as researchers gain additional 
information and insights into the cases. Briefly, steps 1-3 are needed to prepare 
data for use in QCA. Step 4 involves deciding which type of analyses to perform 
(i.e., necessary and/or sufficiency analyses). Steps 5-9 describe how to 
determine which conditions are sufficient for the outcome. Step 10 is the step in 
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which solutions are interpreted to propose “causal models”. 
Step 1: Outcome operationalization and set membership scoring. 
Patient reach was operationalized using two questions assessing the percentage 
of patients who follow-through with genetic counseling and percentage who 
follow-through with genetic testing. Response options were the same for both 
questions: 1 = <10%; 2 = 11-25%; 3 = 26-40%; 4 = 41-55%; 5 = 56-70%; 6 = 71-
85%; and  7 =>85%. The ordered categorical response options for the two 
questions were averaged to create a “patient reach” score ranging from 1-7. After 
arranging cases in descending order by patient reach, two natural breaks in 
patient reach scores were identified (Table III-3, column 1). The first 5 cases were 
grouped into a “high-reach” set (H-R), the second 5 cases into a “mid-reach” set 
(M-R) and the last 5 into a “low-reach” set (L-R). Natural breaks were chosen to 
ensure that cases with very similar values were grouped together in the H-R and 
L-R groups, as has been recommended (Rihoux & De Meur, 2009) 
One key limitation of cs-QCA is that all variables, including the outcome, 
need to be dichotomized so that the case either belongs to the set (dummy 
code=1) or does not belong to the set (dummy code=0). In the current study the 
threshold for inclusion in the H-R set was a patient reach score >5. All other 
cases did not belong in the H-R set. In QCA cases not in a set are referred to by 
placing a tilde before the abbreviation (i.e., ~H-R).   
Step 2: Case selection. Although QCA has been used to analyze data from 
random samples, it was developed to compare cases that are carefully selected 
using one of a number of different selection procedures (Gerring, 2007). In the 
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current study at least a few institutions with high patient reach and a few 
institutions with low patient reach were needed to determine why large 
discrepancies in patient reach might exist across institutions. To maximize both 
sample size and diversity in contextual variables, all cases that met minimal 
inclusion criteria were included and dichotomized according to membership in the 
H-R set. 
Step 3: Selection of key conditions. Although many CFIR constructs were 
measured to assist in gaining an in-depth understanding of each case, only a 
relatively small number of key factors could be used in QCA for two main 
reasons. First, the number of possible configurations increases exponentially 
according to an increase in the number of contextual variables; and this 
increases the likelihood that there will be a number of configurations for which 
there are no cases (i.e.,remainders). Second, when the ratio of conditions to 
cases is high, the probability of getting a solution that just by chance appears 
sound even when the model is misspecified increases (Marx & Dusa, 2011). 
Guidelines from a simulation study by Marx and Dusa (2011) were therefore 
followed by limiting analyses to no more than 4 conditions so that 
misspecification of the model would most likely lead to contradictory cases (i.e., 
cases with the same configuration of conditions, but different outcomes).  
In the current study, processes related to results disclosure and discussion of 
germline testing as well as the individuals involved with these processes were 
hypothesized to have the most direct influence on patient reach. As a first step in 
narrowing down the number of conditions to consider for QCA, a computer 
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spreadsheet of responses from each institutional representative was created by 
the researchers with cases organized from highest to lowest patient reach. 
Frequencies of responses were then generated for each reach category (i.e., H-
R, M-R, L-R). Each contextual factor was evaluated by the researchers in terms 
of how it might relate to patient reach independently or in combination with other 
factors. During the selection process the researchers created a data matrix 
(Table III-3) of membership scores for the factors considered for inclusion in 
QCA. The data matrix was then reviewed by the researchers to narrow down the 
list of conditions. This process consisted of a series of decisions described in 
more detail below whereby similar pairs of conditions were combined to create 
composite conditions (presented in Table III-3); and several conditions were then 
deleted from Table III-3. 
General differences between patient reach groups were found with regard to 
who discloses abnormal (positive) screening results to patients. All 
representatives of the H-R institutions reported that a genetics professional 
discloses abnormal screening results to patients. There were also two M-R 
institutions where a genetics professional discloses positive results. This 
condition was included in QCA and is referred to as (gen_prof_disclose_screen). 
How positive results were disclosed (i.e., by phone or at a follow-up visit) was 
mixed across the patient reach groups; and was subsequently deleted from the 
data matrix.  
Several conditions that could act as barriers to follow-through with genetic 
counseling and germline testing were also considered (Table III-3). Obtaining a 
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referral from a healthcare provider as the primary mechanism for the patient to 
receive germline testing was reported by most ~H-R institutions and was coded 
as (referral_barrier) for use in QCA. Similarities were noted in the pattern of 
responses for other barriers to genetic counseling and barriers to germline 
testing. Therefore analogous pairs of barriers were combined using the Boolean 
operator “OR”, which indicates Boolean addition. As an example, the new 
composite condition (difficulty_contact_pt) was “present” if (1) the institutional 
representatives indicated that difficulty contacting patients to set up genetic 
counseling was a barrier “OR” (2) that difficulty contacting patients to set up 
germline testing was a barrier. Whereas if neither of these barriers were reported, 
then the new composite condition was considered absent. Conditions used to 
create the composite barriers were maintained in the data matrix for possible 
inclusion in QCA. 
Nearly all institutions have genetics professionals provide pretest counseling 
prior to germline testing. Consequently, this condition was deleted from the data 
matrix because unless a condition varies, it cannot be associated with the 
outcome (Rioux ch 3). The revised data matrix contained three conditions 
selected for inclusion in QCA (gen_prof_disclose_screen, referral_barrier, and 
gen_directly_contacts_pt) as well as several additional barriers to consider 
including. Once complete, the principal investigator saved the data matrix (which 
was in an Excel spreadsheet) as a .csv file because this type of file can be 
opened and read by fsQCA2.0 software using the point and click FILE menu 
(“Citing fs/QCA,” n.d.). 
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Step 4: Decide which analyses to run. While the focus of QCA is often on 
identifying conditions that are sufficient for the presence of an outcome, 
researchers have suggested that sufficiency analysis be preceded by identifying 
potential necessary conditions (Schneider & Wagemann, 2010). A necessary 
condition is one that occurs in all cases that demonstrate the presence of the 
outcome. There are many instances where a theory or previous empirical 
observations would lead researchers to hypothesize that certain conditions may 
be either 1) necessary and sufficient for an outcome or 2) necessary but 
insufficient for an outcome. However, in the current study, none of the conditions 
were originally hypothesized to be necessary in all cases. Therefore, only 
analyses to determine sufficiency were performed. 
FsQCA 2.0 software developed by Charles Ragin was chosen to run the 
sufficiency analyses as it is freely available for download online at 
http://www.u.arizona.edu/~cragin/fsQCA. A manual detailing how to use this 
software is also available at the same website. However, to help decrease 
perceived complexity, basic steps performed in the current study are described 
below. Also, to reduce complexity, key terms are defined and illustrated 
throughout the step-by-step description, but QCA jargon is used sparingly.  
Step 5: Determine if conditions are sufficient. Using fsQCA software, 
“Truth Table Algorithm” was selected under the ANALYSE > Crisp sets menu. The 
outcome and conditions were chosen as prompted in the pop-up window before 
clicking the “run” button. The software then created a truth table similar to the 
replica in Table III-4. Each row of the truth table shows a configuration of 
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conditions and lists the number of cases that share that configuration. As is often 
the case, several configurations had no case examples (rows E-H); and these 
are called remainders (Rihoux & Ragin, 2009).  
Step 6: Examine the truth table and resolve contradictions. The objective 
when creating a truth table is to ensure that all cases that share a configuration 
also share the same outcome. The consistency score for each row indicates the 
proportion of cases in the respective configuration that belong to the H-R set (i.e., 
outcome is present). When the consistency is above .9 it indicates that the 
configuration of conditions is almost always associated with the presence of the 
outcome (Rihoux & Ragin, 2009). In the initial truth table (Table III-4) generated 
for the current study, rows A and B have consistency scores of 0.8 and 0.5, 
respectively. This suggests that these rows represent configurations where the 
outcome is inconsistent. Specifically, row A represents a configuration that is 
shared by 4 H-R cases and 1 M-R case; and row B represents a configuration 
that is shared by 1 H-R case and 1 M-R case. The need to resolve such 
contradictions often occurs in QCA (Marx & Dusa, 2011). Contradictions provide 
researchers an opportunity to gain additional understanding of the cases and 
serves as a mechanism for building models (Ragin, 2004). For example, 
contradictions could indicate that a key condition is missing from the model. 
To resolve the contradictions, the research team went back to the reduced 
data matrix to examine the cases and select another key barrier. Logic dictated 
that difficulty contacting patients after a positive screen (difficulty_contact_pt) 
would directly lower patient reach. Once this condition was added, the new truth 
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table contained no contradictions (Table III-5). The consistency scores for the first 
two configurations (rows A-B) were 1 and the consistency scores for the other 
configurations (rows C-F) were 0. Thus, the outcomes of the first two 
configurations (rows A-B) were coded 1 by the researchers and the outcomes of 
all the other configurations for which there were cases (rows C-F) were coded 0. 
Table III-5 does not show configurations (rows) for which there were no cases 
(i.e., remainders), as these configurations were deleted before running a 
standard analysis. 
Step 7: Use software to generate solutions. Although the final truth table 
(Table III-5) is quite revealing in terms of which contextual conditions are 
associated with high patient reach, it can be helpful to have the computer 
software generate three solutions (complex, parsimonious, and intermediate), 
particularly when truth tables are large, multiple different configurations are 
associated with the same outcome, or fuzzy-set QCA (in which outcomes and/or 
conditions are not dichotomized) is used instead of crisp-set QCA. As part of the 
current study, the researchers ran a “Standard Analysis” by clicking this option in 
the menu at the bottom of the window. The computer software used the Quine-
McCluskey algorithm (which is based on Boolean simplification) to make multiple 
comparisons of case configurations and logically simplify the data ("Citing fs/QCA 
2.0," ; Rihoux & Ragin, 2009). The idea behind this minimization procedure is 
that if two configurations differ in only one condition, yet produce the same 
outcome, then the condition that distinguishes the two configurations can be 
considered irrelevant to the outcome and removed to create a simpler 
 80 
 
expression.  
The fsQCA2.0 software determines three solutions with input from the 
researchers. The first is the complex solution, which is determined by the 
computer through minimizing only those configurations for which cases are 
available (i.e., remainders are not used to make simplifying assumptions). When 
there are multiple conditions or multiple configurations leading to the presence of 
the outcome, this solution may be so complex that it is not very useful. This is 
why the software generates a parsimonious and intermediate solution with input 
from the researchers.  
To determine the parsimonious solution, the software makes assumptions 
about what the outcome might be for the configurations that do not have cases 
(i.e., remainders) and uses these remainders to further simplify the expression. 
During the minimization process in the current study, a “prime implicant chart” 
appeared on the screen. A prime implicant chart appears when there are multiple 
ways of simplifying a solution. In order to obtain the most parsimonious solution, 
researchers must choose one prime implicant to cover each configuration in the 
chart. In the notation for prime implicants, the tilde (~) indicates the condition is 
absent. An asterisk (*) indicates Boolean “AND” (meaning that the conditions 
joined by * must both be present). The prime implicant chart in the current study 
showed that the configurations for the H-R cases could be simplified in two 
different ways: (a) ~referral_barrier * ~difficulty_contact_pt; or  (b) 
gen_prof_disclose_screen * ~difficulty_contact_pt. Despite an inability to make a 
compelling argument for choosing one prime implicant over the other, in the 
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current study the researchers chose the first prime implicant so that the software 
would continue the analysis. In some instances (such as the current study) the 
prime implicant chosen to create the parsimonious solution does not influence 
the researchers’ final interpretation because they will reject the parsimonious 
solution if they cannot use logic and knowledge of the topic to substantiate all of 
the simplifying assumptions upon which the parsimonious solution is based.  
Even though it is often the case that assumptions underlying the 
parsimonious solution cannot all be reasonably justified by the researchers, 
certain assumptions might be easy for the researchers to substantiate to create 
an intermediate solution; these are referred to as “easy counterfactuals”(Ragin, 
2004). As part of the analytic process, the computer software automatically opens 
another window so that researchers can decide which simplifying assumptions 
are reasonable. In order for the software to generate the intermediate solution in 
the current study, the following logic-based assumptions were selected: 
1. Absence of each barrier (i.e., ~difficulty_contact_pt and 
~referral_barrier) will contribute to high patient reach (H-R), but the 
presence of each barrier will not contribute to H-R. 
2. Involvement of a genetic professional in the disclosure of screening 
results (gen_prof_disclose_screen) and in directly contacting the 
patient to arrange genetic counseling and testing 
(gen_directly_contacts_pt) will contribute to high patient reach, while 
lack of involvement by genetics professionals will not be associated 
with H-R. 
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Step 8: Determine if the influence of conditions is symmetrical. The 
combinations of factors that are associated with high patient reach may differ 
from those associated with less successful outcomes. In the real world there are 
often more pathways that lead to the failure of a health program than there are 
leading to successful programs. Because QCA is not based on correlations, it 
does not assume that conditions will have a symmetrical influence. To illustrate 
this point, QCA steps 4-6 were repeated using the absence of high patient reach 
(~HR) as the outcome. During this analytic process the latter of the following two 
prime implicants was chosen to be consistent with the initial analysis: (a) 
~gen_prof_disclose_screen or (b) referral_barrier. Assumptions made to 
generate the intermediate solution were the inverse of the assumptions chosen 
for the first analysis (i.e., presence of barriers would contribute to ~H-R, and 
absence of involvement by genetics professionals would contribute to ~H-R).  
Step 9: Evaluate consistency and coverage scores for the solutions. 
Consistency and coverage are interpreted differently when determining whether 
conditions are necessary versus when determining if they are sufficient. When 
performing sufficiency analyses, solution consistency should be close to 1 in 
order for researchers to conclude that the combination(s) of conditions in the 
solution is(are) almost always associated with the outcome of interest (Ragin, 
2004). A solution coverage of 1 indicates that all cases with the outcome of 
interest are represented or covered by at least one of the combinations of 
conditions in the solution. When there are multiple combinations of conditions 
within a solution, raw and unique coverage can be used by the researcher to 
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assess the importance of each combination of conditions and the extent to which 
a case is covered by more than one combination of conditions.  
Step 10: Interpret the resulting solutions and create causal models. 
Even if conditions are consistently associated with an outcome, it does not mean 
they cause the outcome. However, researchers can use solutions in conjunction 
with theory, conceptual frameworks, and detailed knowledge about the cases to 
develop causal models that help unpack potential mechanisms leading to the 
outcome (Ragin, 2004). In the current study the researchers used their 
substantive knowledge of UTS and theoretical framework (CFIR) to interpret the 
solutions and piece together key conditions to create tentative models that were 
intended to be modified as additional details about the cases were obtained.  
Results 
Table III-6 lists the complex, parsimonious, and intermediate solutions 
from the first csQCA analysis performed to determine institutional and 
implementation conditions associated with high patient reach (H-R). The 
parsimonious solution was rejected because all of the simplifying assumptions 
could not be substantiated. The model was based on the intermediate solution, 
which in this case, happened to be the same as the complex solution. This 
intermediate solution is interpreted as meaning that all of the following three 
conditions are together sufficient for high patient reach: 1) a genetics 
professional discloses the results of positive tumor screening to patients; AND 2) 
a referral from another health care provider is not the primary mechanism for the 
patient to receive testing; AND 3) difficulty contacting patients is not a barrier. 
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This combination of three conditions is unique only to the H-R cases, which is 
why the consistency score is 1. The coverage score of 1 verifies that that this 
combination of three conditions characterizes (covers) all 5 cases that belong to 
the H-R set.  
 The bottom of Table III-7 presents all three solutions for the absence of the 
outcome (i.e.,~H-R). The three solutions were all different; thus, the causal model 
was based on the intermediate solution because it was not too simple, but made 
more logical sense than the complex solution. The intermediate solution for 
absence of high reach (~H-R) revealed two distinct sets of conditions that were 
both associated with the absence of the outcome (Table III-6). The intermediate 
solution can be interpreted as meaning that difficulty contacting patients who 
screen positive is sufficient but not necessary to prevent high patient reach. 
Alternatively the following three conditions are together sufficient to prevent high 
patient reach: genetic professionals do not disclose positive screening results, 
AND genetic counselors do not contact patients directly to arrange genetic 
counseling and testing, AND health care provider referral is the key mechanism 
for patients to receive genetic testing. The consistency of the intermediate 
solution was 1, indicating there were no contradictory cases. The coverage score 
of 1 indicates that all cases without high-reach (~H-R ) fit one or both of the 
combinations in the solution. The raw coverage for the first configuration (i.e., 
difficulty contacting patients) was 0.3, indicating that the presence of this barrier 
distinguished 3 of the 10 ~H-R cases from the H-R cases. The unique coverage 
for this configuration was lower (0.2) because 1 of the 3 institutions with difficulty 
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contacting patients also shared the second combination of conditions that 
uniquely covered the other ~H-R cases (Table III-6).  
Discussion 
QCA was used as part of a multiple-case study to formulate tentative 
causal models explaining high variability in patient reach across institutions that 
have implemented a universal tumor screening program. Nevertheless, models 
may be overly simplistic; and findings do not preclude the possibility that other 
combinations of factors could lead to high patient reach at institutions that were 
not part of the current study. Indeed one advantage of QCA is that it can identify 
multiple different “recipes” for success. Subsequently, as more information about 
each institution is obtained and additional cases are identified it is likely that the 
model will be expanded and modified.  
QCA was also useful in identifying additional research questions to be 
explored as part of the ongoing multiple-case study. For example, why did 
representatives from the five high-reach centers report no difficulty contacting 
patients or obtaining a referral from a health care provider? In addition, what may 
prevent stakeholders at low or mid-reach centers from: (a) altering the UTS 
procedures so that genetics professionals contact patients to disclose positive 
screening results; and (b) eliminating the need for a referral? Insights gained 
from QCA have informed the creation of semi-structured interview guides and 
follow-up surveys to answer further questions that were identified during the 
process of QCA, obtain information on the nuanced differences between UTS 
programs at different institutions, and possibly reveal other key conditions that 
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may contribute to patient reach as part of a continuing iterative process to better 
understand how implementation factors influence patient reach. 
Many criticisms that researchers have leveled at QCA originate from what 
Morgan (2007) referred to as the “paradigm wars”. For instance, researchers who 
view QCA using a “quantitative” lens might consider performing multiple analyses 
on the same data to be problematic. However, multiple analyses are consistent 
with the iterative nature of QCA. Furthermore, determining which factors are 
associated with both the presence and absence of the outcome is considered 
good practice by QCA researchers (Schneider & Wagemann, 2010) as it can 
provide broader or more in depth insights into the underlying mechanisms and 
can add to the credibility of the proposed models. Several other concerns that 
critics raise such as the use of purposive sampling and the iterative nature of 
QCA are also unproductive from a pragmatic perspective. Nevertheless, several 
more practical limitations are worth mentioning.  
 One limitation of QCA is the potential for measurement error and case 
misclassification. The current study was based on data that were self-reported by 
a single individual from each institution and may contain inaccuracies or bias. 
Furthermore, the use of natural breaks for set membership scoring does not 
prevent the possibility of misclassification. For example, an open-ended survey 
response from the institutional representative of a mid-reach (M-R) center 
revealed that this institution may instead belong in the high-reach (H-R) set due 
to a unique difference in this institution’s protocol that may have led to an 
underestimation of patient reach. This institution had the highest patient reach 
 87 
 
among the M-R set and was similar to H-R institutions in several ways. However, 
the representative reported difficulty contacting patients as a barrier. Given that 
difficulty contacting patients was sufficient to prevent H-R under the current 
model, reclassification of this institution into the H-R set would unveil a 
contradiction that would need to be resolved through modifications to the model 
based on additional information. For instance, it is possible that the genetic 
professional at this M-R institution has relatively few difficulties contacting 
patients. Unfortunately, the extent to which patient contact is difficult was not 
captured in the survey measure.  
The measurement issue described above illustrates a limitation of crisp-
set QCA, whereby conditions and outcomes must be dichotomized. In contrast, 
fuzzy-set QCA overcomes this limitation by allowing the researcher to code the 
outcome and/or conditions on a calibrated scale from 0 to 1. This fuzzy-score 
represents the extent to which a case falls within the set rather than being fully in 
or fully out of a set (Rihoux & Ragin, 2009). The resulting advantages of fsQCA 
over csQCA include the ability to maintain variation and to more accurately 
represent social reality when outcomes and/or conditions are not truly 
dichotomous. Although bias and measurement error may remain a concern, 
using fsQCA may lead the researcher to assign a set membership score that is 
off by only a small degree rather than misclassifying it into the opposing set; and 
this is expected to have a smaller impact on the results. Unfortunately, the 
advantages of fsQCA also make it more complicated than csQCA. 
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Conclusion 
 Although rooted in a qualitative paradigm, QCA may appeal to researchers 
or journal editors that prefer “quantitative” methods because QCA: (a) takes a 
logical and mathematical approach; (b) can be used to analyze small, medium, 
and large data sets; (c) provides a tool for identifying causal complexity and 
equifinality; (d) allows the researcher to generate solutions (with the aid of a 
computer program); and (e) calculates measures to evaluate the merit of the 
solutions (i.e., solution consistency and coverage). Given that QCA confers 
several advantages over other techniques, one of the purposes of this article is to 
encourage its active diffusion across mixed methods research channels. This 
article has attempted to reduce perceived complexity of QCA by illustrating how 
to perform the simplest type of QCA (i.e., crisp-set QCA). The example presented 
here demonstrated how QCA aids in systematically identifying and simplifying 
key factors (i.e., conditions) that are uniquely associated with an outcome of 
interest. Although the use of cross-sectional data inhibits the ability to 
demonstrate causation, QCA provides solutions that researchers can use to 
propose logical mechanisms by which key factors may act together to facilitate or 
impede outcomes. The iterative nature of QCA allows the researcher to gain an 
in-depth understanding of multiple cases and alter “causal” models as additional 
information is discovered. 
 QCA and other techniques that fuse qualitative and quantitative methods 
(Bazeley, 1999) provide an opportunity to help in bridging the gap that “paradigm 
wars” have created. Ultimately, we believe researchers should first consider how 
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resources or other factors may limit the type of data they can feasibly obtain to 
answer their research questions and then choose one or more of a wide variety 
of analytic tools based on how well-suited the tools are for answering their 
specific research questions. To that end, QCA is another tool that mixed methods 
researchers may find useful. 
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Table III-1. Five Domains of the Consolidated Framework for Implementation Research 
(CFIR) 
CFIR Domain Description and Examples of Associated Constructs 
Intervention  Characteristics of the intervention such as complexity, cost, and relative 
advantage. 
Inner setting Structural, political, and cultural contexts through which implementation 
proceeds. Includes organizational structure, social architecture, 
communication/networks, and implementation climate & readiness. 
Outer Setting Economic, political, and social context in which an organization resides. 
Includes the extent to which the organization has an accurate knowledge 
of patient needs, billing & reimbursement, funding constraints, and ties to 
external organizations. 
Individuals 
involved 
Individuals in the inner or outer setting can promote the implementation 
process and alter program effectiveness via their actions which are 
influenced by motivations, attitudes, etc. 
Implementation 
Process 
Processes include actions that lead to implementation, protocol and 
procedures, and ongoing reflection.  
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Table III-2. Summary of Steps Used to Perform Crisp-set Qualitative Comparative Analysis 
(csQCA) 
csQCA steps Application of QCA steps in the current study 
Step 1: 
(a) Determine, define, 
and operationalize the 
outcome of interest  
(b) Assign 
dichotomous set 
membership scores for 
the outcome  
(a) Outcome =patient reach 
Defined as the percentage of patients who follow-through with genetic 
counseling and germline testing following an abnormal tumor screen at 
each institution. Operationalized based on two survey questions as 
described in the manuscript text.  
(b) Cases naturally fell into three groups or sets: high-reach (H-R); mid-
reach (M-R); and low-reach (L-R). Cases with a patient reach score >5 
were included in the H-R set (coded as H-R=1).  All other cases were 
coded H-R=0 and are referred to with a tilde to indicate they are not in 
the high-reach set (i.e., ~H-R).  
Step 2: Select Cases Several high-reach and several low-reach institutions were needed. 
However, to maximize both sample size and diversity in contextual 
variables, all available cases that met the minimum a priori inclusion 
criteria were used in the analysis.  
Step 3:  
(a) Identify key 
conditions  
(b) Assign 
dichotomous set 
membership scores for 
each condition 
(c) Create a data 
matrix of scores for 
conditions 
(a) As part of the multiple-case study data on many contextual factors 
were collected to gain an in-depth understanding of the cases. Based 
on theory and careful review of the cases, factors (i.e., conditions) for 
possible inclusion in QCA were selected as detailed in the manuscript 
text. 
(b) Although this is often not the case, all of the conditions were already 
dichotomized as either present=1 or absent=0 based on how they were 
asked as part of the survey. 
(c) A data matrix (Table III-3) was created by listing membership scores 
for the outcome and key conditions for each case.  
Step 4: Determine 
which analyses to run 
To determine whether conditions are necessary for the presence of an 
outcome, a separate analysis is recommended. However, none of our 
conditions were hypothesized to be necessary in all cases of high or 
low patient reach. Thus, only sufficiency analyses were conducted.   
Step 5: Determine if 
certain conditions are 
sufficient for the 
outcome using the 
“truth table” approach  
Although not necessary for the presence of high patient reach, 
conditions may be sufficient for the outcome (i.e. H-R) either when 
occurring alone or in combination with other conditions.  Using freely 
available software (fsQCA 2.0), a truth table was created showing all 
possible configurations of conditions (Table III-4). 
Step 6: Examine the 
truth table and resolve 
contradictions 
The first row of the truth table (Table III-4) shows the configuration that 
contains 4 H-R cases as well as 1 M-R case (consistency =.8). The 
second row contains 1 H-R and 1 M-R case (consistency = .5) To 
resolve these contradictions, an additional condition (diff_contact_pt) 
was added to create a revised the truth table (shown in abridged form 
in Table III-5). 
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Table III-2 (continued). 
Step 7: Use computer 
software to generate 
solutions through 
multiple comparisons 
of case configurations 
in the truth table 
Using fsQCA 2.0 software, a “Standard Analysis” was performed to 
identify conditions associated with H-R. This software uses the Quine-
McCluskey algorithm (which is based on Boolean simplification) to 
make multiple comparisons of case configurations represented in the 
truth table and logically simplify the data. During this process input from 
the researchers was required to select prime implicants and determine 
which simplifying assumptions were tenable. The software then used 
this information to generate three solutions (complex, parsimonious, 
and intermediate) for H-R.  
Step 8: Determine if 
the influence of 
conditions is 
symmetrical 
To determine if conditions associated with H-R are the same as those 
associated with the absence of the outcome (~H-R), steps 4-6 were 
repeated using ~H-R as the outcome.  
Step 9: Evaluate the 
consistency and 
coverage of the 
solutions 
The overall solution consistencies were 1 for each of the two outcomes 
evaluated (H-R and ~H-R), indicating that the respective combination of 
conditions were consistently associated with the respective outcome. 
The overall coverage for each solution was 1; indicating that all of the 
cases with the presence (or absence) of the outcome were explained 
(covered) by the respective solution. 
Step 10: Interpret the 
resulting solutions and 
create causal models 
Even when conditions are uniquely and consistently associated with an 
outcome, it does not necessarily mean they cause the outcome. 
However, these solutions in conjunction with theories, frameworks, and 
details about the cases can be used to develop a causal theoretical 
model that describes how the conditions might lead to the outcome. 
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Table III-3. Data Matrix of Conditions Considered for Inclusion in QCA  
Patient 
reach 
scorea 
Set 
member
-shipb 
Out-
come  
Conditions 
(H-R)c d e F G h i j k l m n o 
6 H-R 1 1 0 1 0 0 0 0 0 0 0 1 1 
5.5 H-R 1 1 0 1 0 0 0 0 0 0 0 1 0 
5 H-R 1 1 1 0 0 0 0 0 0 0 0 1 1 
5 H-R 1 1 1 0 0 0 0 0 0 0 0 1 1 
5 H-R 1 1 1 0 0 0 0 0 0 0 0 1 1 
4 M-R 0 1 0 1 0 0 0 0 1 1 1 1 0 
3.5 M-R 0 0 - - 1 1 0 1 1 1 1 1 0 
3 M-R 0 1 1 0 0 0 0 0 1 1 1 1 1 
3 M-R 0 0 - - 1 1 0 0 0 0 0 1 0 
2.5 M-R 0 0 0 1 1 1 0 1 0 0 0 1 0 
1.5 L-R 0 0 0 1 1 1 1 1 0 0 0 1 0 
1 L-R 0 0 - 0 1 0 1 1 0 0 0 1 0 
1 L-R 0 0 1 0 1 1 1 1 0 0 0 1 0 
1 L-R 0 0 - - 1 0 1 1 0 0 0 0 0 
1 L-R 0 0 - - 1 1 1 1 0 0 0 1 0 
Notes: aPatient reach was calculated by averaging the ordinal response options from two 
questions estimating the percentage of patients who follow-through with genetic counseling and 
percentage who follow-though with germline testing after a positive screen. 
bNatural break points were used to initially categorize institutions into three sets based on patient 
reach score (H-R=high reach; M-R=medium reach; L-R=low reach). 
cThe outcome for the initial QCA was high patient reach (presence=1, absence=0). 
dGenetic professional discloses positive screening results (presence=1, absence=0, ). 
ePositive screening results disclosed by telephone (presence=1, absence=0, don’t know = “-“). 
fPositive screening results disclosed at follow-up visit  (presence=1, absence=0, don’t know = “-“). 
gObtaining/receiving a referral from a non-genetics health care provider is primary mechanism for 
genetic testing (presence=1, absence=0) 
hHealth care providers often fail to see the importance of genetic counseling after a positive 
screen  (presence=1, absence=0). 
iHealth care providers often fail to see the importance of germline testing after a positive screen  
(presence=1, absence=0). 
jCombined condition based on Boolean addition “OR” (presence of condition “h” OR condition 
“i”=1, absence of both conditions=0).   
kDifficulty contacting patients to set up genetic counseling after a positive tumor screen 
(presence=1, absence=0). 
lDifficulty contacting patients to arrange germline genetic testing after a positive screen 
(presence=1, absence=0). 
mCombined condition based on Boolean addition (presence of condition “k” OR condition “l”=1, 
absence of both=0). 
nGenetic professional is responsible for pre-test discussion of germline testing with the patient 
(presence=1, absence=0). 
oGenetic professional contacts patient directly to set up pre-test counseling and germline testing 
(presence=1, absence=0). 
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Table III-4. Initial Truth Table of All Potential Conditional Configurations  
Rowa 
 
gen_prof_ 
disclose_
screen b 
referral_ 
barrier c 
gen_directly_ 
contacts_pt d 
# cases fitting 
configuration 
H-R e 
(outcome) 
Raw 
consistency 
A 1 0 1 5  0.8f 
B 1 0 0 2  0.5f 
C 0 1 0 8  0g 
D 0 1 1   (remainder)h 
E 0 0 0   (remainder)h 
F 0 0 1   (remainder)h 
G 1 1 0   (remainder)h 
H 1 1 1   (remainder)h 
Notes: This is a replica of the initial truth table generated using fsQCA 2.0 software. However, the 
first column was added to label configurations and several descriptors were added in 
parentheses. 
aEach potential configuration of conditions is represented by a row. Since there are 3 conditions 
there are 23 (8) possible configurations.  
bGenetics professional discloses positive screening results (presence=1, absence=0) 
cReferral is primary mechanism for patient to receive genetic testing (presence=1, absence=0) 
dGenetic professional contacts patient to set up counseling and testing (presence=1, absence=0) 
eThe outcome column is blank because the software requires the researchers to fill in a 0 or 1 for 
each configuration (row) based on whether or not the cases that share that configuration have the 
outcome of interest (i.e., high patient reach; H-R).  
fThese configurations contain contradictions (as indicated by consistency scores). Consistency 
for row A is 0.8 because 4 of the 5 cases with this configuration have high patient reach (H-R=1). 
Consistency for row B is 0.5 because only one of the two cases in this configuration belongs to 
the H-R set. Contradictions must be resolved before assigning outcome scores. 
gThe consistency score for row C is 0 because none of the cases with this configuration have 
high patient reach. 
hThere are no consistency scores for rows D-H because there are no cases in this sample that fit 
these configurations. These are called remainders. 
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Table III-5. Revised Truth Table 
Rowa 
 
gen_prof_ 
disclose_ 
screen b 
referral_ 
barrier c 
gen_directly_ 
contacts_pt d 
difficulty_ 
contact_pt e 
# cases 
fitting 
configuration 
 
H-R 
(outcome) 
Raw 
consis-
tency 
A 1 0 1 0 4 1 1f 
B 1 0 0 0 1 1 1f 
C 0 1 0 0 7 0 0g 
D 0 1 0 1 1 0 0g 
E 1 0 1 1 1 0 0g 
F 1 0 0 1 1 0 0g 
Notes: The revised truth table was created using fsQCA 2.0 software by adding a fourth condition 
to the original truth table, assigning outcome scores for each configuration, and deleting 
configurations with no cases (remainders). 
aEach row represents a configuration of conditions. Although there are 24 (16) possible 
configurations, but only those configurations for which there are cases are shown.  
bGenetics professional discloses positive screening results (presence=1, absence=0) 
cReferral is primary mechanism for patient to receive genetic testing (presence=1, absence=0) 
dGenetic professional contacts patient directly to set up counseling and testing (presence=1, 
absence=0) 
eDifficulty contacting patients after a positive tumor screen (presence=1, absence=0) 
fThe consistency scores for rows A-B are 1 because all cases with these configurations have high 
patient reach (H-R=1). 
gThe consistency scores for rows C-F are 0 because none of the cases in those configurations 
have high patient reach (H-R=0) 
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Table III-6. QCA Solutions, Consistency and Coverage 
Outcome Solutions Consisten
cy 
Raw 
Coverage 
Unique 
Coverage 
 
 
High 
Patient 
Reach 
(H-R) 
Complex: gen_prof_disclose_screen * 
~referral_barrier *  
~difficulty_contact_pt  
1.0 1.0 1.0 
Parsimonious: ~referral_barrier *  
~difficulty_contact_pt 
1.0 1.0 1.0 
Intermediate:a gen_prof_disclose_screen * 
~referral_barrier *  
~difficulty_contact_pt 
1.0 1.0 1.0 
  
Overall consistency = 1.0 
Overall  coverage  = 1.0 
 
 
 
Absence 
of High 
Patient 
Reach 
(~H-R) 
Complex: gen_prof_disclose_screen * 
~referral_barrier*  
difficulty_contact_pt  
+ 
~gen_prof_disclose_screen * 
referral_barrier * 
~gen_directly_contacts_pt 
1.0 
 
 
 
1.0 
0.2 
 
 
 
0.8 
 
0.2 
 
 
 
0.8 
 
Parsimonious: difficulty_contact_pt  
+ 
referral_barrier    
1.0 
 
1.0 
0.3 
 
0.8 
0.2 
 
0.7 
Intermediate:b  difficulty_contact_pt  
+ 
~gen_prof_disclose_screen * 
referral_barrier * 
~gen_directly_contacts_pt   
1.0 
 
1.0 
0.3 
 
0.8 
0.2 
 
0.7 
  
Overall consistency = 1.0 
Overall coverage  = 1.0 
Notes: A tilde (~) indicates the absence of the outcome or condition. 
The intermediate solutions are bolded because they were determined to be the most theoretically 
sound and not overly simple or complex. 
* The asterisk indicates Boolean multiplication (i.e. logical “AND”) 
+The plus sign indicates Boolean addition (i.e. logical “OR”) 
a The following three conditions are sufficient for high patient reach: 1) a genetics professional 
discloses the results of positive tumor screening; AND 2) obtaining a referral from another health 
care provider for the patient to receive genetic counseling and testing is not a barrier; AND 3) 
difficulty contacting patients is not a barrier.  
b Two distinct sets of conditions could both explain the absence of the outcome (Table III-6). 
Difficulty contacting patients who screen positive is sufficient but not necessary to prevent high 
patient reach. Alternatively, the following three conditions are together sufficient but not necessary 
to prevent high patient reach: 1) genetic professionals do not disclose positive screening;  AND 2) 
genetic counselors do not contact patients directly to arrange genetic counseling and testing ; 
AND 3) the need for a health care provider to refer the patient for genetic counseling and testing 
is a barrier. 
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SECTION IV: CONCLUSIONS AND RECOMMENDATIONS 
Public Health Significance and Practical Implications 
Screening tumors from all newly diagnosed colorectal cancer patients (i.e., 
universal tumor screening; UTS) is a promising method to achieve the Healthy 
People 2020 provisional objective: “Increase the proportion of persons with newly 
diagnosed colorectal cancer [CRC] who receive genetic testing to identify Lynch 
syndrome (LS)”. (“Genomics - Healthy People”). Diagnosing LS allows for the 
prevention or early detection of colorectal and other types of cancer among 
patients and their relatives; thereby reducing associated morbidity and mortality. 
However, the health benefits of tumor screening will only be realized if patient 
reach is high (i.e., a large percentage of patients who screen positive follow 
through with germline testing and genetic counseling.)   
Given that the RE-AIM evaluation framework was designed to increase the 
public health impact of evidence-based programs (Glasgow et al., 1999), this 
framework was used in the current study. Results add to the current literature by 
confirming that centers vary substantially in terms of patient reach. Even more 
importantly the current study identified several key implementation factors that 
characterized institutions with high and low patient reach. These factors included: 
1) streamlining UTS procedures by making BRAF or hypermethylation testing 
automatic in order to rule out a subset of individuals who screen positive but do 
not need to follow-up with genetic counseling and germline testing and by 
eliminating the requirement for referral or systematizing the process of obtaining 
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a referral so that the need for referral is not a barrier); 2) incorporating a high 
level of involvement of genetics professionals in receiving screening results, 
disclosing positive tumor screening results to patients, and initiating genetic 
counseling and germline testing; 3) reducing barriers to patient contact and 
follow-up (i.e., meet patients at post-op appointments, arrange appointments at 
convenient times to coincide with other follow-up appointments, etc). 
Study findings can serve as key leverage points to inform policy decisions 
among stakeholders. Implementing UTS practices and procedures that 
consistently led to high patient reach in this multiple-case study is expected to 
ultimately contribute to the long-term goal of reducing high levels of morbidity and 
mortality associated with hereditary cancer. Indeed the results of this study have 
already prompted one L-R institution to change their follow-up procedures. 
Unfortunately, some centers may be unable to alter their practices; and ways to 
work around barriers may be necessary. Interviews conducted as part of the 
current study for member checks identified additional information that may help 
centers that are implementing UTS and it is expected that much of this 
information will be consolidated and shared on the Lynch Syndrome Tumor 
Screening (LSSN) website. Nevertheless, additional implementation and 
dissemination efforts in conjunction with research studies will be required before 
the provisional Healthy People 2020 objective can be achieved and before UTS 
will have a substantive public health impact.  
Implications for Future Research 
Given that the current study did not comprehensively evaluate all 
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dimensions of RE-AIM, several unanswered research questions remain and are 
listed in Table IV-1. For example, future studies should extend the definition of 
Reach to include the number of family members that are diagnosed as a result of 
UTS programs, particularly because prevention of cancers in family members 
determine a large portion of the public health benefit of UTS programs. 
Interviews with a few institutional representatives suggest that some centers 
have diagnosed several family members as the result of UTS, but systematic 
methods of tracking family members over time will be necessary to more 
thoroughly answer questions pertaining to patient Reach and Maintenance.  
Additionally, widespread Adoption of UTS screening by hospitals and 
cancer centers is critical for UTS to have a large public health impact. Given that 
academic/research institutions appear to have been quicker to adopt UTS 
(Beamer et al., 2012; Cohen et al., 2013), health disparities could increase in 
rural areas or among minority populations that may be less likely to be treated at 
academic/research centers. Smaller, non-academic centers may have fewer 
resources or expertise needed for implementation and may face a greater 
number of barriers. Therefore to help actively disseminate UTS, summaries of 
the current study findings related to overcoming barriers and strategies for 
successful UTS implementation are expected to be posted on the Lynch 
Syndrome Screening Network (LSSN) website (www.lynchscreening.net) where 
several other useful documents and information on UTS are currently housed.  
Additional research is needed to evaluate other UTS programs, 
particularly those implemented in non-academic centers or institutions that do not 
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employ genetics professionals. Evaluating programs that have been able to 
achieve high patient reach but do not conform to the key conditions identified in 
the current study may help to better understand other implementation strategies 
that fit better within certain institutions and are therefore more feasible. Although 
the current study found only a single model leading to successful UTS 
implementation, different recipes to achieve high patient reach are possible.  
Therefore future research is expected to confirm, add to, or refine the institution-
level mechanisms that appeared to consistently lead to effective program 
implementation in the current study.  
By demonstrating the importance of institution-level factors for patient 
outcomes, the current study data has already informed further evaluations of 
UTS. Specifically, LSSN now plans to include institution-level data in addition to 
individual-level patient data in the database that is being developed. Given the 
clustered nature of the data, with patients nested within institutions, multilevel 
modeling (MLM) is necessary when analyzing individual-level data (as opposed 
to aggregated data used in the current study) in order to reduce the type I error 
rate (Kreft, 1996) and prevent any unanalyzed institution-level effects from 
obscuring or exaggerating pooled findings (Seltzer, 1994). A major advantage of 
MLM is that it allows both random (institution-level) effects and fixed (patient-
level) effects to be examined (Seltzer, 1994). In other words, MLM could be used 
to determine the extent to which differences in patient reach across sites are the 
result of institution-level effects versus patient-level characteristics (such as stage 
of cancer, age, gender, or insurance status). MLM will also ensure that individual-
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level factors do not confound institution-level findings and thereby overcome a 
key limitation of the current study. 
Implications for Theory 
Integrating the RE-AIM and CFIR Frameworks 
Given that relatively few implementation studies have employed theoretical 
models (Damschroder & Hagedorn, 2011), results from the current research 
could contribute more broadly to the theoretical underpinnings of implementation 
science. Since its development in 1999 by Glasgow, RE-AIM has been used to 
evaluate the public health impact of many different evidence-based programs 
and is a useful conceptual model. However, RE-AIM does not provide enough 
detail to comprehensively characterize the Implementation dimension or define 
key constructs that are important for Implementation. The Consolidated 
Framework for Implementation Research (CFIR) was developed in 2009 to open 
the “black box of the RE-AIM framework” (Damschroder et al., 2009). Employing 
the RE-AIM evaluation framework together with the CFIR can help to better 
determine how Reach, Effectiveness, Adoption, Implementation, and 
Maintenance interact. In particular, the current study results lend support for the 
critical influence implementation processes have on outcomes, specifically 
patient reach. Using qualitative comparative analysis (QCA), several 
Implementation processes were determined to be key conditions associated with 
patient Reach in the current study. Additionally, interviews performed as part of 
the current study revealed the importance of several other CFIR constructs in the 
decision making process to Adopt UTS and in determining how to Implement 
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UTS. Themes from interviews are now being categorized according to various 
CFIR constructs as shown in Table IV-2 and then will be integrated within the 
broader RE-AIM framework to further illustrate the interactions between RE-AIM 
dimensions. 
Quantitative Measures of CFIR Constructs 
Lack of validated tools is currently a weakness identified in implementation 
and dissemination research (Damschroder et al., 2009). Despite the small 
sample size, the current study provides pilot data to help evaluate the new 
survey tools that were designed to include measures of several CFIR constructs 
that are not specific to the processes of UTS. Further analysis of the current data 
can aid in the refinement of these survey instruments for use in evaluating the 
adoption and implementation of other evidence-based programs or practices.   
Additional Manuscripts 
Development of Quantitative Measures for CFIR Constructs 
A manuscript describing the development and pilot testing of quantitative 
CFIR measures is planned. This will include a discussion of the many problems 
or challenges inherent in developing this type of measure, particularly those 
related to measuring institutional constructs using survey data from individuals. 
The paper will also triangulate findings from interviews with findings from the 
survey measures to determine whether qualitative and quantitative methods of 
identifying key CFIR constructs are consistent. The article will conclude with 
lessons learned during the development and pilot of the instruments as well as 
recommendations going forward that may help improve upon the newly 
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developed measures. 
Policy Implications for Lynch Syndrome Universal Tumor Screening  
Another manuscript will focus on several policy and practical implications of 
the research findings. This will include a more detailed discussion of the barriers 
to implementation and possible challenges to effective implementation and 
dissemination of UTS on a broader scale. For example, during interviews with a 
few individuals who are not genetic counselors, they reported that their institution 
would not have implemented UTS without a genetic counselor on site (and many 
hospitals do not have genetic counselors). Furthermore, disparities in at least 
four cities or large geographical regions became apparent during the interviews. 
Lastly, follow-up on positive tumor screens is not being performed in any 
systematic fashion at some centers; and patients are definitely falling through the 
cracks, whereas other institutions have even begun implementing methods to 
check or ensure that all patients are screened and either follow-through or 
provide informed refusal of follow-up counseling and testing.  
Implementation of Genomic Technologies: Practical & Ethical 
Considerations  
 Another potential manuscript could describe ethical considerations and 
practical issues of widespread implementation of genomic technologies and 
illustrate how UTS can be used as a model for implementation of these other 
technologies. Specifically, sequencing the genome of tumors to help determine 
treatment options is expected to become a common practice in the future. Similar 
to UTS where an abnormal screen must be verified with germline testing, there 
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are likely to be cases where tumor sequencing suggests the potential of a 
germline mutation. These individuals will require genetic counseling so they can 
be informed of the implications that identifying a germline mutation may have for 
themselves and for their family members. Although a couple of key differences 
exist between tumor sequencing and UTS, lessons learned from UTS 
implementation may be useful in preparing for and identifying best methods for 
implementing future genomic technologies. 
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Table IV-1. Future Directions for Applying RE-AIM and Consolidated Framework for 
Implementation Research (CFIR) 
RE-AIM Dimension 
Description 
Relevant Study Result Future Research 
Reach  
Absolute number, 
proportion, and 
representativeness 
of individuals who 
participate. 
• Patient Reach (i.e., proportion of screen 
positive patients who receive information 
on germline testing and follow-through 
with germline testing and genetic 
counseling) is highly variable across 
centers (ranging from <10% to >85%). 
 
• Determine 
characteristics of 
patients who follow-
through  
• Identify the number of 
family members who 
are diagnosed with LS 
as a result of patient 
diagnosis 
Effectiveness 
The impact of an 
intervention on 
outcomes (including 
potential negative 
effects). 
• Institutional representatives report few 
negative effects associated with 
screening.  
• Potential liability was identified by a few 
centers where patient reach is low and 
several expressed concerns that patients 
may not always be referred after a 
positive screen. 
 
• Do patients perceive 
UTS to have a positive 
or negative impact? In 
what ways? 
Adoption 
The absolute 
number, proportion, 
and 
representativeness 
of settings and staff 
who currently offer a 
program. 
Characteristics of 
intervention may 
increase the 
likelihood of 
adoption. 
• Centers report a variety of reasons for 
adopting UTS, but most common reasons 
are the EGAPP recommendation and to 
benefit patients and their families. 
• Multiple stakeholders are typically 
involved in making the decision to adopt 
UTS and changes to the procedures. 
• Projected cost was a common factor in 
weighing the decision to adopt UTS at 
most participating institutions. 
• Overall in the U.S. 
what 
centers/institutions 
have adopted UTS 
and how do they 
compare to others that 
have not adopted 
UTS? 
Implementation 
Consistency of 
delivery, time and 
cost of the program, 
and what 
adaptations to the 
program are made 
in various settings. 
• Centers with direct and high level of 
involvement of genetic counselors in 
disclosing results and follow-up 
procedures is sufficient for high patient 
reach in the absence of two barriers 
including lack of referral from another 
healthcare provider for patient to undergo 
genetic counseling and difficulty 
contacting patients. 
• The number of implementation barriers 
was greater than or equal to the number 
of facilitators for most low-reach centers, 
but only 1 H-R center. 
• Recurring themes and a few unique 
responses were identified regarding how 
centers can facilitate implementation and 
overcome barriers/challenges. 
• Are there other 
procedures that can 
lead to high patient 
reach particularly at 
centers that do not 
have genetics 
professionals? 
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Table IV-1 (continued). 
Maintenance 
Extent to which the 
program is 
institutionalized and 
maintained or 
altered over time. 
 
At the individual 
level, maintenance 
is the long-term 
effects of a program 
on outcomes after 6 
or more months. 
A few centers have changed their screening 
protocol so that genetic professionals disclose 
positive screening results and meet patients at 
a follow-up appointment to discuss germline 
testing. These centers saw improvement in 
patient follow-through and under their current 
protocol they were achieving high patient 
reach.  
 
A few other centers are now in the process of 
changing their procedures.  
 
One low-reach center used to let the genetic 
counselor see all positive screening results 
and follow-up to ensure she received a 
referral for all of these patients. She reported 
that since she could no longer do this it 
reduced the percentages who followed 
through. 
Do other centers that alter 
their procedures to 
resemble those of high-
reach centers in our study 
see improved patient 
reach? 
 
What prevents programs 
from changing to try and 
improve patient reach? 
 
Are patients who have 
been diagnosed with 
Lynch syndrome through 
UTS or as a result of 
cascade testing of at-risk 
relatives undergoing 
recommended cancer 
screening? 
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Table IV-2. Study Themes Consistent with the Consolidated Framework for Implementation 
Research (CFIR) 
CFIR 
Construct  
Description Relevant Findings from 
Current Study  
Intervention Characteristics   
Intervention 
source 
Perception of key stakeholders about whether 
the intervention is externally or internally 
developed to solve a local problem and the 
legitimacy of the source (Greenhalgh, Robert, 
Macfarlane, Bate, & Kyriakidou, 2004). 
Externally developed interventions and lack of 
user input can lead to ineffective implementation 
(Helfrich, Weiner, McKinney, & Minasian, 2007; 
Kitson et al., 2008; Katherine J. Klein, Conn, & 
Sorra, 2001). 
A few GCs cite that if it is simply 
coming from them other 
physicians won’t listen. So need 
to get a pathologist and a 
surgeon on board early on in 
the process. 
Relative 
advantage 
Stakeholder beliefs about the benefits of UTS 
compared with the status quo or an alternative 
(Rogers & Rogers, 2003). Relative advantage 
and observability are constructs from Diffusion 
of Innovations (Rogers & Rogers, 2003). They 
are combined because benefits, if visible to the 
stakeholders, aid adoption and implementation 
(Denis et al., 2002; Feldstein & Glasgow, 2008; 
Greenhalgh et al., 2004; Grol, Bosch, Hulscher, 
Eccles, & Wensing, 2007).  
One GC indicated that once the 
physicians started seeing how 
family members were 
diagnosed and that they were 
using the information to be 
proactive in screening they 
would get on board.  
 
Observing how patients were 
being missed without UTS 
helped some centers get it 
implemented. 
Adaptability Perceptions about whether and how an 
intervention can be tailored to meet specific 
needs or characteristics of an institution (Rogers 
& Rogers, 2003). There are generally 'core 
components' that are necessary elements of the 
intervention and an 'adaptable periphery' 
(Greenhalgh et al., 2004). According to Diffusion 
of Innovations, programs that can easily be 
modified to are more likely to be adopted 
(Rogers & Rogers, 2003).  
Whether or not they do IHC or 
MSI does not appear to be 
necessary for success. 
 
Some centers only do IHC in 
house and that was one reason 
for selecting IHC.  
 
 
Trialability  Ability to test an intervention on a small scale 
and reverse implementation if warranted 
(Rogers & Rogers, 2003). According to Diffusion 
of Innovations, trialability has a strong positive 
association with adoption (Greenhalgh et al., 
2004; Rogers & Rogers, 2003). It also increases 
the likelihood of effective implementation 
because piloting provides experience that can 
be used to improve full scale implementation 
(Kitson et al., 2008; Rycroft-Malone et al., 
2002). 
 
Some centers were already 
screening a sub-set of tumors 
before going to universal 
screening and they reported 
that this helped because 
systems were already in place. 
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Table IV-2 (continued). 
 
Complexity Perceived difficulty of implementation (duration, 
scope, radicalness, disruptiveness, centrality 
and number of steps required) (Rogers & 
Rogers, 2003). According to Diffusion of 
Innovations complexity plays a critical role in the 
decision to adopt an innovation. In addition, 
simple interventions are more likely to be 
effective (Greenhalgh et al., 2004). Assessing 
complexity can also help in understanding and 
avoiding unintended consequences (Kochevar & 
Yano, 2006).  
Perceived difficulty of 
implementation did not appear 
to be consistently associated 
with patient reach but those with 
low-reach reported more 
barriers than facilitators.  
 
GCs expressed how complex it 
is to implement in a hospital or 
hospital system where the 
physicians are private and NOT 
employed by the hospital.  
 
Reduction in complexity of 
follow-up procedures following a 
positive screen appears to be a 
key to success of high reach 
institutions.  
Costs Costs of the intervention as well as 
implementation costs (Rogers & Rogers, 2003). 
Cost is a characteristic from Diffusion of 
Innovations and is negatively associated with 
adoption (Rogers & Rogers, 2003; Teplensky, 
Pauly, Kimberly, Hillman, & Schwartz, 1995). 
Cost is also likely to influence how the 
intervention is implemented and its overall 
effectiveness. 
Costs are a common concern in 
deciding whether to adopt 
universal tumor screening. 
 
Because it is part of DRG when 
performed on resections the 
hospital is essentially adding on 
the screen without recouping 
additional money. 
 
Some centers are going to 
biopsies in part because they 
are outpatient procedures and 
more likely to be reimbursed. 
Outer setting  
Patient 
needs and 
resources 
The extent to which patient needs, barriers, and 
facilitators are accurately known and prioritized. 
(Feldstein & Glasgow, 2008; Graham & Logan, 
2004; Rycroft-Malone et al., 2002). A number of 
implementation theories postulate that taking 
these issues into account will increase the 
chance that the intervention will be effective 
(Ferlie & Shortell, 2001; Kitson et al., 2008; 
Rycroft-Malone et al., 2002). Quality 
improvement initiatives have proven more 
successful if there has been a strong focus on 
the patients' needs (Ferlie & Shortell, 2001). 
Several programs changed their 
protocol to better meet patient 
needs by simplifying follow-up 
procedures and removing 
barriers. 
 
Several centers considered 
patient needs in their discussion 
of whether or not informed 
consent was necessary and 
what information patients 
should be provided. 
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Table IV-2 (continued). 
 
Cosmo-
politanism 
Degree to which the organization is networked 
with other external institutions (i.e., social capital 
of the organization) (Greenhalgh et al., 2004). 
The degree of external networking increases the 
likelihood of implementing new practices quickly 
once advantages become apparent 
(Greenhalgh et al., 2004). 
“You need to keep up to date 
with the literature and use other 
centers that have been doing 
UTS as a resource!” quote  
 
Some centers indicated that 
they modeled their program 
after another one, such as Ohio 
State. This was even one 
reason why they chose IHC. 
 
One GC recommended that 
people should join LSSN if they 
want to implement UTS. 
 
Peer 
pressure 
Competitive pressure to implement an 
intervention (to either obtain a competitive edge 
or because other organizations already have 
implemented it) (Greenhalgh et al., 2004). There 
is strong evidence that peer pressure influences 
organizational adoption or programs / 
interventions / technologies (Greenhalgh et al., 
2004). 
Several centers reported this as 
a reason for implementation as 
follows: 
 
Seeing competitor hospitals 
doing it was a motivation. 
 
Also, one center reported that 
the fact they would be the first 
to implement in their area was 
helpful because administration 
liked the idea of being ahead of 
others. 
External 
policies and 
incentives 
External strategies to spread interventions (e.g., 
mandates, pay-for-performance, political 
directives, recommendations, collaboratives) 
(Greenhalgh et al., 2004; Mendel, Meredith, 
Schoenbaum, Sherbourne, & Wells, 2008). 
Many times these strategies lead to adoption 
and increase effective implementation, but there 
are some exceptions (Greenhalgh et al., 2004; 
Grol et al., 2007; Katherine J. Klein & Sorra, 
1996). 
 
One M-R center indicated that 
they implemented UTS because 
they believed it was “becoming 
standard of care” 
 
 
Some implemented because of 
EGAPP, but more often EGAPP 
was used to support it and they 
wanted to implement to improve 
identification of patients. 
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Table IV-2 (continued). 
 
Inner setting  
Structural 
characteristic 
Social architecture (i.e., how people are 
clustered into smaller groups and how actions 
are coordinated), age, maturity, and size of an 
organization (Damanpour, 1991a; Greenhalgh et 
al., 2004). Several structural characteristics 
have been found to be significantly associated 
with implementation effectiveness, often with 
mixed results (Frambach & Schillewaert, 2002). 
A greater number of departments involved in 
decision making may slow down the process, 
but generally increases successful 
implementation (Damanpour, 1991b; 
Greenhalgh et al., 2004).  
Many of high reach centers are 
NCCN designated academic 
research focused. 
 
If the physicians are not actually 
employed by the hospital this 
made it more challenging for 
some to implement. Also, this 
prevents GCs from being able 
to follow-up at post op 
appointments. 
 
Even one center where GCs 
could follow-up the physical 
structure of having genetics so 
far away required them to rely 
on a nurse who is 
knowledgeable about genetics 
to meet patient at follow-up 
appts. 
 
The more physicians or 
hospitals reported to be part of 
the system the longer it seems 
to have taken to get UTS 
implemented one hospital 
system took 3 years and even 
after that not all came on board.  
Also seen with the affiliate 
hospitals of one center that 
implemented UTS with no 
problem, but affiliate has not 
yet. 
Networks 
and 
communi-
cation 
 
Nature, quality, and extent of social networks 
(social capital). Formal and informal 
communications within an organization 
(Greenhalgh et al., 2004; Helfrich et al., 2007). 
Coordination and teamwork across departments 
and specialties is typically important for effective 
implementation of programs or initiatives 
(Feldstein & Glasgow, 2008; Ferlie & Shortell, 
2001). Clear role definitions and high quality 
communication increase the likelihood of 
success (Simpson & Dansereau, 2007).  
Role definitions and quality 
communication are cited as 
critical to implementation.  
 
Those centers where physicians 
sometimes disclose and GCs 
sometimes disclose tend to 
have lower patient reach. 
 
Teamwork among genetics, 
pathology, and surgeons was 
cited as a key to successful 
implementation by many H-R 
centers. 
 
Lack of communication cited 
among many L-R centers. 
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Table IV-2 (continued). 
 
Implemen-
tation climate 
 
Absorptive capacity for change, shared 
receptivity of those involved, extent to which 
involvement with the intervention is rewarded, 
supported, or expected within the organization. 
(Gershon et al., 2004; Greenhalgh et al., 2004; 
Katherine J. Klein & Sorra, 1996).Climate 
includes the following 6 sub-constructs: 
Tension for change – degree to which 
stakeholders perceive current situation as 
needing change.  
 
Compatibility – degree of fit between the 
meaning and values of the intervention and 
individual's and institution's values as well as fit 
with work flow and systems. Greater perceived 
fit = greater likelihood of adoption according to 
Diffusion of Innovations and empirical research 
(Greenhalgh et al., 2004; Katherine J. Klein & 
Sorra, 1996; Rogers & Rogers, 2003).   
 
Relative priority – shared perception of how 
important implementation is. The higher the 
priority the more likely  it is to be successful 
(Helfrich et al., 2007; Katherine J. Klein, Conn, 
et al., 2001). 
Organizational incentives/rewards – include but 
are not limited to goal-sharing awards, 
performance reviews, raises in salary, increased 
stature or respect. Strong incentives increase 
the likelihood of implementation success 
(Helfrich et al., 2007; Katherine J. Klein, Conn, 
et al., 2001). The number of different types of 
incentives has been positively related to use of 
best practices by healthcare organizations 
(Shortell et al., 2001).  
 
Goals and feedback – Goals that are specific, 
incremental, and attainable increase effective 
implementation. Feedback has been shown to 
have small to moderate effects (Jamtvedt, 
Young, Kristoffersen, O’Brien, & Oxman, 2006). 
 
Learning climate – climate where leaders 
recognize they are fallible and need input, and 
team members feel their input is valued. This is 
hypothesized to influence the ability of an 
organization to fully assimilate an intervention 
(Greenhalgh et al., 2004). 
Having gastroenterologists and 
surgeons who were receptive 
was necessary. 
 
Preliminary analysis using scale 
measure of implementation 
climate those with higher scores 
are the H-R centers. 
 
H-R centers have set goals for 
UTS and keeping track of 
outcomes carefully 
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Table IV-2 (continued). 
 
Readiness 
for 
implemen-
tation 
Tangible and immediate indicators of 
organizational commitment to its decision 
(Greenhalgh et al., 2004; Kitson et al., 2008). 
This includes 3 sub-constructs. 
 
Leadership engagement – commitment, 
involvement, and accountability of managers. 
This is critical to successful implementation 
(Meyer & Goes, 1988; Repenning, March). It 
leads to a stronger implementation climate 
(Helfrich et al., 2007; K J Klein, Conn, et al., 
2001). 
 
Available resources – level of resources 
implemented (i.e., money, time, space). The 
level of resources is positively associated with 
implementation, but does not guarantee 
success (K J Klein, Conn, et al., 2001).  
 
Access to information and knowledge – Access 
to easy to use information about UTS and how 
to incorporate it is essential for successful 
implementation (Greenhalgh et al., 2004; 
Helfrich et al., 2007; K J Klein, Conn, et al., 
2001). Timely, on the job training (particularly if 
provided at a team level) contributes to success 
(Greenhalgh et al., 2004). This is also critical to 
get key stakeholders engaged (Grol et al., 
2007). 
Not all centers had to have the 
administration on board (tended 
to be academic centers). 
 
Community hospitals reported 
the need for administration on 
board for implementation. 
 
Community hospitals may have 
fewer resources and more 
difficult to implement.   
 
One hospital indicated if they 
did not have a GC on site they 
probably would not have 
implemented it. 
 
 
Characteristics of individuals  
Knowledge 
and beliefs 
about the 
intervention 
Familiarity with principles related to the 
intervention and how-to knowledge as well as 
positive and negative attitudes about the 
intervention and value placed on the 
intervention (Katherine J. Klein & Sorra, 1996; 
Rogers & Rogers, 2003). Principles and how-to 
knowledge are constructs from Diffusion of 
Innovations (Rogers & Rogers, 2003).  Attitudes 
are key constructs in some theories that explain 
individual behavior change, specifically the 
Theory of Reasoned Action (Fishbein & Ajzen, 
2009). 
Genetic professionals may be 
more knowledgeable. 
 
Lack of knowledge among 
physicians more often cited as 
barrier by L-R centers. 
Self-efficacy Individual belief in capability to execute behavior 
needed to achieve implementation goals. 
Perceived ability to perform a specific action 
within a specific context (Bandura, 1977). This 
construct is included in multiple theories of 
behavior change (Glanz, Rimer, & Viswanath, 
2008) However, self-efficacy is originally 
attributed to Bandura and is a key construct in 
Social Cognitive Theory (Bandura, 1977).  
Not measured here 
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Table IV-2 (continued). 
 
Individual 
stage of 
change 
Progression toward use of the intervention. 
Stage depends on the specific model used (i.e., 
Prochaska's Transtheoretical model, Roger's 
Diffusion of Innovations, etc) (Levesque, 
Cummins, Prochaska, & Prochaska, 2006; 
Prochaska & Velicer, 1997; Rogers & Rogers, 
2003). 
NA 
Individual 
identification 
with the 
organization  
How individuals perceive the organization and 
their relationship and commitment to the 
organization (“AHRQ Innovations Exchange | 
Will It Work Here? A Decisionmaker’s Guide to 
Adopting Innovations,” n.d.; Cropanzano, Rupp, 
& Byrne, 2003). This can affect the willingness 
of individuals to fully engage in implementation 
efforts, but this construct has not been widely 
studied in health care settings . 
Not assessed, except for the 
finding that those centers where 
the physicians are not actually 
hospital employees reported 
more difficulty implementing.  
Though actual commitment to 
organization was not assessed. 
Process  
Planning Degree to which the methods and tasks for 
implementation and evaluation are developed 
(Damanpour, 1991b; Greenhalgh et al., 2004; 
Rogers & Rogers, 2003). Although planning is 
generally necessary for implementing 
institutional programs (Greenhalgh et al., 2004), 
additional research is needed into how planning 
influences implementation effectiveness. 
Level of planning may be 
important in outcomes. One 
hospital system worked on 
implementation and planning for 
3 years and are a H-R 
institution. 
Engaging Attracting and involving appropriate people in 
implementation using social marketing, 
education, role modeling, training, and other 
activities (“AHRQ Innovations Exchange | Will It 
Work Here? A Decisionmaker’s Guide to 
Adopting Innovations,” n.d.; Greenhalgh et al., 
2004; Kitson et al., 2008; Lukas et al., 2007; 
Pronovost, Berenholtz, & Needham, 2008). If 
implementation leaders are similar to intended 
users they are more likely to adopt the 
intervention (Greenhalgh et al., 2004). Chances 
of success are greater if all stakeholders are 
engaged early on in the process (Greenhalgh et 
al., 2004).  
Multiple stakeholders need to 
be in agreement, upfront, to 
implementing this screening.  
More people "on board" from 
the beginning means less 
problems that arise after the 
screening begins. (/Tia) 
 
Having a champions that are 
pathologists and GI / surgeons, 
etc was helpful in getting others 
on board.  
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Table IV-2 (continued). 
 
Executing Carrying out the implementation according to 
plan (Carroll et al., 2007; Damanpour, 1991b; 
Edmondson, Bohmer, & Pisano, 2001; Helfrich 
et al., 2007). In cases where there is not a plan, 
assessing execution is difficult. Execution quality 
may be related to the following: level of fidelity 
to the plan, intensity of implementation, 
timeliness of task completion, and degree of 
engagement of key stakeholders (Carroll et al., 
2007; Edmondson et al., 2001). 
my institution used to allow me 
to review all MSI/IHC results so 
I could make sure a referral was 
made.  Because of HIPAA 
concerns this was stopped.  IF 
we institute this again I believe 
genetic counseling would 
increase.   
 
I also had a problem with 
receiving the results for reflex 
tests when I was screening, 
specifically BRAF, so that I 
couldn't determine if a patient 
needed genetic counseling as 
almost all of our abnormal 
results were loss of expression 
of MLH1 and PMS2.  If the 
reflex process and reporting 
process were cleaned up this 
would also assist in increaseing 
genetic counseling referrals.  
 
Have genetic counselors review 
all pathology reports and follow 
up with patients on their own 
 
Need to get them in the door to 
discuss testing  
 
 
 
Reflecting 
and 
evaluating 
Quantitative and qualitative feedback about the 
progress and quality of implementation. Team 
debriefing and reflection (“AHRQ Innovations 
Exchange | Will It Work Here? A 
Decisionmaker’s Guide to Adopting 
Innovations,” n.d.).  
Actually getting the data has 
helped some centers make 
changes.   
 
After talking to a pathologist he 
said it got him thinking of ways 
to better streamline the process 
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Appendix A: Literature Review 
Public Health and Hereditary Colorectal Cancer 
Healthy People genomics objectives. According to the Healthy People 
(HP) 2020 website, the addition of genomics as a topic area reflects “the 
increasing scientific evidence supporting the health benefits of using genetic 
tests and family health history in clinical and public health interventions” 
(“Genomics - Healthy People,” n.d.). Two objectives have been included in the 
HP 2020 genomics topic area. My focus will be on the following provisional 
objective: “Increase the proportion of persons with newly diagnosed colorectal 
cancer (CRC) who receive genetic testing to identify Lynch syndrome (or familial 
CRC syndromes).”  
Prevention of disease and death. Colorectal cancer (CRC) is the third 
most common type of cancer and third leading cause of cancer-related deaths in 
the United States (U.S.) (“Colorectal Cancer Facts & Figures 2011-2013,” n.d.). 
In 2011, an estimated 141,210 people will be diagnosed with CRC and 49,380 
people in the U.S. will die of the disease (“Colorectal Cancer Facts & Figures 
2011-2013,” n.d.) Occurring in approximately 1 out of every 35 patients with CRC 
(Hampel et al., 2008), Lynch syndrome (LS) is the most common cause of 
hereditary CRC. LS confers a lifetime risk for CRC as high as 78%-80% (Aarnio, 
Mecklin, Aaltonen, Nyström-Lahti, & Järvinen, 1995; H. F. Vasen et al., 1996). 
However, due to probable ascertainment bias, more accurate CRC risks likely fall 
in the range of 54-69% for men with LS and 43-52% for women with LS (Barrow 
et al., 2008; Hampel, Stephens, et al., 2005; E. Stoffel et al., 2009). The average 
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age of onset of CRC among individuals with LS ranges from 44-62 years 
(Hampel, Stephens, et al., 2005). It is also important to note that risks of CRC 
and age of onset appear to vary based on which gene is implicated as the cause 
of LS (Bonadona et al., 2011; E. Stoffel et al., 2009).  
LS is also referrred to as hereditary nonpolyposis colorectal cancer 
(HNPCC) despite being associated with substantial increases in risk for several 
other types of cancer including: endometrial, ovarian, gastric, small bowel, 
pancreatic, hepatobiliary, brain, and urothelial cancers (Barrow et al., 2009; 
Kastrinos et al., 2009; Watson et al., 2008). Notably, the second most common 
malignancy associated with LS is endometrial cancer. Risks for women with LS 
to develop endometrial cancer range from 32-54% (Barrow et al., 2009; Hampel, 
Stephens, et al., 2005; E. Stoffel et al., 2009). Studies have found that 
approximately 2% of patients with endometrial cancer have LS (Hampel et al., 
2006). In 2011, an estimated 46,470 women will be diagnosed with endometrial 
cancer in the United States and approximatelyt 8,120 women will die of the 
disease (“Cancer Facts & Figures 2011,” n.d.).  
The greatest public health benefit of identifying LS among newly 
diagnosed patients with CRC is the opportunity it provides to prevent cancer 
among patients' at-risk relatives. Given the autosomal dominant inheritance 
pattern of LS, first degree relatives of patients with LS have a 50% chance of 
having inherited the same cancer-predisposing gene mutation. Furthermore, 
depending on which side of the family the gene was inherited, second degree 
relatives may have a 25% chance of having LS. 
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Fortunately for at-risk relatives, early identification of LS has been proven 
to reduce cancer incidence, morbidity, and mortality through both primary and 
secondary cancer prevention (Heikki J Järvinen et al., 2009; H J Järvinen et al., 
2000; “Recommendations from the EGAPP Working Group,” 2009; Schmeler et 
al., 2006; Stupart, Goldberg, Algar, & Ramesar, 2009; H. F. A. Vasen et al., 
2010). With early and intensive surveillance, such as colonoscopy every one to 
two years (beginning at age 20-25 years) (“NCCN Clinical Practice Guidelines in 
Oncology,” n.d.), the incidence of CRC can be reduced by approximately 59-62% 
(Heikki J Järvinen et al., 2009; H J Järvinen et al., 2000; Stupart et al., 2009) and 
overall mortality can be decreased by at least 65% (H J Järvinen et al., 2000). 
Furthermore, evidence suggests that genetic testing improves compliance with 
screening procedures (“Hereditary Nonpolyposis Colorectal Cancer: Diagnostic 
Strategies and Their Implications: Structured Abstract,” n.d.). Chemoprevention 
may also become a routine prevention strategy in the future in light of recently 
published results from a randomized trial demonstrating that among individuals 
with LS, long-term use of aspirin reduces the risk of CRC by around 60% 
compared to no aspirin use (Chan & Lippman, 2011). Evidence has also 
demonstrated the efficacy of surgical options (i.e., hysterectomy and 
salpingoophorectomy) for reducing risks of ovarian and endometrial cancers 
(Auranen & Joutsiniemi, 2011; Koornstra et al., 2009; H. T. Lynch & Casey, 2007; 
“NCCN Clinical Practice Guidelines in Oncology,” n.d.; Schmeler et al., 2006). 
Although annual transvaginal ultrasound and endometrial sampling (biopsy) are 
often recommended beginning at age 30-35, published evidence that these 
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screening methods reduce mortality is insufficient (“NCCN Clinical Practice 
Guidelines in Oncology,” n.d.; Auranen & Joutsiniemi, 2011; Koornstra et al., 
2009; Barrow et al., 2009). The utility of screening for other cancers among 
patients with LS has not been established, but surveillance for gastric cancer has 
been recommended for patients born before 1935 (Barrow et al., 2009) or for 
families with more than one member affected by this type of cancer (Koornstra et 
al., 2009). Additional surveillance measures have also been recommended for 
individuals with more than one urinary tract cancer in the family (Koornstra et al., 
2009; “NCCN Clinical Practice Guidelines in Oncology,” n.d.).  
The HP genomics objective clearly has the potential “to prevent disease, 
disability, and premature death”, which is an overarching HP goal (“About Healthy 
People - Healthy People 2020,” n.d.). This potential is greatest for family 
members of patients with LS. Nevertheless, identifying LS in patients with CRC 
may help to prevent secondary cancers and improve clinical treatment. More 
specifically, a diagnosis of LS alters future cancer surveillance recommendations 
and cancer prevention options due to increased risks for developing additional 
cancers (Balmaña, Castells, & Cervantes, 2010; Rex et al., 2006). Given that one 
in four women with CRC related to LS will go on to develop endometrial cancer 
within 10 years (Obermair et al., 2010), diagnosing LS can be particularly 
beneficial if these women choose to pursue hysterectomy and 
salpingoophorectomy (Ladabaum et al., 2011). If LS is suspected based on 
screening performed on a tumor biopsy, the diagnosis may help inform surgical 
treatment options (i.e., subtotal colectomy versus segmental colectomy) 
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(Natarajan, Watson, Silva-Lopez, & Lynch, 2010). There is also preliminary (yet 
highly controversial) evidence to suggest that patients with LS respond differently 
to adjuvant chemotherapy with 5-fluorouracil than other patients whose tumors 
demonstrate microsattelite instability as a result of somatic mutations (Tejpar, 
Saridaki, Delorenzi, Bosman, & Roth, 2011).  
Screening and/or germline testing for LS has historically been offered to 
certain patients who are at high risk for the syndrome based on their personal 
and/or family medical histories (Park et al., 1999; Umar et al., 2004), yet many 
cases remain unrecognized due, in part, to limitations in the collection and 
interpretation of family history (De Bruin et al., 2006; Singh, Schiesser, Anand, 
Richardson, & El-Serag, 2010; Sjursen et al., 2010). Screening all tumors from 
newly diagnosed patients with CRC, a process referred to as universal tumor 
screening (UTS) (Bellcross et al., 2011), has been shown to substantially improve 
the identification of LS (Hampel, Frankel, et al., 2005; Hampel et al., 2008; 
Ladabaum et al., 2011; Mvundura, Grosse, Hampel, & Palomaki, 2010; 
“Recommendations from the EGAPP Working Group,” 2009; Tranø, Sjursen, 
Wasmuth, Hofsli, & Vatten, 2010). UTS presents an opportunity to identify most 
of the estimated 28% to 50% of individuals with LS who would not otherwise be 
identified with the common practices of limiting tumor screening to patients who 
fulfill family history or age criteria (Hampel et al., 2008; Mvundura et al., 2010).  
Although not specifically stated in the provisional HP genomics objective, 
UTS is a promising method of achieving this objective. Furthermore, if UTS is 
successful, it could serve as a model for implementing other evidence-based 
 138 
 
public health genomic  applications. The potential population health impact if 
screening were to be performed on all tumors from both newly diagnosed 
patients with CRC and newly diagnosed patients with endometrial cancer (EC) in 
the U.S. is detailed in a paper by Bellcross et al. (Bellcross et al., 2011).  
Despite substantial clinical evidence demonstrating the feasibility and 
efficacy of UTS for LS (Bellcross et al., 2011; Hampel et al., 2008; Palomaki, 
McClain, Melillo, Hampel, & Thibodeau, 2009; “Recommendations from the 
EGAPP Working Group,” 2009; Sjursen et al., 2010; Tranø et al., 2010), evidence 
to support the real-life effectiveness of screening programs is limited (Hall, 2010) 
and consensus or best practice measures for UTS have not been established 
(“Recommendations from the EGAPP Working Group,” 2009).  
Health care costs. Given limited health care resources, public health 
genomic applications should not be implemented without first considering the 
fiscal impact. Simulation and modeling of various different CRC tumor screening 
protocols have demonstrated that the incremental cost-effectiveness ratio of 
screening CRC tumors for LS is comparable to other preventive cancer 
screening services provided in the U.S. (Gudgeon et al., 2011; Ladabaum et al., 
2011; Mvundura et al., 2010; S D Ramsey et al., 2001). More specifically, costs 
associated with screening tumors of patients < 50 years have been estimated in 
three separate studies with the following results: $7,556 per life year saved (S D 
Ramsey et al., 2001); $7,832 per life year saved (Mvundura et al., 2010), and 
$27,900 per life year saved (Ladabaum et al., 2011). Despite the lower costs 
associated with limiting screening to individuals under age 50, this approach 
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would miss approximately 50% of LS cases (Mvundura et al., 2010). As such, 
additional estimates have been calculated. A U.S. wide system of universal 
voluntary screening with 2/3 uptake after counseling was determined to have an 
incremental cost effectiveness ratio relative to age-targeted testing of $22,552 
per life year saved (Mvundura et al., 2010). Two additional cost effectiveness 
studies that have been published also concluded that costs associated with UTS 
may be acceptable (Gudgeon et al., 2011; Ladabaum et al., 2011). More 
specifically, Gudgeon et al. estimated that screening tumors of all patients who 
are newly diagnosed with CRC within their single managed health care system 
will cost a minimum of $10,369 per case detected (Gudgeon et al., 2011) Taking 
a broader U.S. health system perspective, Ladabaum et al. calculated the 
increased cost effectiveness ratio for UTS to be $88,700 per life year gained, as 
compared to $44,200 per life-year gained when limiting screening to individuals < 
70 years (Ladabaum et al., 2011). Differences in these cost-effectiveness models 
presumably result from differences in their underlying assumptions as well as 
differences in the number and types of factors that were taken into account. An 
important limitation, pertinent to all of these models, is that assumptions may not 
be consistent with real-world practice.  
Cost-effectiveness of tumor screening is highly dependent on the behavior 
of those who screen positive and their family members (Gudgeon et al., 2011; 
Ladabaum et al., 2011; Mvundura et al., 2010). Although systematic reviews 
have found adequate test uptake among individuals with CRC and their relatives 
(Palomaki et al., 2009; “Recommendations from the EGAPP Working Group,” 
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2009), centers that have already begun UTS for LS have found varying success 
rates in terms of the percentage of patients with an abnormal screen who follow-
through with genetic counseling/testing (Bellcross et al., 2011; South et al., 
2009). Without high compliance from patients, these types of large-scale public 
health screening programs will fail to be effective in terms of both cost and ability 
to decrease morbidity and mortality. Therefore UTS programs should be 
evaluated to determine real-world effectiveness.  
Educational Needs 
 With respect to UTS, Bellcross et al., eloquently and succinctly point out 
that “multi-level education” will be needed to ensure the following: 
“...that entities at all layers—patients, family members, health care providers, 
public and private health systems, policy makers—are operating from the same 
understanding of the rationale for universal LS screening, the importance of 
genetic counseling and diagnostic testing for individuals whose tumor screens 
are positive, and the need to follow through with identification of at-risk family 
members and ensure appropriate surveillance of mutation-positive individuals” 
(Bellcross et al., 2011, p. 7). 
 
 Education of the general public. At the most fundamental level, 
educational efforts are needed to increase awareness of the existence of genetic 
tests for hereditary cancer. According to the 2000 National Health Interview 
Survey (NHIS), only 44.4% of the U.S. adult population had even heard of 
genetic testing for inherited susceptibility to cancer (Wideroff, Thomas 
Vadaparampil, Breen, Croyle, & Freedman, 2003). Awareness varied 
substantially by race/ethnicity, with approximately 50% of whites having heard of 
testing versus 33% of African Americans, 32% of American Indians/Alaskan 
Natives, 28% of Asian/Pacific Islanders, and 21% of Hispanics (Wideroff et al., 
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2003). Data from the 2005 NHIS showed similar trends in racial/ethnic disparities 
as well as an overall 2.9% decrease in awareness of genetic testing since 2000 
(Vadaparampil, 2009). Results from the 2010 NHIS survey are not yet published, 
but it is likely that the need to increase awareness still exists, particularly among 
non-white racial/ethnic groups.  
 Additional genetics information is necessary for patients to understand 
what genetic screening/testing will mean for them in order to make informed 
decisions. Condit points out that determining which information is “decision-
relevant” is challenging (Condit, 2010); and she describes steps needed to 
address the general lack of genetics education among the public as follows:  
“If prescriptions for the contents of public education are not merely to expand to 
the unrealistic desire to convey the entire universe of existing expert knowledge 
of genetics, there remains a pressing need for carefully designed empirical 
examinations of what information people actually can and will use and benefit 
from most in their decision making processes (Condit, 2010, p. 7).  
 
 Although I strongly agree that additional research involving patients is 
needed, there are some specific knowledge gaps, already identified among the 
public, which may be particularly relevant. More specifically, the general public is 
largely lacking in an understanding of molecular genetics (Condit, 2010). Without 
basic knowledge about molecular genetics, it may be difficult to understand 
various aspects regarding tumor screening for LS. However, the amount and type 
of information that CRC patients need or desire in order to make informed 
decisions about UTS is unknown. I suspect that many people view genetics a lot 
like I view computers. I wouldn't really care to nor would I need to know details 
about a computer virus. I would simply need to recognize that my computer got a 
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virus, know who can fix it, determine whether my laptop could also be affected, 
and find out what I can do to prevent getting a computer virus again. My 
husband, on the other hand, loves computers. If I were to get a computer virus 
he would probably start telling me all of the technical details about the virus and 
what he needs to do to determine the extent of the damage. In turn, I would tune 
him out and may even miss important information that I really need to know. 
Similarly, patients may not care about the technical details of tumor screening, 
which protein(s) is/are missing, or what additional reflex testing may be 
performed. Genetics health professionals therefore run the risk that critical 
information will be missed unless they engage patients in the process of 
determining how much molecular genetic information to include in educational 
materials.  
Compared to molecular genetics, heredity is viewed as a much more 
salient aspect of genetics by the general public (Condit, 2010). It is easier for 
people to see the direct impact of heredity in their lives, which probably explains 
why family history has a substantial influence on an individuals' perceptions of 
whether cancer is likely to be hereditary (Lucke, Hall, Ryan, & Owen, 2008). 
Individuals' understandings of inheritance may, however, conflict with the medical 
perspective due to the complex ways in which people perceive vulnerability and 
personalize risk (Walter, Emery, Braithwaite, & Marteau, 2004) UTS for LS may 
be particularly challenging because human beings generally have difficulty 
understanding probabilities (Visschers, Meertens, Passchier, & de Vries, 2009) 
and individuals who lack a strong family history of cancer or who hold 
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misconceptions may fail to see how screening and genetic counseling are 
applicable to them.  
There are several additional examples of how perceptions about heredity 
could act as barriers to the achievement of the HP genomics objectives. One 
example is the finding that variable penetrance alleles, including genes 
associated with LS, can result in the perception that hereditary cancer “skips 
generations” and lead to misconceptions regarding the probability that an 
individual or their offspring inherited the disease causing allele (Henderson & 
Maguire, 2000). Misconceptions about hereditary breast/ovarian cancer may be 
even more prevalent or concerning because a fair number of individuals, 
including health care providers, fail to take paternal family history into 
consideration when assessing risks due to the mistaken belief that males cannot 
inherit or cannot pass on the cancer causing allele to their offspring (Miesfeldt, 
Cohn, Ropka, & Jones, 2001; Yong, Zhou, & Lee, 2003).  
Education to address common misconceptions pertaining to heredity and 
risk is important, but it will not address the many other attitudes, fears, or 
misconceptions that may influence decisions related to genetic testing (Balmaña, 
Stoffel, Emmons, Garber, & Syngal, 2004; Cragun, Malo, Pal, Shibata, & 
Vadaparampil, 2012; Esplen et al., 2001, 2007; L. A. Keogh et al., 2009; Kinney, 
DeVellis, Skrzynia, & Millikan, 2001; Scott D Ramsey, Wilson, Spencer, 
Geidzinska, & Newcomb, 2003; Rose, Peters, Shea, & Armstrong, 2005; Sally W. 
Vernon et al., 1999). For example, patients who take a fatalistic viewpoint or are 
unaware of advantages and medical benefits of identifying hereditary cancer for 
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themselves and/or their family members may be less likely to demonstrate 
interest in or pursue genetic testing (Balmaña et al., 2004; Cragun et al., 2012; 
Sally W. Vernon et al., 1999). Educating the public about the benefits of genomic 
information is essential. Education about state and federal laws designed to 
protect against genetic discrimination in the contexts of employment and health 
insurance are also needed, as fears of genetic discrimination have been 
negatively related to interest in or uptake of genetic counseling and/or genetic 
testing (Balmaña et al., 2004; L. A. Keogh et al., 2009; Kinney et al., 2001; Scott 
D Ramsey et al., 2003; Sally W. Vernon et al., 1999). Although it is possible that 
fear of discrimination may have declined in recent years with the implementation 
of the federal Genetic Information Nondiscrimination Act (GINA) in 2009, data 
from a representative sample of Michigan residents in 2010 revealed that only 
13% were aware of GINA (“Genetic Testing and Genetic Non-Discrimination 
Laws,” 2011). 
Education for health professionals and health educators. Health Care 
Professionals also need to be educated about GINA. Results from a national 
survey of family physicians approximately 17 months after GINA was signed 
revealed fewer than half of respondents were aware of this federal law (Laedtke, 
O’Neill, Rubinstein, & Vogel, 2011). Even more concerning, however, was that no 
significant correlation was found between concerns about discrimination and 
knowledge of GINA among these physicians (Laedtke et al., 2011). Additional 
evidence for why this is a critical issue comes from another study which found 
that physician's concern about genetic discrimination was a reason for non-
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referral among a minority of Californian physicians surveyed (Lowstuter et al., 
2008).  
In addition to knowledge about GINA, health care professionals and 
members of the public health workforce who may be involved with UTS or the 
related HP genomics objective should, at a minimum, possess the following 
genomics competencies: 1) a basic understanding of the rationale behind UTS; 
2) the ability to identify the limits of his/her genomic expertise; and 3) knowledge 
regarding where to go for information, resources, and referrals (Bellcross et al., 
2011; “Genomics|Training|Competencies,” n.d.). Additional genomics 
competencies will be necessary for health care professionals who will be 
interpreting tumor screening results and/or discussing them with patients. Given 
that screening tests are not conclusive, health professionals must be educated 
about best practices for discussing a positive screen and about the need to 
emphasize the importance of follow-up genetic counseling and genetic testing to 
their patients, even in the absence of a strong family history of cancer.  
As part of the public health workforce, public health educators have been 
identified as having the potential to play a unique role by helping health 
professionals communicate with community groups and individuals regarding 
genomic information and related technologies, relaying or reflecting communities' 
concerns to health care professionals or policy makers, and providing 
educational and health promotion services in the context of a multidisciplinary 
team to facilitate informed decision-making related to genomics and health (L.-S. 
Chen & Goodson, 2007). Even though over 88% of U.S. public health educators 
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who responded to a survey strongly agreed or agreed with genomics 
competencies that have been proposed by the CDC for the public health 
education workforce (L.-S. Chen & Goodson, 2007; 
“Genomics|Training|Competencies,” n.d.), they perceived many barriers to 
incorporating genomics into health promotion (L.-S. Chen & Goodson, 2009). 
Barriers included lack of genomics knowledge, limited training in genomics, 
having to deal with lay public member's reaction, and lack of priority, time and 
resources (L.-S. Chen & Goodson, 2009). Possible ways to remedy the 
ambivalent attitudes and knowledge gap would be to incorporate more genomics 
into the curriculum of public health education programs.  
The inability to utilize the talents and skills of public health educators due 
to their current lack of training and knowledge regarding genomics would be 
unfortunate, but even more concerning is the potential that their lack of 
knowledge will lead to misrepresentation of genomic information to the public and 
the possibility that public health educators could hinder progress toward the HP 
genomics objectives. 
Educational resources for institutional implementation of UTS. As 
more centers consider implementing UTS, there is a need for accessible 
educational resources such as tumor screening protocol algorithms, samples of 
laboratory reports, guidelines for interpreting results, fact sheets, ways to deal 
with procedural concerns or issues that may arise, samples of patient 
letters/brochures, information regarding insurance and reimbursement, and 
lessons learned from other centers. Collecting and dissemination educational 
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resources is one of the primary goals of the Lynch Syndrome Screening Network 
(LSSN), which is a group of representatives from approximately 35-40 institutions 
who have formed a collaborative group to improve Lynch syndrome screening 
and increase the capacity for institutions to implement UTS.  
Evolution of Genomic Research and Practice 
 
“Scientific and technological advances in genomics are revolutionizing our 
approach to genetic counseling and testing, targeted therapy, and cancer 
screening and prevention, fulfilling the promise of personalized medicine (Weitzel 
et al., p. 1) (Weitzel, Blazer, MacDonald, Culver, & Offit, 2011).” 
 
In oncology, the use of presymptomatic testing for germline mutations and 
the use of ‘‘targeted therapies’’ tailored to the molecular genetic characteristics of 
tumors are often part of routine evaluation and care (Robson, Storm, Weitzel, 
Wollins, & Offit, 2010; J. N. Weitzel et al., 2011). Despite a number of successes, 
translating research into practice is often complex and there is always the risk 
that promising genomic discoveries may never successfully be translated into 
practice or that tests may be implemented widely before there is sufficient 
evidence of clinical validity (i.e., accuracy with which the test predicts a particular 
outcome (Burke et al., 2002) and/or clinical utility (i.e., capacity for the test result 
to inform clinical decision making and facilitate the prevention of adverse health 
outcomes) (Burke et al., 2010; Grosse & Khoury, 2006).  
Since the completion of the human genome project a substantial amount 
of research and resources have focused on identifying the contribution of genetic 
variants to the pathology of common diseases such as cancer (S D Schully, 
Benedicto, Gillanders, Wang, & Khoury, 2011). Many single nucleotide 
polymorphisms (SNPs) associated with increased risks for cancer have been 
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identified via genome wide association studies (Jostins & Barrett, 2011; 
Wacholder et al., 2010). GWAS studies may be providing valuable information 
about biological pathways involved in cancer and other diseases (Tuma, 2009). 
However, these studies have generally found SNPs that confer only small relative 
risks; and/or the clinical validity and clinical utility of testing for these SNPs 
remain somewhat uncertain (Jostins & Barrett, 2011; Robson et al., 2010; 
Wacholder et al., 2010).  
To address the growing concern about potential limitations regarding the 
practical relevance of genomic research to the primary causes and remedies of 
diseases, an international, multidisciplinary meeting was held in May 2010 in 
Ickworth, United Kingdom (Burke et al., 2010). Key themes from this meeting 
centered around a need to reconfigure the focus of genomic research so that 
greater attention is given to areas with greatest potential health impact and so 
that a greater emphasis is placed on the translation of basic science to practical 
applications (Burke et al., 2010). Although translational research appears to be 
increasing in recent years (Muin J Khoury, Gwinn, & Ioannidis, 2010), nearly all 
(98.2%) genetics-related grant funding by the National Cancer Institute from 
Fiscal Year 2007 was dedicated to discovery research (S D Schully et al., 2011), 
whereas translational research that evaluates a candidate genetic application to 
develop evidence based recommendations, assesses how to integrate an 
evidence-based recommendation into cancer care and prevention, or that 
evaluates health outcomes and population impact has been extremely under-
represented in both funding and similarly in the published literature (S D Schully 
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et al., 2011).  
The new challenge for epidemiology is to work with allied disciplines to 
integrate knowledge and effective interventions into various societal settings to 
ensure that interventions have their intended effects on individual and public 
health (Hiatt, 2010). The HP 2020 provisional genomics objective takes on this 
challenge by focusing efforts on improving the identification of individuals who 
have Lynch syndrome (LS) and other hereditary colorectal cancer (CRC) 
syndromes so that effective prevention and treatment options can be 
implemented to reduce associated morbidity and mortality.  
Evidence in Favor of Lynch Syndrome (LS) Tumor Screening  
Utilizing the ACCE (analytical validity; clinical validity; clinical utility; and 
ethical, legal, and social issues) framework, the Evaluation of Genomics 
Applications in Practice and Prevention (EGAPP) working group found sufficient 
clinical validity and clinical utility evidence in favor of offering tumor screening to 
all newly diagnosed patients with CRC for purposes of identifying family 
members at increased risk for Lynch syndrome (LS) (“Recommendations from 
the EGAPP Working Group,” 2009). EGAPP did not recommend a specific 
protocol or screening methodology for universal tumor screening (UTS), but 
possible screening methods have a number of different benefits and limitations 
(Mvundura et al., 2010; Shia, 2008). Notably, immunohistochemistry (IHC) for the 
presence or absence of DNA mismatch repair (MMR) proteins in tumor samples 
is more cost effective than microsattelite instability (MSI) testing, particularly 
when V500E mutation testing in the BRAF gene is added as an additional reflex 
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test in cases where the MLH1 stain is absent on IHC (Ladabaum et al., 2011; 
Mvundura et al., 2010).  
Regardless of the screening protocol that is chosen, abnormal results are 
not considered diagnostic of LS. Therefore patients with an abnormal tumor 
screen require subsequent germline testing of one or more of the genes that can 
cause LS (i.e., MLH1, MSH2, MSH6, PMS2, and EPCAM) as well as genetic 
counseling to discuss associated implications and recommendations for cancer 
prevention or early detection.  
Germline genetic testing has been distinguished from genetic screening 
performed on tumors, in that the former involves DNA analysis from blood or 
saliva to identify inherited mutations that increase risks for cancer, whereas the 
latter is typically used to predict cancer prognosis or treatment response (Robson 
et al., 2010). MSI and IHC are performed on tumor tissue and can provide 
prognostic information (A. J. Clark, Barnetson, Farrington, & Dunlop, 2004; 
Gologan & Sepulveda, 2005). Preliminary evidence also suggests that MSI and 
IHC could possibly provide information about treatment response (de la Chapelle 
& Hampel, 2010; Tejpar et al., 2011). However, these screening tests are unique 
in that they have generally been employed for the purpose of determining 
whether an individual is at increased risk for LS, thereby leading to debate about 
whether or not explicit informed consent is necessary. On one hand, Chubak et 
al. argue that informed consent for IHC may be required because unlike MSI, 
IHC can reveal information about a patient's germline (Chubak, Heald, & Sharp, 
2011). In contrast, others argue that because neither IHC nor MSI are definitive 
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genetic tests, explicit informed consent is not required (Ladabaum et al., 2011). 
Valid concerns have been raised that a lack of explicit informed consent may 
infringe upon an individuals' autonomy or “right not to know”(Peres, 2010). 
However, requiring explicit informed consent is concerning from a logistical 
standpoint due to the time and effort it requires. Furthermore, suggesting to 
patients that their cancer might be hereditary before screening is completed 
could lead to unnecessary increases in anxiety and additional decisional burdens 
among newly diagnosed CRC patients, the vast majority of whom do not have LS 
(Peres, 2010). 
Implications of Universal Genetic Testing Policies for Adult Populations 
 The impact that universal genetic testing policies will have on adult 
populations is largely uncertain as UTS for LS is truly the first universal genetic 
screening to be implemented for the purpose of detecting hereditary disease in 
adults. Other genetic screening programs that have been widely implemented 
are aimed at identifying genetic conditions in fetuses and infants or determining 
carrier status among healthy couples to assess genetic risks for offspring. 
Although not specific to adults, lessons learned from universal newborn 
screening (NBS) may offer several insights into potential implications of universal 
tumor screening (UTS).  This is explored in more depth in the ethical implications 
paper that is included as part of the dissertation.  
 One of the key ethical considerations involves informed consent. 
Programs that automatically screen all tumors from newly diagnosed CRC 
patients have the potential to identify the greatest number of patients with LS. 
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This approach also raises ethical concerns related to autonomy (M. J. Hall, 
2010). On the other hand, if screening requires explicit informed consent, this will 
make implementation much more challenging and could reduce the number of 
individuals with CRC who are screened for LS. Genetic testing of adults up until 
this point has mainly been performed on individuals who actively sought out 
genetic counseling and testing. With UTS programs, particularly those that do not 
require explicit informed consent, the patient is being confronted with the 
possibility of a genetic risk factor that he or she is not expecting, did not seek out, 
and may not even want.  
 Assessing potential harms of UTS will be important. There have been no 
published studies designed to identify risks or unintended outcomes associated 
with UTS. Although risks are believed to be minimal (H. Hampel, 2010), a couple 
of anecdotal reports from my own personal correspondence with genetic 
counselors suggest that UTS can result in substantial psychological distress for 
at least a few patients with who are erroneously led to believe they have LS. 
Furthermore, in several studies that occurred prior to UTS implementation, 
patients with CRC expressed concern that genetic testing for hereditary CRC 
may lead to adverse psychological outcomes for themselves or their family 
members (Kinney et al., 2000, 2001; Lerman, Marshall, Audrain, & Gomez-
Caminero, 1996; Scott D Ramsey et al., 2003). Patients with CRC have also 
expressed concerns about costs associated with genetic testing (Kinney et al., 
2001; Scott D Ramsey et al., 2003). Confirmatory genetic testing for LS is 
approximately $1,000 to $3,000 and it is not always covered by insurance (J. N. 
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Weitzel et al., 2011). Having a positive screen, but not being able to follow-
through with genetic counseling and/or testing may invoke anxiety and worry. 
UTS, if enacted widely throughout the U.S., therefore has the potential of adding 
to the financial and/or psychological burdens of over 190,000 patients who are 
diagnosed with CRC in the U.S. each year (“Colorectal Cancer Facts & Figures 
2011-2013,” n.d.). Prior to wide-spread implementation, studies should be 
conducted to identify whether there are any unanticipated harms associated with 
UTS so that risks can be minimized. 
 Despite the possibility of negative outcomes, the potential benefits of UTS 
are substantial and anecdotal reports have indicated that patients are often 
appreciative of the additional information they obtain from UTS (Peres, 2010). 
Nevertheless, it is possible that the estimates of benefit in terms of reducing 
morbidity and mortality may be overstated. If penetrance in certain families 
identified through UTS is lower than current estimates and age of cancer onset is 
later, a higher cost-benefit ratio may result from applying existing cancer 
screening protocols (Bellcross et al., 2011). As such, if studies continue to show 
varying penetrance with consistent genotype/phenotype correlations, 
recommendations may need to change to ensure that individuals do not undergo 
unnecessary procedures that would be of little clinical benefit and could cause 
harm (Kempers et al., 2011; Henry T Lynch, Lynch, Snyder, & Riegert-Johnson, 
2011).  
 Comparisons between NBS and UTS are useful when considering the 
potential impact of UTS. In addition, applying standardized state-wide laboratory 
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and follow-up processes similar to those that have been implemented for NBS 
has been proposed as a potential way to reduce cost and improve 
standardization, quality of care, and access to genetic counseling by trained 
health care providers (Bellcross et al., 2011). Thus NBS may serve as a model to 
help decrease the likelihood of negative UTS outcomes. 
Institutional Lynch Syndrome Screening Policies and Procedures  
 Published data on policies and procedures related to tumor screening for 
Lynch syndrome (LS) are limited (Bellcross et al., 2011), and most of what is 
known comes from the results of two surveys that were shared during the first 
Lynch Syndrome Screening Network (LSSN) meeting in September of 2011. 
Based on these surveys, at least 30 centers are performing routine screening for 
LS on tumors from all newly diagnosed CRC patients and several others are 
screening based on specific criteria. Some centers are also screening 
endometrial tumors to identify additional patients at increased risk for LS 
(Bellcross et al., 2011; Peres, 2010).  
 UTS protocols vary widely across institutions. Several specific details 
come from a 2010 survey of institutions across the U.S. including 39 NCI-
designated Comprehensive Cancer Centers (NCI-CCCs) (63% response rate), 
50 randomly selected ACS-accredited Community Hospital Comprehensive 
Cancer Programs (COMPs) (50% response rate), and 50 randomly selected 
Community Hospital Cancer Programs (CHCPs) (40% response rate) (Beamer et 
al., 2012). Of the respondents, IHC and/or MSI is being conducted on at least 
some tumors at 71% of NCI-CCCs, 36% of COMPs, and 15% of CHCPs. Most 
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(48% ) use IHC, 14% use MSI, and 38% use both. Of the institutions performing 
screening, 38% test all CRC patients, 27% test those diagnosed under the age of 
50, 14% test those diagnosed under the age of 60, and 21% use other selection 
criteria. Only 14% offer an option to opt-out of screening for LS and only 3.5% 
offer pre-operative information on LS tumor screening. Centers reported that 
results go to the surgeon alone (27.6%), to the surgeon and another provider 
(55.2%), to a genetic health provider alone (6.9%), or to a non-surgeon and non-
genetic health provider (6.9%); whereas 3.4% indicated that results go to no one. 
Most of the centers expect the person receiving the results to initiate a referral to 
genetics. However, among the NCI-CCCs 18% indicated that referrals were 
initiated using an automatic electronic mechanism and 17% were initiated by a 
specialist. The majority of centers have implemented a genetics referral tracking 
mechanism and problems with patient follow-through with genetic counseling 
were reported by 53% of the NCI-CCCs, 33% of COMPs, and 67% of CHCPs 
that track this information.  
Universal Tumor Screening (UTS) Evaluation 
 Data evaluating the real-world effectiveness of UTS programs is extremely 
limited. As such, several studies that are not specific to UTS will also be included 
in the following literature review in order to provide a better understanding of 
three of the key steps that patients and/or at-risk family members must take in 
order for UTS to be successful once it has been implemented. These key steps 
include: 1) Patient Reach – patients must accept tumor screening (if consent is 
required) and patients must follow-through with genetic counseling and testing in 
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cases where screening is abnormal; 2) Cascade testing of family members 
(Bellcross et al., 2011) –  patients who are found to have LS need to 
communicate with their at-risk family members who must then follow-through with 
genetic counseling and testing; 3) Adherence to cancer screening 
recommendations and/or cancer risk reduction through uptake of surgical options 
by patients and family members who are diagnosed with LS. Although literature 
pertaining to all of these steps will be reviewed below, the focus will be primarily 
on patient reach, as this is most pertinent to my dissertation research.  
UTS Evaluation: Patient Reach (i.e., follow-through with genetic counseling & 
testing)  
 Factors related to genetic counseling and germline genetic testing uptake 
may be similar; however, differences may also exist. Based on unpublished 
survey results, it is clear that variability in patient follow-through with genetic 
counseling exists across centers that are performing UTS. Differences in patient 
reach could be the result of individual-level differences in patient populations. 
However, it is also likely that variations in screening protocol or institutional 
factors may help facilitate or hinder compliance with genetic counseling and 
testing (P. M. Lynch, 2011).  
 The experience at Ohio State University, one of the first centers to 
implement universal screening, found that uptake of genetic counseling dropped 
substantially once their research protocol ended and clinical implementation of 
UTS was begun. Under the research protocol, counseling and testing were free 
and travel was not required because counseling could be provided by phone (H. 
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Hampel et al., 2008). Once screening was initiated on a clinical basis, only 27% 
of those who screened positive followed up with genetic counseling (South et al., 
2009).  
 In an editorial published in the journal Diseases of the Colon and Rectum, 
Dr. Patrick Lynch reports that follow-through with genetic counseling at his 
institution, M.D. Anderson, is about 80% (P. M. Lynch, 2011). This is an important 
contrast to the experience reported at Ohio State where patient follow-through is 
substantially lower (27% ). Differences between these centers may contribute to 
this wide variability (P. M. Lynch, 2011). For example, instead of having to make 
an appointment in a separate genetics department, as is the case at Ohio State, 
genetic counselors are present within the GI centers at M.D. Anderson, 
potentially making referrals “more seamless” (P. M. Lynch, 2011). Additional 
insights into possible reasons for variability in patient follow-through come from a 
variety of studies discussed in more detail below that are not directly related to 
UTS. 
 Genetic counseling interest and uptake. Only a couple of studies have 
explored issues related to interest or uptake of genetic counseling for hereditary 
CRC. Secondary data analysis of surveys from patients with CRC who were at 
various levels of risk for hereditary CRC reveal offers several insights. Compared 
to those with no intention of making an appointment (n=70) to discuss genetic 
testing for hereditary CRC, those with positive intention (n=18) perceived there to 
be greater medical benefits from genetic testing (p=.02) and were less fearful of 
insurance and/or employment discrimination (p=.04). They were also more likely 
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to perceive themselves to be appropriate candidates for genetic testing 
regardless of their personal and family history of cancer (p<.001) (Cragun et al., 
2012). A German study compared individuals at high risk for CRC based on 
whether they attended a genetic information session (Monika Keller et al., 2004). 
Those who attended the session reported more distress about the possibility of 
CRC being hereditary. No group differences were found in terms of awareness of 
potential hereditary predisposition or clinical criteria suggestive of LS. 
 Uptake of genetic counseling for hereditary breast cancer may also 
provide relevant insights (Chin et al., 2005; O’Neill, Peters, Vogel, Feingold, & 
Rubinstein, 2006; Thompson et al., 2002; Vadaparampil et al., 2009). Factors 
shown to positively influence or correlate with genetic counseling uptake for 
patients with breast cancer include increased awareness of genetic counseling 
and/or hereditary breast cancer, perceived benefits of counseling, and a 
perception that genetic counseling is personally relevant to them. Factors that 
were negatively associated with pursuit of counseling include confusion about a 
referral in the absence of a strong family history of cancer, financial concerns 
about the cost of genetic counseling, and concerns about the potential for 
negative outcomes as a result of having genetic testing. 
 In a recent study of endometrial cancer patients, 26 of 47 patients who 
had an abnormal tumor screen for LS responded to a survey (Backes, Mitchell, 
Hampel, & Cohn, 2011). Of these, 20 (77%) reported that they were referred by 
their physician for genetic counseling, but only nine saw a genetic counselor. The 
most common reason for not seeing a genetic counselor was lack of adequate 
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insurance coverage or concern about the cost of the visit followed by anxiety 
about the results. Nine patients also stated that they or their family members did 
not want to know information regarding hereditary cancer risk. 
 Genetic testing interest and uptake. Interest or uptake of genetic testing 
among patients with CRC has varied widely across studies (ranging from 17-
100%) (Balmaña et al., 2004; Esplen et al., 2007, 2001; Hadley et al., 2003; M 
Keller et al., 2002; Monika Keller et al., 2004; L. A. Keogh et al., 2009; Kinney et 
al., 2000, 2001; Loader, Shields, Levenkron, Fishel, & Rowley, 2002; Metcalfe, 
Werrett, Burgess, Chapman, & Clifford, 2009; Scott D Ramsey et al., 2003; 
Ramsoekh et al., 2007; S W Vernon et al., 1997). This wide variability may be 
due to differences in recruitment of study participants and/or inconsistencies 
between studies in terms of the patient population sampled, information provided 
to participants, and ways in which cost and other contextual factors were 
addressed. Two studies, which each analyzed responses from nearly 100 
surveys of CRC patients, found that the respective percentages of CRC survivors 
interested in genetic testing for hereditary CRC were 67% (Cragun et al., 2012) 
and 72% (Kinney et al., 2000). These two studies provide the only published 
estimates that could be identified regarding interest in genetic testing among 
CRC patients who were not all at high risk for hereditary cancer or were not 
already pursuing genetic counseling. Nevertheless, the level of interest in genetic 
testing reported in these two studies may not be representative of CRC patients 
in general due to sampling issues and potential participation bias. 
Nonparticipants would in all likelihood be less inclined to pursue genetic testing 
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for many of the same reasons they chose not to participate in the respective 
surveys (e.g., medical complications from cancer treatment). As such, it is 
possible that a substantial proportion of CRC patients (at least 28-33%) are not 
interested in or are uncertain whether they would undergo genetic testing for 
hereditary CRC if it were made available to them.  
 Among patients with CRC, statistically significant associations between 
various demographic variables (i.e., gender, number of family members with 
cancer, age) and interest in or uptake of genetic testing for hereditary CRC have 
been inconsistent across studies (Cragun et al., 2012; Monika Keller et al., 2004; 
Kinney et al., 2000; Loader et al., 2002; Sally W. Vernon et al., 1999). Some 
studies have found that interest in or uptake of genetic testing for hereditary CRC 
is associated with the following demographic factors: being a parent (Loader et 
al., 2002); having more cancer in the family (Loader et al., 2002); having a larger 
social network (Loader et al., 2002); younger age (Kinney et al., 2000); and less 
advanced disease stage (Kinney et al., 2000); however, the magnitude of these 
associations was relatively small. Furthermore, other studies of CRC patients 
have either failed to find similar relationships or demographic variables do not 
remain statistically significant after controlling for attitudinal variables (Cragun et 
al., 2012; Monika Keller et al., 2004; Sally W. Vernon et al., 1999). Given that 
demographic variables generally cannot be altered, attitudinal factors that 
strongly correlate with interest in or uptake of genetic testing may serve as better 
leverage points or targets for improving the reach of UTS for LS.  
 Among patients with CRC, interest in and uptake of genetic testing has 
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consistently been associated with and/or attributed to perceptions of positive 
outcomes of genetic testing, including: helping other family members; 
determining cancer risks for offspring; improving the ability to make more 
informed decisions about cancer treatment/screening; and/or increasing one's 
ability to plan for the future (Balmaña et al., 2004; Cragun et al., 2012; Esplen et 
al., 2001, 2007; Hadley et al., 2003; Kinney et al., 2001; Metcalfe et al., 2009; 
Scott D Ramsey et al., 2003; Sally W. Vernon et al., 1999). More frequent 
thoughts, worry, or distress about CRC being hereditary may also have a 
significant positive correlation with interest in genetic testing (Kinney et al., 2000) 
and intention to learn genetic test results (Sally W. Vernon et al., 1999). Although 
few studies appear to have asked CRC patients about the influence of health 
care providers on their decision, one study reported that CRC patients' decisions 
to undergo genetic testing was influenced by a recommendation from a physician 
or genetic counselor (Esplen et al., 2007).  
 Studies suggest that negative attitudes regarding testing (e.g., concerns 
about negative psychological consequences and insurance discrimination) may 
also influence genetic testing decisions (Balmaña et al., 2004; L. A. Keogh et al., 
2009; Kinney et al., 2000, 2001; Sally W. Vernon et al., 1999). However, in two 
studies that have performed multivariable analyses, the relationship between 
negative attitudes and either interest in testing or intention to receive test results 
were no longer statistically significant after controlling for positive attitudes about 
genetic testing (Cragun et al., 2012; Sally W. Vernon et al., 1999).  
 After controlling for attitudes toward testing, a belief that personal and/or 
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family history makes individuals appropriate candidates for testing remained 
significantly associated with interest in testing (Cragun et al., 2012). An 
implication of this finding is that requiring explicit informed consent for tumor 
screening may result in relatively low rates of uptake unless patients are 
convinced that they are appropriate candidates for screening. Automatic 
screening of all tumors may therefore be more successful as long as patients 
who screen positive can be convinced that genetic counseling is appropriate for 
them.  
 Although interest in genetic testing may be a necessary precursor for 
action, uptake of testing is generally lower than interest (Monika Keller et al., 
2004). One potential reason for the discrepancy between interest and uptake 
may be financial barriers. Based on the collective experience of members of the 
Lynch Syndrome Screening Network, insurance typically covers the cost of 
screening which generally ranges between $250-$500, depending on the 
laboratory and screening strategy. The costs of germline testing are higher, 
generally between $900 to $3,000 depending on the number of genes tested. 
Lack of insurance or insufficient insurance coverage for genetic counseling and 
germline testing has been shown to be an important barrier to interest in or 
uptake of hereditary cancer counseling and genetic testing (Backes et al., 2011; 
Chin et al., 2005; Cragun et al., 2012; Kinney et al., 2001; Scott D Ramsey et al., 
2003; Weitzel et al., 2011). In one study, the percentage of CRC patients who 
indicated they would be willing to pay $2,000 for genetic testing (13.6%) was 
substantially lower than the 67% who indicated being interested in having genetic 
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testing before cost was mentioned (Cragun et al., 2012). Assessing the maximum 
amount that individuals would be able or willing to pay and determining the 
likelihood that insurance would cover costs associated with germline testing may 
be helpful before implementing UTS, as this will likely affect overall effectiveness. 
Although insurance and financial issues are individual barriers, changes to the 
health care system and insurance plans will likely be needed so that cost barriers 
do not prevent patients from choosing to undergo genetic counseling, 
confirmatory germline testing, colonoscopy, and other cancer surveillance or 
prevention measures. 
Cascade testing of family members. High levels of patient follow-
through with genetic counseling and genetic testing is essential to ensure that 
UTS programs are effective. However, it is the patients' unaffected family 
members who stand to gain the most benefit from UTS, and the prevention of 
cancer in unaffected relatives is critical in UTS cost-benefit sensitivity analyses 
(Gudgeon et al., 2011; Ladabaum et al., 2011; Mvundura et al., 2010). In order 
for testing of family members to occur, patients must understand the potential 
implications for family members, recognize the benefits of diagnosing LS in other 
family members, and communicate this information effectively with at-risk family 
members. Although genetic health professionals can play an important role in this 
process (Mesters, Ausems, Eichhorn, & Vasen, 2005; Pentz et al., 2005), the 
responsibility of informing family members often resides with the patients due to 
confidentiality issues (“Genetics of Colorectal Cancer (PDQ®) - National Cancer 
Institute,” n.d.).  
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 Several studies have explored genetic risk communication patterns among 
patients with LS and their families (K. I. Aktan-Collan et al., 2011; Ersig, Hadley, 
& Koehly, 2011; C. L. Gaff, Collins, Symes, & Halliday, 2005; Mesters et al., 2005; 
Susan K Peterson et al., 2003; Elena M Stoffel et al., 2008). Individuals are 
generally willing to share genetic test results with family members, but tend to 
favor a cascade approach whereby they inform first-degree relatives and then 
those family members inform other immediate family members (Gaff et al., 2005; 
Mesters et al., 2005; Susan K Peterson et al., 2003; Elena M Stoffel et al., 2008). 
Family role and gender differences have been reported in communication 
patterns (Gaff et al., 2005; Koehly et al., 2003; Susan K Peterson et al., 2003). 
Although communication is generally viewed as an open process (“Genetics of 
Colorectal Cancer (PDQ®) - National Cancer Institute,” n.d.), several barriers 
have been identified including: lack of close relationship, desire not to worry 
relatives, presence of familial conflict, and perceptions that relatives were either 
too young, would not understand, or would not be interested (Gaff et al., 2005; 
Mesters et al., 2005; Elena M Stoffel et al., 2008). 
 Once informed about the potential hereditary risk, family members must 
seek genetic counseling and genetic testing. A review of several studies revealed 
that about half of family members pursued genetic counseling and most who 
underwent counseling pursued germline testing (“Recommendations from the 
EGAPP Working Group,” 2009). However, uptake of genetic testing for LS among 
at-risk individuals can be highly variable and may depend on the context in which 
testing is offered (“Genetics of Colorectal Cancer (PDQ®) - National Cancer 
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Institute,” n.d.). Many factors influence whether family members pursue genetic 
counseling/testing for LS, such as: perceived benefits to self and family 
members; higher perceived risk of or worry about developing CRC; and concerns 
about genetic discrimination, ability to cope with results, or cost (K. Aktan-Collan 
et al., 2000; Claes, Denayer, Evers-Kiebooms, Boogaerts, & Legius, 2004; 
Codori et al., 1999; K Glanz, Grove, Lerman, Gotay, & Le Marchand, 1999; 
Hadley et al., 2003; L. Keogh et al., 2011; Kinney et al., 2001; Lerman et al., 
1999, 1996; J. T. Lowery, Marcus, Horick, Finkelstein, & Ahnen, 2011; Petersen 
et al., 1999; Ramsoekh et al., 2007; Sally W. Vernon et al., 1999; Warner, 
Curnow, Polglase, & Debinski, 2005).  
Cancer screening adherence. In order for individuals with LS to 
decrease associated morbidity and mortality it is important that they follow 
appropriate cancer screening guidelines and/or pursue surgical options to reduce 
cancer risks. In a review article, adherence to colonoscopy recommendations 
among individuals with LS was found to range from 53% to 100% 
(“Recommendations from the EGAPP Working Group,” 2009). Adherence to 
gynecologic surveillance ranged from 69% to 97% in three studies of women who 
either have LS or are at 50% risk for LS (V. R. Collins et al., 2007; Heikki J 
Järvinen et al., 2009; Anja Wagner et al., 2005) Little is known about uptake of 
prophylactic surgeries to reduce risks for endometrial and ovarian cancer.  
 Colon cancer screening adherence among individuals with LS or 
individuals who are at high risk for hereditary CRC has been associated with 
reminder letters, strong family history of cancer, having a medical 
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recommendation to screen, having been referred for a genetic evaluation, and 
encouragement to screen from family members (Bleiker et al., 2005; Ersig, 
Hadley, & Koehly, 2009; Murff, Peterson, Greevy, Shrubsole, & Zheng, 2007; 
Rees, Martin, & Macrae, 2008; Elena M Stoffel et al., 2010). Many of the barriers 
to colonoscopy in high risk individuals are similar to those in the general 
population (e.g., discomfort, cost, embarrassment) (Bleiker et al., 2005). 
Additional steps for successful UTS implementation. There are 
several additional steps involving health care professionals that are likely to be 
necessary to the success of UTS. These include effective communication of 
screening results, patient referrals, and coordination between various specialists 
and primary care providers to facilitate the process by which patients and their 
family members receive genetic counseling, genetic testing, and appropriate 
screening. Detailed information regarding these steps has not been reported and 
research and additional research in this area is needed. 
Summary 
 The Healthy People (HP) 2020 provisional genomics objective is intended 
to help translate genomic medicine into individual and public health benefits 
through improving the identification of individuals with hereditary colorectal 
cancer (CRC). Achievement of the HP 2020 provisional genomics objective has 
the potential to substantially reduce morbidity and mortality among unaffected 
relatives of CRC patients who are identified with Lynch syndrome (LS). Making a 
diagnosis of LS in patients who already have CRC may also benefit the patients 
directly, given that having LS may influence clinical treatment and will certainly 
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alter future screening recommendations due to high risks for additional cancers.  
 Universal tumor screening (UTS), whereby tumors from all newly 
diagnosed patients with CRC are screened for Lynch Syndrome (LS), has the 
potential to help achieve this HP objective and result in population health benefits 
at a reasonable cost. However, in order for this approach to be successful, 
education will be needed at many levels. At a minimum, all individuals involved 
with UTS and patients who are found to have an abnormal screen should be 
aware of the rationale for UTS, the importance of genetic counseling and 
diagnostic testing for individuals with abnormal tumor screens (regardless of 
family history or age at diagnosis), the need for follow-through with identifying at-
risk family members, and the importance of increased cancer surveillance for all 
individuals identified with LS. Additional education will be needed to dispel 
misconceptions about inheritance, to increase awareness of state and federal 
laws that are designed to protect against genetic discrimination, and to improve 
awareness of the positive health benefits associated with making a diagnosis of 
LS if appropriate cancer screening recommendations are followed. Educational 
resources that are being compiled by the Lynch Syndrome Screening Network 
(LSSN) will be extremely valuable in the dissemination of UTS, but systematic 
evaluation of existing UTS programs will also be needed to fully inform centers 
that are considering how to best implement UTS at their institution. Additional 
research and collaborative efforts are needed to help prioritize or determine 
additional educational efforts that may be necessary in order to help 
practitioners, health educators, patients, and other stakeholders achieve the HP 
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2020 genomics objective.  
 The feasibility of UTS has been demonstrated in research and clinical 
settings. However, prior to widespread implementation of UTS, lessons from 
universal newborn screening and potential ethical, legal and social implications of 
universal genetic screening for adults should be considered. Further research 
into “real-world” implementation is needed to determine whether there are any 
risks or unintended consequences associated with UTS and to collect additional 
data that is necessary to justify the development of infrastructure and cost that 
would be required for implementation of UTS on a national level (Bellcross et al., 
2011). To assess “real-world” effectiveness the following data will be critical: 
patient reach (i.e., follow-through with genetic counseling and testing after an 
abnormal screen); initiation of cascade testing of at-risk family members; 
adherence to recommended cancer surveillance for individuals identified with LS; 
and uptake of surgical prevention options.  
 Among centers already performing UTS, there is evidence of wide 
institutional variability in terms of UTS screening protocols and patient reach. 
Reasons for this institutional variability have not been explored. Research has 
established that patient factors may influence interest in and uptake of genetic 
counseling and testing outside the context of UTS, but data is needed to confirm 
that similar patient factors contribute to follow-through with genetic counseling 
and testing among patients who receive an abnormal tumor screen. There is also 
some evidence to suggest that contextual factors (e.g., patient-provider 
communication and policies or practices of health insurance providers and health 
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care institutions) may be influential in patient follow-through with genetic 
counseling and testing, either directly by creating barriers/facilitators or indirectly 
by altering patients' attitudes, knowledge, and perceptions. Comparing existing 
UTS programs can determine the extent to which different protocols/procedures 
are effective or ineffective in specific contexts in order to help identify best 
practices. This type of research is a critical step toward reaching the longer-term 
goals of optimizing current UTS programs and wide-spread diffusion of effective 
UTS practices. 
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